Applications of sortase A in disulfide-rich peptide engineering by Kwon, Soohyun
  
 
 
 
 
Applications of sortase A in  
disulfide-rich peptide engineering 
 
Soohyun Kwon 
BSc, MSc 
 
 
 
 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy at 
The University of Queensland in 2016 
Institute for Molecular Bioscience 
 ii 
 
Abstract 
 
While the global peptide drug market has been constantly growing, the intrinsic limitations of 
peptides, such as chemical and physical instability and poor oral bioavailability, continue to require 
innovative peptide engineering to facilitate the uptake of peptides by the pharmaceutical industry. In 
recent years, plant-derived cyclotides have been investigated for this purpose because cyclotides are 
remarkably stable against chemical, enzymatic or thermal attack. The stability of cyclotides is 
derived from their unique structure, which comprises a head-to-tail cyclized backbone and three 
disulfide bonds forming a knotted core. Although the overall structure of cyclotides is rigid, certain 
loops are ‘plastic’ enough to accommodate their synthetic replacement with a foreign peptide 
epitope. More than a dozen published studies have already demonstrated that bioactive peptide 
sequences can be grafted onto cyclotide scaffolds and thereby stabilized, while maintaining activity.  
 
Following lessons learnt from studies of cyclotides, other naturally occurring disulfide-rich cyclic 
peptides, including sunflower trypsin inhibitor I (SFTI-1) and θ-defensins, have been studied for 
similar purposes. Furthermore, cyclization has been applied to disulfide-rich neurotoxin peptides, 
derived from cone snails or scorpions, and has resulted in improved therapeutic potential. This 
thesis investigates a range of these natural peptides for their role as drug templates and explores 
novel approaches to produce them.  
 
The benefits of engineering cyclotides and other disulfide-rich peptides for therapeutic purposes can 
be maximized by efficient production systems. In this thesis, an efficient strategy to produce 
disulfide-rich cyclic peptides is investigated using the enzyme sortase A. Sortase A, originally 
discovered in Staphylococcus aureus, recognizes a penta-amino acid motif, LPXTG, and cleaves the 
peptide bond between Thr and Gly to form a thioacyl intermediate. This intermediate undergoes 
nucleophilic attack by an N-terminal poly-Gly sequence, forming a new peptide bond between the 
Thr and N-terminal Gly. This site-specific ligation (transpeptidation) activity of sortase A allowed 
the successful cyclization of a synthetic cyclotide precursor in a straightforward and safe manner 
compared to traditional chemical methods.  
 
The semi-enzymatic method was also readily applied to produce other disulfide-rich cyclic peptides, 
including SFTI-1, cVc1.1, and cyclic chlorotoxin. Furthermore, by considering cyclotides in a 
structural model, cyclization of the κ-conotoxin PVIIA originating from the venom of Conus 
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purpurascens was also explored. Interestingly, κ-PVIIA and other conopeptides, which belong to 
the O1 gene superfamily of conotoxins, are topologically very similar to cyclotides except that their 
backbones are linear. In this thesis, cyclization of κ-PVIIA was studied as a proof-of-concept for 
other conopeptides in the O1 superfamily. Furthermore, this study provides insights into successful 
cyclization by suggesting factors to be considered to obtain the desired peptide activity. 
 
Even with enzymatic cyclization, chemical synthesis of disulfide-rich peptides is not as cost-
effective as recombinant expression in large scale manufacturing. Therefore, recombinant 
expression of cyclotides, which are 28-37 amino acid long, is desirable for them to be attractive as 
potential therapeutics. In this thesis, bacterial periplasmic expression of kalata B1 precursor was 
investigated. To aid solubility of hydrophobic kalata B1 in the bacterial periplasm, maltose binding 
protein (MBP) was used as a fusion protein and sorting motifs were placed at both N and C 
terminus of kalata B1 sequence for subsequent cleavage from MBP and head-to-tail cyclization of 
kalata B1. 
 
Lastly, sortase A-mediated engineering was used to enable targeted delivery of cyclotides via 
conjugation to a single-domain antibody fragment (VHH). A non-natural amino acid, azidolysine, 
was incorporated during cyclotide synthesis, and bacterially expressed anti MHC Class II VHH was 
equipped with cyclooctyne using sortase A to enable a click reaction between them. The 
conjugation resulted in the improvement in immunogenicity of cyclotides by targeting antigen 
presenting cells. Overall, this strategy facilitates the application of a targeted delivery of cyclotides 
for therapeutic purposes.  
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Chapter 1.   Introduction 
 
1.1.    Overview 
Peptides play critical roles as hormones, neurotransmitters or ligands targeting a wide range of 
receptors. For example, peptide neurotoxins have attracted attention as potential drug candidates 
because of their inhibitory activity, coupled with high specificity and potency, against ion channels. 
However, peptides are generally susceptible to proteolysis, and are typically unstable in vivo and 
have poor bioavailability. Another problem for peptides as therapeutics is that they go through renal 
clearance rapidly due to their small size (<5 kDa). To overcome such obstacles, which limit the 
potential of peptides in drug development, a number of strategies have been introduced to 
chemically engineer them, including PEGylation (1,2), conjugation (3,4) or incorporation of 
unnatural amino acids (5-7). In addition, cyclization of peptides has been showing promising results 
of improved stability, compared to their linear counterparts. It is believed that protecting the N- or 
C- terminus of a peptide from exposure to proteases makes peptides resistant (8-10). Although there 
are many approaches to cyclize a peptide utilizing side chains of amino acids, this thesis will focus 
on head-to-tail backbone cyclization.    
 
The concept for an engineering strategy is often inspired by nature and cyclization is no exception. 
Naturally occurring cyclic peptides are found in bacteria, fungi, plants and animals and are 
typically very stable due to their unique conformation. Of the cyclic peptides present in nature, 
ribosomally synthesized cyclic peptides are expressed as gene-encoded precursors and post-
translationally cyclized. (11,12). They belong to the cyclic ribosomally synthesized and post-
translationally modified peptides (RiPPs) family of proteins (13), which exist in all kingdoms of 
life (13) and exist in all kingdoms of life. Bacterial-derived circularin A and gassericin A (14), 
animal origin of θ-defensins (15,16) and plant-derived cyclotides are well-known examples. In 
general, they are significantly more resistant to proteases than their linear counterparts (17). There 
are a variety of biosynthetic mechanisms to generate the cyclic peptides, but cyclic backbones are 
typically formed via head-to-tail cyclization (12), thioether crosslinks (18), or cysteine sulfur to α-
carbon crosslinks (19). Nonribosomal cyclic peptides are also synthesized via several strategies 
(20). For example, gramicidin S is cyclized via oligomerization, bacitracin is cyclized between an 
amino acid branch and the C-terminal peptide end, and cyclosporine is head-to-tail cyclized (20). 
The backbone of cyclosporine is also N-methylated via post-translational modification involving 
Chapter 1. Introduction 
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complex enzyme cascades during non-ribosomal synthesis. Notably, cyclosporine, which is a 
currently marketed immunosuppressant, is orally bioavailable (21).  
 
This chapter reviews disulfide-rich cyclic peptides focusing on cyclotides in particular. Cyclotides 
are plant-derived and remarkably stable due to a complex topology known as a cyclic cystine knot 
(CCK). This chapter also describes the use of cyclotides in drug design as well as how their unique 
topology has been inspiring chemical, structural engineering of peptide nerotoxins via cyclization. 
Among various studies published in the last decade on the usefulness of cyclization, cyclization of 
conopeptides and scorpion toxin is specifically addressed. Finally, this chapter also introduces 
sortase A which has been employed as an alternative tool to engineer peptides throughout research 
described in this thesis. 
 
Declaration of authorship 
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"Discovery and applications of disulfide-rich cyclic peptides" 
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Soohyun Kwon, Tunjung Mahatmanto, Anjaneya Swamy Ravipati and revised by Masa Cemazar 
and David Craik. This chapter includes the part describing conotoxins and chlorotoxin. 
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1.2.    Cyclotides 
1.2.1. Discovery, structure and biological activities of cyclotides 
Cyclotides were initially discovered by a Norwegian doctor, Lorents Gran, who identified kalata B1 
in a traditional medicine taken by Congolese women to facilitate childbirth during labor (22). 
Kalata B1 consists of ~30 amino acids forming a unique structural motif called a cyclic cystine knot 
(CCK) (23) which is characterized by a head-to-tail backbone and three disulfide bonds in a knotted 
topology, i.e. two disulfide bonds forming a ring and penetrated by a third disulfide bond (23,24). 
Since the discovery of kalata B1, a number of related plant-derived cyclic peptides were 
independently discovered during the 1990s and categorized with the family name ‘cyclotide’(23). 
 
Cyclotides are divided into three sub-groups, Möbius, bracelet and trypsin inhibitors (Figure 1A). 
The Möbius group, including kalata B1, possess a conceptual twist formed by a cis-Pro peptide 
bond in loop 5 of the cyclic backbone while the bracelet group, typified by cycloviolacin O1, do not 
have such a twist. The third small sub-group, which is consisted of trypsin inhibitors such as 
MCoTIs identified from Momordica cochinchinensis. Cyclotides within a sub-family share a 
common structural characteristic as well as their sequences. On average, Möbius possess a 40% 
hydrophobic surface whereas bracelet cyclotides possess a 57% hydrophobic molecular surface (25).  
 
The native role of cyclotides in plants is believed to be as a defense against insects (26,27) and 
other pests (28). However, cyclotides have also been reported to posssess pharmaceutically 
beneficial activities including antiviral (29), antibacterial (30), antifungal (31), antifouling (32), and 
cytotoxic (33) properties. These activities are thought to be related to the binding and disruption of 
lipid membranes in the case of kalata B1 (34-36). 
 
1.2.2. Biosynthesis of cyclotides 
Ribosomally synthesized cyclotides originate from their precursor proteins, which consist of an 
endoplasmic reticulum (ER)-targeting sequence, a pro-region, a highly conserved N-terminal repeat 
(NTR) region, a cyclotide domain, and a C-terminal tail (Figure 1B). The cyclotide domain may 
include multiple copies of sequences that are the same or different, but multiple copies are usually 
separated by additional NTR sequences. Cyclization is known to take place during post-
translational processing, but many details of the process have not yet been completely elucidated. 
However, it has been recently confirmed that a conserved Asn or Asp at the C-terminal cleavage 
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site is subjected to catalysis of asparaginyl endoproteinase (AEP) or butelase (37-40). AEP was 
originally reported to be involved in post-translational peptide bond formation to process 
concanavalin A from jackbeans (41), and plants transformed to express a cyclotide precursor 
produced a decreased amount of cyclotides when AEP was inhibited (37).  
 
 
Figure 1. Cyclotides from three categories and biosynthesis (A) kalata B1 (PDB ID: 1NB1) from 
Möbius (42), cycloviolacin O1 (PDB ID: 1NBJ) from bracelet (42), and MCoTI-II (PDB ID: 1IB9) 
from trypsin inhibitors (43), (B) Schematic representation of AEP-catalyzed cyclization of cyclotide 
precursor. This figure is adapted from Sancheti et al (44). 
 
 
1.2.3. Chemical biology and applications of cyclotides 
Cyclotides comprise six loops divided by cysteines in the sequence (Figure 2). Certain loops are 
more flexible than others implying they can accommodate addition or modification of amino acids 
without perturbation of the overall structure of the cyclotide scaffold. Therefore, cyclotides have 
been re-engineered to gain a selected biological function or remove an unwanted natural function 
(45). The engineering can be as simple as a single residue deletion/insertion, or grafting of a 
bioactive peptide epitope into a loop (46,47). One motivation for doing this is that the cyclotide 
scaffold shields the linear peptide epitope from proteolysis. Activities conferred to a cyclotide via 
epitope grafting include anti-angiogenic (48), pro-angiogenic (49), antiviral (50), and 
cytomodulatory activities (51). The cyclotide scaffold and selected loops for grafting are shown in 
Figure 2.  
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One of the breakthroughs recently achieved by an epitope grafted cyclotide was accessing an 
intracellular target, as such targets are typically difficult to address with peptide or protein 
therapeutics (52). Ji et al. chose MCoTI-I as a scaffold to accommodate a 15 amino acid, α-helical 
peptide which can modulate protein-protein interaction to activate p53 tumor suppressor pathway. 
To maintain the α-helical conformation of the epitope they placed a linker derived from apamin, a 
bee-venom neurotoxin, which had been previously used to correctly display p53-derived helical 
peptides (52,53). Overall, these proof-of-concept experiments provide support for generalization of 
the concept that cyclotides have high potential to be a drug scaffold.  
 
 
Figure 2. Applications of cyclotide as scaffolds. (A) Kalata B1 was used as a template for grafting 
a vascular endothelial growth factor-A (VEGF-A) antagonist sequence in place of a Pro residue in 
loop 3 (highlighted in circle). The epitope was stabilized and active upon grafting without 
perturbing the structure of kalata B1, thus illustrating the tolerance of the CCK motif to size 
modification (48), (B) MCoTI-II has been used as a scaffold for several grafting applications. The 
trypsin inhibitory site residue lysine (K, highlighted in circle) was replaced with Ala or Val and 
shown to redirect the activity of the native scaffold towards human leukocyte elastase (HLE) (50); 
and when substituted to Glu, the resultant MCoTI-II analogue was active against foot and mouth 
disease virus 3C protease (FMDV 3Cpro) (50). Another study demonstrated that grafting 
extracellular matrix protein epitopes onto loop 6 
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imparted MCoTI-II with angiogenic activity (49). Together, these studies demonstrate the use of 
cyclotides as carriers for delivering a desired activity of a short peptide sequence. The large gray 
arrows indicate the grafting sites; the small black arrow indicates the cyclization site in native 
cyclotide biosynthesis. The 3D structures of kalata B1 (PDB 1NB1) and MCoTI-II (PDB 1IB9) 
were generated using YASARA v11.9.18. Figure taken from Cemazar et al (47). 
 
 
1.3.    Conotoxins 
Conotoxins are peptides of 12–35 amino acids produced in the venoms of marine cone snails from 
the Conus genus (54). Conoserver (http://www.conoserver.org) provides extensive information on 
more than 1000 of these peptides (55). Their classification is based on gene superfamily, cysteine 
frameworks and pharmacological activities (56), and they are named using acronyms that include a 
Greek letter referring to the pharmacological family, a capital letter from the name of the source 
Conus species, and a Roman number indicating the cysteine framework, followed by a capital letter 
to show the order of discovery. Conotoxin κ-PVIIA, for example, is a conotoxin targeting voltage-
gated K+ channels that originated from Conus purpurascens (57). Another example, conotoxin ω-
MVIIA (PRIALT®), was approved by the US Food and Drug Administration in 2004 for the 
treatment of chronic pain (58). Despite its highly selective mechanism against N-type voltage-
sensitive calcium channels, it is administered by direct infusion into the spinal cord, which is 
invasive for patients, costly, and has a risk of infection. Therefore, approaches were sought for the 
oral delivery of bioactive conotoxins. In this work, structural studies of a wide range of conotoxins 
have provided a basis for the design of re-engineered drug leads (59-62). 
 
First, backbone cyclization was proven to improve stability against proteases using the α-conotoxin 
MII (8). Cyclization by joining the ends of the peptide, with a linker consisting of six alanine and 
glycine residues, resulted in higher stability with no loss of bioactivity. The structures of linear and 
cyclized MII are shown in (Figure 3A). This work was subsequently extended the cyclization 
approach to another α-conotoxin, Vc1.1. Cyclizing Vc1.1 with a 6-amino acid linker, without 
perturbation of the original structure (Figure 3B), resulted in more potent selective inhibition of 
calcium channels via a GABAB receptor dependent pathway. Furthermore, its stability in simulated 
intestinal fluid and human serum was increased relative to the linear counterpart. CyclicVc1.1 was 
tested in a chronic constriction injury rat model of neuropathic pain and found to be more than two 
orders of magnitude more potent than the clinically used gold standard for neuropathic pain, 
gabapentin (9). 
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Figure 3. Linear and cyclic α-conotoxin MII and Vc1.1. (A) Linear MII (PDB 1MII) and 
cyclized MII (PDB 2AKO) by 7 amino acid linker (8), (B) Linear Vc1.1 (PDB 2H8S) and its 
cyclized form by 6 amino acid linker (9). Figure taken from Cemazar et al (47). 
 
 
1.4.  Chlorotoxin 
Chlorotoxin is a 36 amino acid peptide isolated from the venom of the Israeli scorpion Leiurus 
quinquestriatus quinquestriatus. Its disulfide-rich knotted topology contributes to its high stability 
(63). Its name originated from the fact that it inhibits chloride channels in embryonic rat brain and 
epithelia (64), and interest in the molecule was particularly sparked by the discovery that it binds to 
glioma cells (65-67). Chlorotoxin has subsequently been shown to interact with a number of other 
tumor cell types, including medulloblastomas, neuroblastomas, ganglioneuromas, melanomas, 
pheochromocytomas and lung carcinomas (68). The tumor binding of chlorotoxin is supported by 
its interaction with matrix metalloproteinase-2 (MMP-2) isoforms, which are upregulated in 
gliomas and other cancers (69).  
 
Chlorotoxin uptake by glioma cells is different to its entry into normal cells. It enters glioma cells 
through a clathrin-mediated pathway and localizes near the trans-Golgi apparatus, whereas in 
normal cells it enters via micropinocytosis and localizes in the cytoplasm (70). The difference in 
uptake is advantageous for the development of glioma therapeutics (70) and synthetic chlorotoxin 
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(TM-601) was conjugated to iodine-131 (131I) and administered intracavitarily to patients having 
recurrent glioma in recent clinical trials. 131I-TM-601 showed an anti-tumor effect and was well 
tolerated without dose-limiting toxicity (71). 
 
Based on its specific binding ability to brain tumors, chlorotoxin has been conjugated to the near-
infrared fluorescent dye Cy5.5 to visualize tumors during surgery (72,73). The dye conjugates to 
lysine, which chlorotoxin has three of (Lys15, 23, 27) resulting in 75-85% mono-labeled peptide at 
Lys27 along with di- and tri-labeled side products. Ideally, monolabeled compound is preferred for 
commercialization and in a recent study, linear chlorotoxin was successfully mono-labeled by 
substitution of Lys15 and Lys23 with alanine or arginine (74). The study also demonstrated that 
cyclized chlorotoxin, using a 7-amino acid linker without any lysine substitution, produced only 
mono-conjugation of the dye, providing an unexpected advantage of cyclisation. A schematic 
illustration of the cyclization and conjugation of chlorotoxin to Cy5.5 is shown in (Figure 4). 
Cyclization resulted in enhanced serum stability compared to the linear form of chlorotoxin when 
conjugated with Cy5.5. 
 
Recently, other targets of chlorotoxin have been reported, including proliferating vascular 
endothelial cells, where chlorotoxin can play a role in inhibiting angiogenesis. The anti-angiogenic 
activity was not obstructed in the presence of angiogenesis stimulating factors such as VEGF 
(vascular endothelial growth factor), whereas the activity of the current anti-VEGF antibody 
therapeutic, bevacizumab, was reduced (75). Co-administration of chlorotoxin and bevacizumab 
significantly decreased blood vessel formation in tumors (75). Annexin A2 was recently proposed 
to be another potential target for chlorotoxin on tumor cell surfaces (76). Annexin A2 is expressed 
in a wide range of tumor cells and plays a role in tumor recurrence (77). It is also expressed in 
vascular endothelial cells and a part of regulation of angiogenesis (78). Taking its multi-target 
activity into consideration, chlorotoxin has great potential to be used in a variety of ways as a 
therapy for cancer. The cyclic derivatives are currently being developed in our laboratory offer 
potential for enhancing these applications. 
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Figure 4. Schematic illustration of chlorotoxin (PDB 1CHL) cyclization and conjugation with 
cy5.5 (A) Sequence of chlorotoxin including 7-amino acid linker and its disulfide bond connectivity 
(B) Natural linear chlorotoxin results in mono-, di-, and tri-labeled products when conjugated with 
Cy5.5 whereas cyclic chlorotoxin is only mono-labeled (74). Figure taken from Cemazar et al (47). 
 
 
1.5.    Sortase A 
1.5.1. Discovery, recombinant expression, and structure of sortase A 
Sortase A (SrtA) is a transpeptidase consisting of 206 amino acids. Its mechanism of action was 
found in the process of understanding how Staphylococcus aureus displays cell surface proteins. 
These proteins present a NH2-terminal domain on the cell surface, while anchoring the COOH-
terminus including conserved LPXTG motif to the bacterial cell wall (79). The LPXTG motif has 
an crucial role in the anchoring mechanism of the staphylococcal cell surface protein as it is a 
specific site to be recognized by SrtA. Transpeptidase SrtA cleaves the peptide bond between Thr 
and Gly in the LPXTG motif so that Thr can form a new peptide bond with pentaglycine 
crossbridge in the cell wall (80,81). In the process, a thioacyl intermediate is found as a single 
cysteine (Cys184) on the active site of SrtA forms a thioester with the threonyl carboxyl end. (80-
82). The intermediate subsequently is resolved by the amino group of pentaglycine crossbridge in 
the cell wall via a new peptide bond. 
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Understanding the rationale of activity and sequence of SrtA enabled its recombinant expression 
which is subsequently led to its structure determination. Recombinant expression was possible by 
removing 59 amino acids on the N-terminus including the transmembrane domain of native SrtA, 
and a fully functional recombinant SrtA was achieved via bacterial cell culture with high yield  
(82,83). The structure of SrtA, resolved using nuclear magnetic resonance and X-ray 
crystallography (84,85) revealed eight stranded β-barrel folds. Histidine in the active site of SrtA 
was initially reported to form a thiolate-imidazolium ion pair with cysteine, and participate in 
nucleophilic attack by protonating the amide atom of the substrate peptide for Cys/Ser proteases to 
act (84). Although Cys184 and His120 are conserved in all sortases, later studies found the histidine 
in the active site of SrtA was uncharged, and thus, does not function as a protonator/deprotonator 
(85,86). Instead Arg197 is positioned in a catalytic dyad with Cys184. In the same study, calcium 
binding sites were also determined based on other cysteine proteases (85).  
 
 
1.5.2. Application of sortase A  
The first application of SrtA was anchoring heterologous proteins to the cell wall of Gram-positive 
bacteria via a genetic fusion of the sorting motif to the protein. The heterologous protein decorates 
the bacterial cell surface with help from endogenous SrtA and this led to an understanding of the 
protein sorting and anchoring mechanism in bacteria and the application of bacteria in vaccination 
(79,87,88).  
 
Due to its site-specific activity and ready recombinant expression, SrtA has been widely used in 
protein engineering over the last decade. It has been especially useful in labeling proteins at their N- 
or C- terminus (83). In the case of C-terminal labeling of a protein, the LPXTG motif is placed at 
the C-terminus and a probe containing a NH2-Glyn is required (Figure 5A). Similarly, for N-
terminal labeling, a protein to be labeled requires Glyn at its N-terminus and the LPXTG motif 
needs to be added to the probe. Such SrtA-mediated N- or C-terminal labeling can overcome 
limitations of traditional genetic approaches. While these genetic approaches allow two protein 
fusion in a head-to-tail fashion, the site-specific SrtA reaction allows unusual protein fusion 
techniques such as N-to-N and C-to-C fusion in combination with click chemistry by incorporating 
cyclooctyne and azide for conjugation (89). There are two advantages when using this tool. Two of 
the same or two different proteins can be folded prior to conjugation, whereas recombinant 
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expression following genetic fusion may result in incorrectly folded side products requiring a 
refolding step. In addition, fusion proteins achieved via this approach can possess bispecific 
functions (89).  
 
Finally, SrtA can be used in head-to-tail backbone cyclization in protein or peptide engineering (90-
93) (Figure 5B). Backbone cyclization is known to improve the in vivo half-life of proteins (12). To 
date, this cyclization has mostly been achieved by native chemical ligation (NCL) (94,95), or by 
split-intein methods performed in conjunction with NCL (96-98). Whereas NCL and split-intein 
methods require chemical modifications to generate a thioester linker, SrtA-mediated cyclization 
requires a modest modification with an N-terminal oligoglycine nucleophile and a C-terminal 
LPXTG motif. The high efficiency and general applicability of SrtA-mediated cyclization was 
confirmed in initial studies on a variety of proteins, including Cre recombinase (~41 kDa), eGFP 
(~30 kDa), the loop of the ubiquitin C-terminal hydrolase UCHL3 (~26 kDa), and p97, which is a 
hexameric AAA-ATPase (~97 kDa) (90). In addition, Popp et al. showed that a cyclized cytokine 
was more resistant to thermal denaturation than its linear counterpart (93), and that SrtA-mediated 
cyclization could improve the therapeutic properties of some proteins (93). Indeed, the method was 
subsequently applied to the 38-mer peptide, histatin, with the cyclic version showing significantly 
improved wound closure activity (91). The study also pointed out factors to be considered when 
cyclizing peptides. First, active domains should not be located at N- or C-termini to maintain 
biological activities of peptides. Second, peptide ligands should adopt their bioactive conformations, 
i.e., the conformation that occurs after initial binding to the receptor (91,99). Third, the minimum 
length for linear SrtA substrates is 12 amino acids, excluding the sorting motif and glycine 
nucleophile (100). Finally, the length and region of the protein fragment used for cyclization can 
affect its activity (101). In addition, the minimum length for linear SrtA substrates is 12 amino acids 
excluding the sorting motif and glycine nucleophile (100), optimization of the length and region of 
protein fragment for cyclization resulted in improved or reduced activity (101). The summary of 
peptides and proteins cyclized using SrtA in recent years is shown in Table 1. 
 
Chapter 1. Introduction 
 
13 
 
 
Figure 5. Schematic representation of SrtA-mediated protein engineering (A) C-terminal 
labeling of a protein, (B) SrtA-mediated cyclization requires both sorting motif and nucleophilic 
Gly in the sequence of a protein. 
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Table 1. Proteins and peptides that have been cyclized using SrtA (adapted from van ‘t Hof et 
al (102)). 
  
  Substrate Description Structure Size Ref. 
re
co
m
bi
na
nt
 p
ro
te
in
 
G-Cre-LPETG-
His6 
human recombinase Two distinct domains 
forming a C-shaped clamp 
~41 kDa (90,103) 
G5-eGFP-
LPETG-His6 
Enhanced green 
fluorescent protein 
the N and C termini were 
positioned on the same end 
of the β-barrel 
~30 kDa (90) 
G-His6-p97-
LPETG-XX 
human hexameric 
AAA-ATPase 
N and C termini of 
adjacent p97 units were 
sufficiently close to permit 
covalent crosslinking 
~97 kDa (90) 
G-His6-UCHL3-
LPETG-XX  
human ubiquitin C-
terminal hydrolase 
sortase recognition site 
installed in the crossover 
loop 
~26 kDa (90) 
GG-GCSF-3-
LPETG-His6 
human granulocyte 
colony-stimulating 
factor 
A four-helix bundle 
structure 
~20 kDa (93) 
GG-IFNα2-
LPETG-His6 
human interferon-α A four-helix bundle 
structure 
~20 kDa (93) 
GG-EPO-
LPETG-His6 
human 
erythropoietin 
∼40% of its mass is 
composed of bulky, 
charged N-linked glycans 
~20 kDa (93) 
sy
nt
he
tic
 o
r r
ec
om
bi
na
nt
 p
ep
tid
e 
GG-histatin 1-
LPETGG 
human salivary 
peptide 
Lack of order in solution 
structure 
~ 5 kDa (91) 
GG-
VTGalNacSGalNac 
APDTGalNac-
LPKTGGS 
human MUC1 
glycopeptide 
N/A ~ 2 kDa (100) 
GGG-kalata B1-
TGG 
plant cyclotide Three disulfide bonds, 
cyclic cystine knot  
~3 kDa (92) 
G-αVc1.1-
GLPETGGS 
marine cone shell 
neurotoxin 
Two disulfide bonds, 
globular conformation 
~2.5 kDa (92) 
GG-SFTI-1-
LPETGG 
sunflower trypsin 
inhibitor 
One disulfide bond 
cyclic backbone 
~2.2 kDa (92) 
GG-LFcinB17-41-
LPETGG 
bovine lactoferricin N/A ~ 4 kDa (101) 
GGG-MCoTI-II-
LPETGG 
plant cyclotide Three disulfide bonds, 
cyclic cystine knot 
~3.5 kDa (104) 
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1.5.3. Mutagenesis of SrtA and improvement of SrtA reaction  
SrtA requires Ca2+ to be activite (84). In the study of Ilangovan et al., recombinant SrtA required 
about 2 mM of Ca2+ for activity whereas other divalent ions including Fe2+, Zn2+, Cd2+, and Co2+ or 
monovalent K+ cation resulted in SrtA not being able to cleave peptide bonds. The Ca2+ presumably 
binds to the β3-β4 loop and β6-β7 loop where glutamic acids with negative electrostatic surface 
potential exists in a structurally ordered site (84). However, how Ca2+ activates SrtA in vivo is not 
fully understood. Since the Ca2+-dependency can be an obstacle to using SrtA in an environment 
with low Ca2+ concentration such as the cytoplasm, or in the presence of Ca2+ binding compounds 
such as phosphate, carbonate, and ethylendiaminetetraactic acid (EDTA), Ca2+-independent SrtA 
was produced by making mutations on Ca2+ binding glutamic acids located on the β3-β4 loop 
(E105K/E108A or E105K/E108Q) (105).  
 
Another potential drawback of SrtA reaction is its poor catalytic efficiency. A strategy using a 
yeast-display system for evolving catalytic activity of the enzyme was applied to SrtA (106). This 
strategy isolated SrtA mutants with significantly improved Km values from 7.6 mM to 170 μM for 
the LPXTG motif (106), implying improved applicability of SrtA in protein engineering.     
 
Another characteristic of SrtA is that it functions as a hydrolase when there is no nucleophilic 
peptidoglycan or its mimics (107). Given that the product of the SrtA transpeptidation incorporates 
the  LPXTG motif which can be cleaved by SrtA, the hydrolysed side-product with a LPXT 
sequence has been a drawback in utilizing SrtA in protein engineering. Furthermore, the release of 
the Gly amine nucleophile from the original LPXTG substrate cleavage makes the SrtA reaction 
reversible (Figure 6A). Therefore, several studies have investigated how to overcome this 
reversibility of the SrtA reaction. Firstly, Li et al. (108) used a new nucleophile probe instead of 
Gly so that the SrtA reaction would not result in re-formation of the LPXTG motif in the product. 
Using hydrazine as a probe in the same SrtA reaction buffer, substrate proteins become 
hydrazinolysed thus avoiding recognition by SrtA (Figure 6B). Secondly, Row et al. found a way to 
improve efficiency of the SrtA reaction via removal of cleaved Gly from the LPXTG motif (109). 
Based on the fact that GGH has a high affinity for Ni2+ when present on the N-terminus of proteins 
or peptides (110), they used protein substrates equipped with a LPETGGH motif for SrtA in the 
presence of NiSO4 (Figure 6C) and observed the yield of final products was increased. Other 
approaches to overcome reversibility of the SrtA reaction include employing depsipeptides (Figure 
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6D) (111,112), a β-hairpin formation through the introduction of a Trp zipper around the LPXTG 
motif (Figure 6E) (113).    
 
 
Figure 6. Methods to improve the efficiency of the SrtA reaction. 
 
1.6. Summary and outlook 
Cyclotides are topologically very interesting as they are the only class of proteins known to contain 
the CCK motif. This motif confers them with exceptional stability and thus potentiates their 
applications as drug scaffolds. Their ability to tolerate sequence substitutions and modification has 
led to a range of cyclotide grafting studies, from which potential peptide drugs have been designed 
and demonstrated to have high stability and potency. Although none of the cyclotides has yet 
reached the clinic, new approaches to produce or engineer them using an enzyme like sortase A 
could add more favorable biopharmaceutical properties to cyclotides and inspire additional 
applications to other classes of disulfide-rich peptides.  
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1.7. Scope of this thesis  
The broad aim of this thesis is to explore the application of sortase A in disulfide-rich peptide 
engineering, and particularly cyclotides and conotoxins were studied because of their properties 
such as exceptional stability and specific activities that are interesting from pharmaceutical 
perspectives. 
 
Chapter 1 of this thesis provides the background information to define the molecules studied and 
to highlight their importance. Chapter 2 describes the main experimental techniques that were used 
in this thesis, including solid-phase peptide synthesis (SPPS) and nuclear magnetic resonance 
spectroscopy. 
The synthesis of the cyclic peptides has been mostly achieved via native chemical ligation (NCL), 
which requires anhydrous hydrogen fluoride (HF) to release the peptide from the resin that was 
assembled based on Boc-SPPS and to remove their side chain protecting groups. Despite the 
advantages of Boc-SPPS, Fmoc-SPPS became more widespread than Boc-SPPS as it is generally 
safer by excluding handling HF in the process. To find an alternative way to produce cyclic 
peptides, Chapter 3 reports semi-enzymatic cyclization of disulfide-rich peptides. Following 
successful Fmoc-SPPS of several peptides that are not related and with different number of 
disulfide bonds, cyclization was achieved using srtA. Each peptide had LPXTG motif at their C-
terminus that SrtA can recognize and catalyze transpeptidation with oligoglycine equipped at the N-
terminus of the peptide.       
Encouraged by the successful sortase A-mediated cyclization, Chapter 4 reports on effective 
conversion of an ICK motif to a CCK motif using sortase A. κ-conotoxin PVIIA, which blocks 
Shaker K+ channel of Drosophila melanogaster and possesses an ICK structural motif was cyclized 
and its structure and activity relationships were analyzed. Cyclization of chlorotoxin, which 
comprises an ICK motif with an extra disulfide bond, was also studied as another example in this 
application.   
Chapter 5 explores the bacterial expression of a cyclotide to overcome a drawback found in the 
method reported in Chapter 3 and 4. As the semi-enzymatic method required separate steps for 
synthesis, folding and cyclization in which purification is necessary in between, a molecular 
biological approach was employed to express folded kalata B1 linear precursor in the bacterial 
periplasm which is an oxidative environment.       
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In Chapter 6, sortase A was applied for delivery of cyclotides to dendritic cells to examine the 
potential of cyclotides as vaccination material. Although peptides are not generally immunogenic, a 
cyclotide, McoTI-I and its variant could elicit antibody response in mouse when they were 
conjugated to a dendritic cell specific antibody. In the conjugation process, sortase A was used to 
modify the antibody and the cyclotides were conjugated via click chemistry. The immunization 
study and its western blot analysis shows potential applications of antibodies elicited by cyclotides.   
In summary, cyclization of disulfide-rich peptides and ligation of a cyclotide to another entity using 
SrtA have been investigated in this thesis. The work described in each chapter shows feasibility of 
the application of SrtA in engineering disulfide-rich peptides and a potential for bacterial 
expression of cyclotides.   
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2. Peptide synthesis and nuclear magnetic resonance (NMR) spectroscopy 
2.1. Overview 
This chapter describes the main general experimental techniques that were used in this thesis, i.e., 
solid-phase peptide synthesis performed either manually or using an automated peptide synthesizer 
and nuclear magnetic resonance (NMR) spectroscopy for peptide structure determination. 
Experimental techniques specific for individual projects can be found in the corresponding chapters. 
 
2.2. Solid-phase peptide synthesis 
2.2.1. Synthesis procedure 
All peptides described in this thesis were synthesized using fluorenylmethyloxycarbonyl (Fmoc) 
chemistry. Rink amide 4-methylbenzhydrylamine (MBHA) was used when a C-terminal amide was 
required after cleavage of peptide from the resin otherwise 2-chlorotrityl chloride (CTC) resin was 
used. The resin was swelled in DMF for 30 min prior to synthesis and the Fmoc protecting group 
was removed with 20% piperidine in DMF (2 x 5 min). Amino acid (4 eq) were activated by 
dissolving in 0.5 M 2-(1Hbenzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate 
(HBTU) in DMF and N,N-diisopropylethylamine (DIPEA) (4 eq) was added. Each coupling 
(except proline) was subjected to a ninhydrin test which is based on the fact that primary amines 
react with ninhydrin generating a blue-colored product, thus allowing a check of coupling 
efficiency to ensure that no free primary amines remained (1,2). Briefly, the procedure included 
adding 2 drops of 76% w/w phenol in ethanol, 4 drops of 0.2 mM potassium cyanide (KCN) in 
pyridine, and 2 drops of 0.28 M ninhydrin in ethanol to a small amount of the resin followed by 
incubation at 95 °C for 5 min. When coupling efficiency was low even after repeating the coupling 
step with the same amino acid, the N-terminus of the peptide was acetylated by treating the resin in 
6% acetic anhydride/0.2M DIPEA/DMF for 2 x 15 min Following coupling of the last amino acid 
(i.e. first residue at the N-terminus) and final deprotection by 20% piperidine, the resin with peptide 
assembled on it was thoroughly washed with DMF, followed by DCM. The resin was dried by 
nitrogen (1 h) to prevent air oxidation of thiol groups. Figure 1 shows a schematic illustration of the 
peptide synthesis procedure based on Fmoc-chemistry. 
 
2.2.2. Peptide cleavage 
The advantage of the Fmoc-solid phase peptide synthesis (SPPS over BOC (tert-butyloxycarbonyl)-
SPPS is that peptides can be cleaved using mild acidic conditions while BOC-SPPS requires the use 
of hydrogen fluoride (HF). Fmoc cleavage conditions typically requires 95% TFA/2.5% TIPS 
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(scavenger)/2.5% water in which the resin is incubated for at least 2 h. The TFA is evaporated using 
a rotary evaporator and the released peptide is precipitated with ice-cold ether.  
 
 
Figure 1. Overview of Fmoc-solid phase peptide synthesis (SPPS). Fmoc is a Nα-protecting 
group that is base-labile and acid-stable. Amino acid building blocks with the Fmoc protecting 
group usually have a side-chain protecting group that is also acid-labile and cleaved after 
completion of synthesis unless it requires selective deprotection (eg. Acm for Cys). The synthesis 
proceeds from the C- to the N-terminus and it can be fully automated using peptide synthesizer. 
 
 
2.2.3. Fmoc-based synthesis of cyclotides 
Cyclotides studied in our laboratory have, until recently, been produced by thioester-mediated 
native chemical ligaion (NCL). As the thioester-linker is base-labile, Boc-SPPS has been used (3-5) 
instead of Fmoc-SPPS, which requires piperidine for deprotection of each amino acid. Boc-SPPS 
allows attachment of a thioester linker to a peptide on resin, which subsequently can make a peptide 
bond with a thiol group of N-terminal Cys. In spite of the usefulness of NCL, alternative methods 
for cyclization/ligation are desirable as Boc-SPPS requires repetitive use of highly corrosive TFA to 
remove the Boc-protecting group of each amino acid, which complicates the use of automated 
peptide synthesizers (6). The use of highly toxic HF to release peptides from resins is another 
drawback of Boc-SPPS. Furthermore, as fluorophores, click handles (such as azides), and diazirine-
based photoaffinity labels are HF-sensitive, the subsequent use of these peptides for in vitro or in 
vivo assays is restricted (7). Therefore, many ligation methods compatible with Fmoc chemistry 
have been developed in recent years using various thioester surrogates (6-13). Following Fmoc-
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based synthesis of cyclotides via thioesterification and NCL (13,14), a straightforward, in-solution 
cyclization method was reported (7). The procedure includes peptide chain assembly, peptide 
cleavage from the 2CTC resin, head-to-tail cyclization with the side-chain protecting groups 
remaining on the amino acids, deprotection of side chains, and oxidation of cysteines. This method 
is particularly advantageous because it does not require an N-terminal cysteine or a thioester linker. 
Therefore, peptides that did not require enzymatic cyclization in this thesis were made using Fmoc-
based cyclization (7).  
 
Firstly, peptides were synthesized by Fmoc SPPS with a Symphony automated peptide synthesizer 
(Protein Technology Inc, USA) using standard protocols. After final deprotection of the terminal 
Fmoc group, the dried resin was treated with 5 mL of 1% TFA in DCM (v/v) for 5 min in a reaction 
vessel and this step was repeated 10 times. The eluate contained peptides released from the resin 
but with the side-chain protecting group still attached. This was collected in a round-bottomed flask 
containing 150 mL of 50% ACN, 0.05% TFA in water (v/v) since DCM is highly volatile. Prior to 
lyophilizing the peptide, residual DCM and TFA were removed using a rotary evaporator. For 
cyclization, the lyophilized peptide was dissolved in DMF at a concentration of 2 mM and 
N,N,N’,N’-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU) was 
added to a final concentration of 5 mM. In addition, 10 mM DIPEA was added after HATU was 
completely dissolved. The reaction was stirred for 3 h at room temperature, diluted with twice the 
volume of 50% ACN (0.05% TFA) and lyophilized overnight. Side-chain deprotection was carried 
out as described in the section on peptide cleavage. Figure 2 summarizes the procedure with 
schematic illustrations.  
 
2.3. NMR spectrometry 
All peptides were analysed using a Bruker 500 MHz or Bruker 600 Avance MHz spectrometer 
equipped with a cryoprobe. Following acquisition, spectra were processed using Topspin (Bruker, 
Germany). For each experiment, a one-dimensional spectrum was initially run as it gives an 
indication of peptide folding status. However, for a peptide containing ~30 amino acids, a one-
dimensional spectrum often displays overlapped peaks. Therefore two-dimensional experiments 
such as TOCSY and NOESY were usually run to resolve peak overlap. Further details of two-
dimensional experiments required for structure calculation of peptides are discussed in the 
following sections. 
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Figure 2. Fmoc-based cyclization of disulfide-rich peptides. The procedure includes peptide 
chain assembly, peptide cleavage from the 2CTC resin, head-to-tail cyclization with side-chain 
protecting group remained on amino acids, deprotection of sidechains, and oxidation of cysteines. 
 
 
 
2.3.1. TOCSY  
Total correlation spectroscopy (TOCSY) (11), also known as Hartmann-Hahn spectroscopy 
(HOHAHA) (15), shows all protons of one spin system while correlated spectroscopy (COSY) (16) 
shows protons directly connected (Figure 3). The characteristic pattern from each amino acid on F1 
axis of TOCSY spectra allows identification of an amino acid. Amino acids such as Ala, Gly, Val, 
Glu, Gln and Pro display particularly distinctive chemical shifts and are good starting points for 
sequential assignment. Therefore, TOCSY is commonly used for structural analysis, D2O exchange, 
temperature and pH titration experiments (17).  
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Figure 3. An example of TOCSY and COSY. Signals of threonine on the diagonal divide the 
spectrum in two equal halves. Symmetrical to this diagonal (another half not shown), cross signals 
are generated by TOCSY (red) or COSY (green). TOCSY shows all protons of one spin system 
while COSY shows protons directly connected.   
 
 
2.3.2. NOESY  
Nuclear Overhauser effect spectroscopy (NOESY) allows the identification of protons at a distance 
of less than 5 Å apart (18). In other words, NOESY experiments produce peaks based on spatial 
couplings by using the dipolar interaction of spins, nuclear Overhauser effects (NOE), for protons. 
The intensity of the NOE is proportional to 1/r6, with r representing the distance between protons. 
The NOESY experiment correlates not only protons that are in close proximity, but also protons of 
amino acids that are distant in the sequence but spatially close due to tertiary structure. Therefore, 
NOESY is the most crucial spectral tool to determine protein structures. Access to TOCSY and 
NOESY spectra will allow for the sequential assignment of a peptide, which is typically followed 
by the assignment of non-sequential peaks.  
 
2.3.3. Dihedral angle restraints 
The backbone conformation of a peptide is determined by the dihedral angles, i.e., ϕ, ψ, and ω, of 
each amino acid. Because peptide bonds are usually in the trans conformation and the ω angle is 
thus assumed to be 180°, mainly the values of ϕ and ψ need to be determined from experiments. 
The ϕ angle restraints of a peptide backbone can be determined from the 3JHα-HN couplings derived 
from a double-quantum filtered correlation spectroscopy (DQF-COSY), or a one dimensional 
spectrum if the signals in the region of HN are not overlapped. The correlation between the 
observed coupling constant (3J) and dihedral angle, ϕ, (Figure 4A) is based on the Karplus equation 
(Figure 4B) (19). In general, the value of ϕ ranges from -30° to -180° (20) and it is common to set 
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the value of ϕ at -120 ± 30° for 3JHα-HN >8 Hz and -60 ± 30° for 3JHα-HN <6 Hz in structure 
calculation. In addition, secondary structures of a peptide tend to have characteristic values of 
coupling constant such that 3JHα-HN >8 Hz for β strands, and 3JHα-HN <6 Hz for α-helix (Figure 4C) 
(21).  
 
 
Figure 4. (A) Newman projection showing the concept of dihedral angle, ϕ (B) The Karplus 
equation. A, B, and C are experimentally determined parameters whose values are variable 
depending on the atoms and substituents involved. The original paper determines them as A=4.22, 
B=-0.5 and C=4.5 (19), (C) Relationship of coupling constant 3JHα-HN and backbone dihedral angle 
ϕ (19,22). Approximate values of ϕ associated with secondary structures (α helix and β sheet) are 
highlighted in grey and these two elements determine values of 3JHα-HN <6 Hz, 3JHα-HN >8 Hz 
respectively (21,23). 
 
 
The ψ backbone dihedral angle is not as readily experimentally measurable as ϕ because the relative 
coupling constants are usually small (23). However, it is possible to estimate both ϕ and ψ via the 
TALOS program (24,25), which is based on the fact that conformation affects secondary chemical 
shifts of the 1Hα, 13C, 13Cα, 13Cβ, and amide nitrogen nuclei (26-28). Therefore, the TALOS 
program searches the best match in a protein database to predict both dihedral angles using 
chemical shifts given as input (29).   
 
In addition to the backbone dihedral angles, the sidechain dihedral angle χ1 provides important 
information for structure calculation. For amino acids with a β-methylene group χ1 can be 
determined by measurement of 3JHαHβ2 and 3JHαHβ3 and stereospecific assignment of β-methylene 
protons can be achieved in combination with certain NOEs patterns. The coupling constants usually 
correspond to one of the three possible staggered rotamers, in which each atom attached to Cβ is 
either in one of the two gauche positions relative to Hα or in the trans position (Figure 5). To 
measure 3JHαHβ experimentally, exclusive correlation spectroscopy (ECOSY) (30) is used, which is a 
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modified COSY experiment but simplifies the multiplet structure of the Hα-Hβ crosspeaks, 
however spectral overlap is often found for large proteins. 
 
 
Figure 5. Newman projections of the three possible staggered conformers for the χ1 dihedral angle. 
χ1 can be defined from information combining 3JHαHβ2 and 3JHαHβ3 coupling constants and NOE 
intensity. 
 
 
 
2.3.4. Hydrogen bonds 
 
There are two main methods to identify protons that are shielded from the solvent and therefore 
potentially involved in hydrogen bonding. These two methods are D2O exchange experiments and 
temperature coefficient experiments.  
 
D2O exchange experiment 
Hydrogen bond restraints can be identified by D2O exchange, in which amide protons will 
exchange rapidly if they are not involved in a hydrogen bond. The exchange rates are usually 
measured by recording a series of 1D and/or TOCSY spectra immediately after dissolving the 
peptide sample in 100% D2O whereby slow-exchanging amide protons can be traced over time. 
Protons buried within the peptide structure or involved in a hydrogen bond will exchange with 
deuterium at a slower rate compared to those exposed to the surface (31). In such deuterium 
exchange experiments, it is only the hydrogen bond donor that is detected, so preliminary structures 
are required to identify H-bond acceptors. Protons still present after >4 h are considered shielded 
and thus possibly involved in hydrogen bonding.   
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Temperature coefficient experiment 
Temperature coefficients measure the rate of change of amide proton chemical shifts with 
temperature. A slow rate of the change indicates protection of amide protons from solvent by being 
involved in hydrogen bonds. The most common interpretation is that a temperature coefficient 
value less negative than -4.5 ppb/K is indicative of HN solvent protection (32).  
 
2.3.5. Structure calculation 
After obtaining chemical shifts, dihedral angles, and hydrogen bonds, the structure of a peptide can 
be calculated using programs including CYANA, which produces a set of preliminary structures 
(33). Those structures need to be refined using programs such as CNS (34) which use more rigorous 
molecular dynamics and includes solvents. In general, the angles and distance restraints that violate 
the restraints set within the program are corrected or removed, and final structures with the lowest 
overall energies are chosen. These structures are analyzed in MolMol (35) to calculate the overall 
root-mean-square deviations (RMSD), which is a good indicator of structural precision. Finally, the 
quality of the structures is judged by Molprobity (this can be accessed online at 
http://molprobity.biochem.duke.edu) (36), which generates a report including a Ramachandran plot 
with bond angles, dihedral angles and unfavorable sidechain rotamers.   
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Background: Sortase A (SrtA) is a transpeptidase capable of catalysing the formation of amide bonds. 
Results: SrtA was used to backbone cyclize disulfide-rich peptides including kalata B1, α-conotoxin Vc1.1 
and SFTI-1. 
Conclusion: SrtA-mediated cyclization is applicable to small disulfide-rich peptides. 
Significance: SrtA-mediated cyclization is an alternative to native chemical ligation for the cyclization of 
small peptides of therapeutic interest. 
Keywords: cyclic peptides, cyclotides, enzymatic cyclization, sortase A, kalata B1  
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3.3. Abstract 
Disulfide-rich cyclic peptides have generated great interest in the development of peptide-based therapeutics 
due to their exceptional stability toward chemical, enzymatic, or thermal attack. In particular, they have been 
used as scaffolds onto which bioactive epitopes can be grafted to take advantage of the favorable biophysical 
properties of disulfide-rich cyclic peptides. To date, the most commonly used method for the head-to-tail 
cyclization of peptides has been native chemical ligation. In recent years, however, enzyme-mediated 
cyclization has become a promising new technology due to its efficiency, safety, and costeffectiveness. 
Sortase A (SrtA) is a bacterial enzyme with transpeptidase activity. It recognizes a C-terminal penta-amino 
acid motif, LPXTG, and cleaves the amide bond between Thr and Gly to form a thioacyl-linked intermediate. 
This intermediate undergoes nucleophilic attack by an N-terminal poly-Gly sequence to form an amide bond 
between the Thr and N-terminal Gly. Here, we demonstrate that sortase A can successfully be used to cyclize 
a variety of small disulfide-rich peptides, including the cyclotide kalata B1, α-conotoxin Vc1.1, and 
sunflower trypsin inhibitor 1. These peptides range in size from 14 to 29 amino acids and contain three, two, 
or one disulfide bond, respectively, within their head-to-tail cyclic backbones. Our findings provide proof of 
concept for the potential broad applicability of enzymatic cyclization of disulfide-rich peptides with 
therapeutic potential. 
 
3.4. Introduction 
Disulfide-rich cyclic peptides are generating great interest in the field of drug design because of their 
remarkable stability toward enzymatic, thermal, or chemical attack (1). Additionally, anecdotal evidence of 
some of them being orally bioavailable in indigenous medicine applications (2) has recently received support 
from studies demonstrating oral activity of engineered cyclic peptides in animal pain models (3, 4). Several 
classes of cyclic peptides, including the sunflower trypsin inhibitors and cyclotides, have now been 
discovered in a variety of plant species (5). In addition to the plant-derived cyclic peptides, disulfide-rich 
peptides isolated from cone snails, including α-conotoxins, have successfully been cyclized (3, 6) and are 
showing promise as potential treatments for neuropathic pain (3). Sunflower trypsin inhibitor 1 (SFTI-1) 
comprises 14 amino acids with a head-to-tail cyclized backbone. It was isolated from sunflower seeds and 
specifically inhibits trypsin activity at 0.1 nM (7), which makes it the smallest and most potent serine 
proteinase inhibitor known. It was also reported to have inhibition activity against the epithelial serine 
protease matriptase at subnanomolar concentration (8). Its structure consists of two antiparallel β-strands 
connected by an extended loop and a sharp hairpin turn containing a cis-proline residue. The β-strands are 
constrained by a single disulfide bond, which stabilizes the molecule and divides it into two regions: the 
active site loop and the cyclization loop (7) (Fig. 1A). 
 
Cyclotides are characterized by the combination of head-totail backbone cyclization and six conserved Cys 
residues forming a distinctive disulfide linkage pattern in which one disulfide bond passes through a ring 
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formed by two other disulfide bonds (9, 10) (Fig. 1B). The combination of a cyclic backbone and a knotted 
arrangement of three disulfide bonds is known as the cyclic cystine knot motif, and this motif is believed to 
be responsible for the exceptional stability of cyclotides toward chemical, enzymatic, or thermal degradation 
(1). Although thought to have a natural function as defense molecules in plants via their pesticidal activities 
(11–13), cyclotides possess a range of pharmaceutically interesting biological activities, including uterotonic 
(2), anti-HIV (14), antimicrobial (15), and insecticidal (11,16) activities, and are cytotoxic to tumor cells (17, 
18). Thousands of cyclotides are thought to exist in nature, and more than 250 sequences have been 
described so far (see the CyBase Web site) (19), making them one of the most abundant plant protein 
families discovered. 
 
Cyclotides are able to accommodate the synthetic introduction of a range of biologically active sequence 
motifs in the backbone loops between the conserved Cys residues while retaining thermal, chemical, and 
enzymatic stability. This toleranceto sequence substitutions makes them ideal scaffolds for the development 
of stable peptide-based drugs incorporating epitopes of therapeutic value. For example, a kB1 hybrid, with 
an anti-angiogenic epitope incorporated into loop 3, combined anti-angiogenic activity with the native 
stability of kB1 (20). Likewise, molecules possessing activity against foot-and mouth disease (21), inhibitory 
activity against β-tryptase and human leukocyte elastase (22), angiogenic activity (23), and the ability to 
antagonize intracellular p53 degradation (24) have also been achieved by grafting relevant bioactive epitopes 
into the cyclotide MCoTI-I or MCoTI-II. The capacity to target intracellular sites is consistent with a range 
of recent biophysical studies demonstrating the ability of disulfide-rich cyclic peptides to internalize into 
cells (24–28). As well as being valuable scaffolds, naturally occurring cyclic peptides, such as cyclotides and 
SFTI-1, have inspired the concept of using artificial head-to-tail backbone cyclization as a stabilizing 
strategy for peptides and proteins of therapeutic interest (3, 6). For example, Clark et al. (3) showed that 
cyclization of α-conotoxin Vc1.1, a potential neuropathic pain treatment, endowed it with oral activity. Thus, 
great interest has been shown in the development of cost-effective and efficient methods for the N- to C-
terminal backbone cyclization of synthesized or expressed proteins (29, 30). In the case of cyclic Vc1.1 
(cVc1.1), the termini of the naturally occurring 16-residue peptide were covalently linked using a 6-amino 
acid linker, as illustrated in Fig. 1C (3). 
 
Currently, the most widely used strategy for backbone cyclization of synthetic peptides is native chemical 
ligation (NCL) (31, 32), which utilizes an N-terminal cysteine and a functionalized C terminus to form a 
thioester-linked intermediate that undergoes an S,N-acyl migration to form a native peptide bond (32). In 
general, peptides are synthesized using solid phase peptide synthesis, using either t-butoxycarbonyl or Fmoc 
protection. Despite the usefulness of NCL for splicing or cyclizing protein, there is still a demand for 
alternative methods of amide bond formation that are chemoselective, rapid, cheap, safe, and waste-free (30). 
Moreover, the requirement for an N-terminal cysteine and a C-terminal thioester in NCL is not always 
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compatible with Fmoc solid phase peptide synthesis or recombinant expression. Accordingly, a number of 
different approaches to backbone cyclization have been developed (29), including expressed protein ligation 
(33, 34), intein-mediated protein trans-splicing (35), and genetic code reprogramming (36).  
 
Recently, a family of thiol-containing transpeptidases, known as the sortases, was found to successfully 
cyclize linear proteins (37–40). Sortases are found in most Gram-positive bacteria, where their primary 
function is to attach surface proteins to the bacterial cell wall (41). This ligation reaction has been exploited 
for a variety of protein engineering purposes, in most cases utilizing sortase A (SrtA) from Staphylococcus 
aureus (42). SrtA recognizes a 5-residue sequence motif, LPXTG, and cleaves the peptide bond between the 
Thr and Gly residues, forming an acyl enzyme intermediate between a cysteine at the active site of SrtA and 
the carboxylate at the truncatedCterminus of the substrate (43, 44). Although in a natural system, this 
covalent intermediate is resolved by nucleophilic attack from a pentaglycine side chain in a peptidoglycan 
precursor, a variety of glycine-based nucleophiles can activate SrtA-catalyzed transpeptidation (38). The 
result is the efficient attachment of various moieties to the protein substrates, and this process has been 
applied to site-specific protein labeling (45), PEGylation (46), protein thioester generation (47), and protein-
protein fusion (48). When such glycine-based nucleophiles originate from the N terminus of the substrate, 
intramolecular transpeptidation reactions occur to yield covalently closed (circular) polypeptides by amide 
bond formation between the two termini (38–40). So far, this approach has been examined only for a limited 
number of possible substrates and has not been explored for disulfide-rich peptides.  
 
In the current study, we demonstrate the efficient enzymatic cyclization of disulfide-rich peptides, including 
SFTI-1, cVc1.1, and kalata B1 (kB1), containing one, two, or three disulfide bonds, respectively, by SrtA 
without the need for a thioester linker and using Fmoc chemistry. This study provides a proof of concept that 
SrtA-mediated ligation can be utilized to cyclize disulfide-rich peptides ranging from the simple one-
disulfidecontaining SFTI-1 to the complex cyclic cystine knot-containing cyclotide structure of kB1 while 
retaining the native disulfide bond connectivity that is vital for the stability of these proteins. Fig. 1D 
summarizes the cyclization strategy for kB1. 
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Figure 1. (A) Representation of the sequence and structure (PDB code 1JBL) of native SFTI-1, (B) native 
kB1 (PDB code 1NB1), which is the prototypic cyclotide, (C) native linear Vc1.1 (PDB code 2H8S), which 
has been cyclized by a 6-amino acid linker using native chemical ligation (3, 32). The disulfide bonding 
network is shown as sticks, with the cysteine residues numbered. Amino acids are represented by their one-
letter code. (D) The linear oxidized [GGG]kB1[TGG] contains a SrtA recognition sequence (LPVTG) and 
undergoes an intramolecular transpeptidation reaction catalyzed by SrtA to form cyclo-[GGG]kB1[T].  
 
 
3.5. EXPERIMENTAL PROCEDURES 
3.5.1. Peptide Synthesis 
The linear peptides [GGG]kB1[TGG], [G]Vc1.1[GLPETGGS], and [GG]SFTI-1[LPETGG] were 
synthesized by solid-phase peptide synthesis using an automatic peptide synthesizer (Symphony®, Protein 
Technologies, Inc.) following standard Fmoc chemistry on a 2-chlorotrityl chloride resin. Acetamidomethyl 
(Acm) protecting groups were used on Cys4 and Cys17 of [G]Vc1.1[GLPETGGS] for selective disulfide 
bond (CysII–CysIV) formation. Cleavage of the peptide from the resin was achieved using trifluoroacetic acid 
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(TFA)/triisopropylsilane/water (95:2.5:2.5) at room temperature for 2 h. The TFA was evaporated, and the 
peptide was precipitated with ice-cold diethyl ether and dissolved in 50% acetonitrile (ACN) containing 0.05% 
TFA and lyophilized. Wild type Vc1.1 and SFTI-1 were prepared as described previously (3, 49). 
SrtA Expression—The plasmid of and recombinant expression protocol for S. aureus SrtA, which comprises 
the catalytic domain (residues 60–206 with an N-terminal hexahistidine tag), was as described by Popp et al. 
(50). Briefly, an overnight culture of Escherichia coli BL21 (DE3) transformed with SrtA plasmid was 
cultured in the presence of kanamycin (50 μg/ml) until A600 reached ~0.7. The protein expression was 
induced by adding isopropyl β-D-thiogalactopyranoside to a final concentration of 1mM for 3 h at 37 °C. 
The cells were then harvested by centrifugation at 7000 x g at 4 °C for 10 min. Cells were then resuspended 
in ice-cold lysis buffer (50 mM Tris-HCl, pH 8.0, 150mM NaCl, 25mM imidazole, and 10% glycerol) and 
lysed by passing through a cell disrupter (TS Series Bench Top) operating at 26,000 p.s.i. The cell debris was 
removed by centrifugation at 12,000 x g at 4 °C for 30 min. The lysate was subjected to immobilized metal 
ion affinity chromatography using a 5-ml nickel-nitrilotriacetic acid FF column (GE Healthcare). The 
column was washed extensively with lysis buffer after sample loading, and SrtA was eluted with a linear 
gradient over 10 column volumes using elution buffer (50mM Tris-HCl, pH 8.0, 150 mM NaCl, and 500 
mM immidazole). Fractions containing SrtA were buffer-exchanged (50 mM Tris-HCl, 150 mM NaCl, and 
10% glycerol) and concentrated by using a centrifugal concentrator 
(<10 kDa). The SrtA was then stored at -80 °C until further use. The protein concentration was calculated by 
its extinction coefficient at 280 nm. 
 
3.5.2. Oxidative Folding 
The linear precursor [GGG]kB1[TGG] was oxidized in 50% isopropyl alcohol (v/v), 0.1 M NH4HCO3 with 1 
mM reduced glutathione at pH 8 for 20 h at room temperature (51). The progress of oxidation was monitored 
by analytical reversed-phase high performance liquid chromatography (RP-HPLC) with a gradient from 0 to 
50% ACN (0.05% TFA) in 50 min at a flow rate of 0.3 ml/min using an analytical C18 column (Agilent 
ZORBAX 300SB-C18, 5 μm, 2.1 x 150 mm). The oxidation yield was calculated based on HPLC profile. 
The mixture was then purified by RP-HPLC using a 0.5% gradient, and the molecular weight was confirmed 
by mass spectrometry. Native kB1 was isolated from Oldenlandia affinis as described previously (9, 52). 
Both linear precursor [G]Vc1.1[GLPETGGS] and cyclic reduced [G]Vc1.1[GLPET] were oxidized in 0.1 M 
NH4HCO3 at a 0.1 mg/ml concentration for 24 h to form disulfide bond CysI–CysIII. Purified Vc1.1 (both 
linear and cyclic) with one disulfide bond was then dissolved in 50% acetic acid to a final concentration of 
0.5 mg/ml under N2. Excess iodine dissolved (10 eq with respect to the Acm-protected Cys) in 50% acetic 
acid was added until the color of the reaction became yellow, and the reaction was left at room temperature 
for 24 h. The reaction was quenched by the addition of ascorbic acid until the solution became colorless, 
followed by RP-HPLC purification using a gradient of 0–60% acetonitrile in 60 min. 
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3.5.3. Cyclization 
The concentration of modified kB1 was determined by its molar extinction coefficient at 280 nm using 
NanoDrop2000c (Thermo Scientific). Linear oxidized [GGG]kB1[TGG] and linear precursor [GG]SFTI-
1[LPETGG] (150 μM) were incubated with SrtA (50 μM) in the reaction buffer (50 mM Tris, pH 7.5, 150 
mM NaCl, 10 mM CaCl2) at 37 °C until the reaction was completed. The cyclization progress was 
monitored using RP-HPLC with a gradient from 0 to 50% ACN (0.05% TFA) in 50 min at a flow rate of 1 
ml/min using an analytical C18 column (GraceSmartTM RP18, 5 μm, 4.6 x 150 mm). After completion of 
cyclization, the reaction was loaded to a semipreparative C18 column (Phenomenex, Jupiter 5UC18, 300 Å, 
250 x 10.0 nm, 5 μm), eluted with a gradient from 36 to 45% ACN (0.05% TFA) in 30 min at a flow rate of 
3 ml/min. The molecular mass of purified cyclo-[GGG]kB1[T] was confirmed by matrix-assisted laser 
desorption/ionization time of flight (MALDI-TOF). The fractions showing the correct mass were lyophilized 
for further assays. 
 
The concentration of Vc1.1 was also determined as described above. 10 μM linear precursor 
[G]Vc1.1[GLPETGGS] was incubated with 0.2 μM SrtA in the reaction buffer containing 10mM TCEP for 
24 h at 4 °C. SrtA was then removed from the sample using a 5-ml nickel-nitrilotriacetic acid FF column 
(GE Healthcare), and the flow-through containing cyclic reduced [G]Vc1.1[GLPET] was collected and 
purified by RP-HPLC for oxidation. 
 
Because there were no aromatic residues present, the concentration of SFTI-1 was determined at 214 nm 
using the NanoDrop2000c (Thermo Scientific) UV-visible function with the extinction coefficient calculated 
based on the equation, ε214 nm = (nAA ̶ 1 + nN + nQ)2846 + nF7200 + nH6309 + nW22735+nγ5755 (53). 150μM 
[GG]SFTI-1[LPETGG] and 50μM SrtA were incubated in the reaction buffer at 37 °C with pH adjusted to 
8.5 to form a disulfide bond at the same time. The progress of cyclization was monitored using analytical 
RP-HPLC with a gradient from 0 to 50% ACN (0.05% TFA) in 50 min at a flow rate of 1 ml/min using an 
analytical C18 column (GraceSmartTM RP18, 5 μm, 4.6 x 150 mm). 
 
3.5.4. Nuclear Magnetic Resonance Analysis 
Cyclo-[GGG]kB1[T] was dissolved in 90% H2O, 10% D2O (v/v) or 100% D2O to a final concentration of 1 
mM and pH 6.1 (54). Cyclo-[G]Vc1.1[GLPET] and cyclo-[GG]SFTI-1[LPET] were dissolved in 90% H2O, 
10% D2O (v/v) to a final concentration of ~1mM and pH 3.1. All two-dimensional nuclear magnetic 
resonance (NMR) spectra were acquired at 298 K. Spectra recorded for assignments and Hα secondary 
chemical shift analysis included TOCSY with an 80-ms mixing time and NOESY with a 200-ms mixing time. 
All spectra were acquiredon a Bruker Avance 600-MHz NMR spectrometer equipped with a cryogenically 
cooled probe (Bruker, Karlsruhe, Germany). 
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Water suppression for two-dimensional TOCSY and two-dimensional NOESY spectra were achieved by 
using excitation sculpting (55). Spectra were recorded with 2048 data points in the direct F2 dimension and 
600 increments in the indirect F1 dimension. Additional spectra recorded for cyclo-[GGG]kB1[T] to be used 
in full structure calculations were NOESY with a 100-ms mixing time as well as E.COSY (56), DQF-COSY, 
and 13C HSQC to produce the carbon chemical shifts. All spectra were processed using Topspin (Bruker) and 
analyzed by CCPNMR (57) and Xeasy (58). The temperature coefficients were determined from recording 
TOCSY spectra from 283 to 303 K in steps of 10 K. Chemical shifts were referenced to internal 2,2-
dimethyl-2-silapentane-5-sulfonate (DSS) at 0.0 ppm (59). The peaks in the NOESY spectra with mixing 
times of 100 and 200 ms were manually picked, intraresidual and sequential NOEs were assigned, and a full 
list of interproton distances was generated using the AUTO function in CYANA (tolerances used for 
CYANA were set to 0.02 ppm for both indirect and direct 1H dimension) (60). Several rounds of AUTO, 
including additional restraints, such as disulfide bonds, hydrogen bonds, and dihedral angle restraints derived 
from TALOS_, were run to ensure correct peak assignment. Hα, HN, Cα, and Cβ chemical shifts derived 
from 1H-1H NOESY and 1H-13CHSQCwere used to generate φ and ψ backbone dihedral angles using 
TALOS+(61). The ANNEAL function in CYANA was used to perform 10,000-step torsion angle dynamics 
to generate an ensemble from which 20 with the lowest penalty function were chosen for further analysis. 
Several rounds of ANNEAL were run to resolve distance and dihedral constraint violations. Using protocols 
from the RECOORD database (62), 50 structures were calculated using CNS (63) with force fields 
distributed with Haddock version 2.0 (64) and refined in a water shell (65) as described previously (66). A 
set of 20 structures with no NOE violations of greater than 0.3 Å and dihedral violations greater than 3.0º 
was chosen for MolProbity analysis (67). MOLMOL (68) was used for generating figures and final 
superimposition. 
 
3.5.5. Hemolytic Activity Assay on [GGG]kB1[T] 
The hemolytic assay was conducted as described previously (69). Briefly, erythrocytes were isolated from 
human blood and washed in phosphate- buffered saline (PBS, pH 7.4) with repeated centrifugation at 1500 x 
g. The hemolytic activities of cyclo-[GGG]kB1[T], linear oxidized [GGG]kB1[TGG], and kB1 were 
determined with eight concentration points from 300 to 1.17μM by serial dilution with a 2-fold interval with 
a final volume of 20 μL/well in a 96-well plate. Triton X-100 solution (1% (v/v), 20 μL) was used as a 
positive control to achieve the 100% lysis, and PBS solution (20 μL) was used as a negative control. 100 μL 
of erythrocyte stock solution was added to each well and incubated at 37 °C for 1 h. After centrifugation of 
intact cells from the 96-well plate, the supernatant of each well was measured by visual absorption 
spectroscopy at 415 nm. Each experiment was performed in triplicate. 
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3.5.6. Serum Stability Assay on [GGG]kB1[T] 
The stability of cyclo-[GGG]kB1[T] in human serum was evaluated using a method described previously 
(23). Briefly, human serum from maleABplasma (Sigma-Aldrich) was centrifuged at 17,000xg for 10 min to 
remove the lipid component. The resultant supernatant was collected and incubated for 15 min at 37 °C 
before the assay. Cyclo-[GGG]kB1[T], linear oxidized [GGG]kB1[TGG], and kB1 were tested at a final 
concentration of 20 μM. Stock solutions of peptides were diluted 1:10 with human serum, whereas the 
dilution with PBS was a negative control and a linear 12-mer peptide tested in parallel was a positive control 
of the peptidase activity of the serum. Controls and test peptides were incubated at 37 °C, and 40 μl of 
samples was taken for measurements at time points of 0, 1, 2, 3, 5, 8, 11, and 24 h. Serum proteins in 
samples were denatured with 40 μl of 6M urea at 4 °C for 10 min and precipitated with an additional 40 μl of 
20% trichloroacetic acid at 4 °C for 10 min. The supernatant containing peptides was recovered by 
centrifugation at 17,000xg for 10 min. 100 μl of supernatant from each time point of the serum-treated and 
PBS-treated (control) peptides was injected and analyzed in triplicate on an analytical RP-HPLC column 
(Phenomenex) at a flow rate of 0.3 ml/min with a gradient of 0–50% ACN over 50 min. The retention time 
for each peptide was determined by PBS control at the zero time point. The stability of each peptide at each 
time point was calculated as the percentage of the integrated peak area of the serum-treated peptide over that 
of the 0-h serum-treated peptide on RP-HPLC at 215 nm. 
 
 
3.6. RESULTS 
3.6.1. Protein Production and Purification 
Linear precursors, with a SrtA recognition motif (LPXTG) at the C terminus and an oligoglycine motif at the 
N terminus (full sequences as follows:[GGG]kB1[TGG], 
GGGCGETCVGGTCNTPGCTCSWPVCTRNGLPVTGG;[G]Vc1.1[GLPETGGS], 
GGCCSDPRCNYDHPEICGLPETGGS;[GG]SFTI-1[LPETGG], GGGRCTKSIPPICFPDLPETGG (with 
the native sequences in boldface type)), were assembled using automated Fmoc chemistry, cleaved from the 
resin with TFA, and purified using RPHPLC. No oxidation of cysteine residues was observed during the 
purification process, as determined using mass spectrometry. The molecular mass and purity were confirmed 
using mass spectrometry and analytical RP-HPLC, respectively. 
 
3.6.2. Oxidation and Cyclization of [GGG]kB1[TGG] 
In preliminary experiments two approaches were used to obtain oxidized, cyclic kB1 using SrtA-mediated 
cyclization. First, linear reduced [GGG]kB1[TGG] was cyclized using the SrtA reaction buffer but with the 
addition of a 2 mM concentration of the reducing agent TCEP. The peptide was then oxidized after 
completion of the cyclization reaction. Second, the linear peptide [GGG]kB1[TGG] was oxidized prior to 
cyclization with SrtA, which proceeded without the addition of reducing agent to the reaction buffer. 
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Cyclization prior to oxidation resulted in higher yields of cyclic reduced peptide as determined by RPHPLC 
(~80%; data not shown), but subsequent oxidative refolding yielded several isomers (<10% yield for each 
isomer; data not shown), presumably due to misfolding during the oxidation reaction. Oxidation prior to 
cyclization resulted in a predominance of correctly folded peptide, and this approach was therefore used for 
subsequent experiments. 
 
The oxidative folding of the linear precursor [GGG]kB1[TGG]was monitored by RP-HPLC (Fig. 2A), and 
the yield of correctly folded product was ~27% based on RP-HPLC peak integration. Following oxidative 
folding, linear [GGG]kB1[TGG] was purified by RP-HPLC, and the correct folding was confirmed by NMR 
analysis (data not shown). 
 
Cyclization of 150 μM linear oxidized [GGG]kB1[TGG] with 50 μM SrtA was monitored over 24 h using 
RP-HPLC (Fig. 2B). The reaction was not extended beyond 24 h due to the possibility of a competing 
hydrolysis reaction in which SrtA irreversibly hydrolyzes the LPVTG motif (70). After 24 h, ~49% of linear, 
oxidized [GGG]kB1[TGG] was converted to the cyclic product (highlighted in Fig. 2B). MALDI-TOF 
analysis of the highlighted peak fraction showed a monoisotopic mass (3162.92 Da) corresponding to that of 
cyclo-[GGG]kB1[T] (Fig. 2C), which was purified to _95% purity. Interestingly, the elution time of this 
peak (40.8 min) was similar to that of native kB1(Fig. 2D) despite the additional amino acids in the sequence. 
Apart from this peak, two other peaks, at ~37 and 40 min, appeared to be intermediate species in the 
cyclization reaction because their abundance over time was negatively correlated with the abundance of 
correctly folded cyclo-[GGG]kB1[T] (Fig. 2B). A small peak appearing at ~42.8 min contained a peptide 
with the mass corresponding to that of cyclo-[GGG]kB1[T]. This peak also increased during the course of 
the experiment and is most probably an alternatively folded form of the peptide (Fig. 2B). 
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Figure 2. (A) HPLC profile of [GGG]kB1[TGG] oxidation at 0 and 20 h. A major peak of linear precursor 
peptide and linear oxidised product is marked with schematic representation of the peptide. (B) Time course 
analysis of the SrtA reaction progress monitored by RP-HPLC. Aliquots were taken from the reaction 
mixture at 0, 4, 8, 12 and 24 h, and loaded onto an analytical RP-HPLC. MALDI-TOF analysis of cyclo-
[GGG]kB1[T] revealed a mass corresponding to the linear oxidised [GGG]kB1[TGG] minus two glycines 
and a water molecule, indicative of the formation of a amide bond between the N-and the C-terminal. (C) 
Analytical RP-HPLC profile of purified cyclo-[GGG]kB1[T]. 
 
 
3.6.3. Characterization of the cyclo-[GGG]kB1[T] by NMR 
The NMR signals of cyclo-[GGG]kB1[T] were well dispersed in the amide proton region, indicating that the 
peptide is folded and has a well defined structure. The individual amino acid spin systems were readily 
assigned using the sequential assignment procedure based on TOCSY and NOESY spectra (71). Cyclization 
was confirmed based on observation of a sequential αHi-HNi+1 NOE between Thr30 and Gly31, indicative of 
the amide linkage of the C-terminal LPVT and N-terminal GGG motif (Fig. 3,4). Chemical shifts are 
extremely sensitive to the local chemical environment, and H_ chemical shifts were thus used to compare the 
structure of cyclo-[GGG]kB1[T] with that of native kB1. Overall, the chemical shift differences between the 
two molecules are minimal (Fig. 3). With the exception of residues 1 and 27–33 (numbering system in Fig. 
3), which are in loop 6 and either very close to or part of the SrtA sorting motif, no other cyclo-[GGG]kB1[T] 
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residue exhibited significant deviations from the corresponding residue in native kB1. The very small shifts 
from random coil values for residues 1 and 27–33 of cyclo-[GGG]kB1[T] indicate that this region is 
disordered, and this was confirmed in the three-dimensional structure of cyclo-[GGG]kB1[T] (Fig. 5A). The 
solution structure was calculated using CYANA (60) followed by refinement in a water shell using CNS (63) 
based on 388 NOE distance restraints; 53 dihedral angle restraints, including 26 φ, 20 ψ, and 6 χ1 dihedral 
angle restraints; and five hydrogen bonds derived from temperature coefficient data (Table 1). The 20 
conformers with the lowest energy superimposed with a backbone root mean square deviation of 0.53 ±0.14 
Å across resides 1–24 (Fig. 5A). Comparison of the cyclo-[GGG]kB1[T] structure with that of native kB1 
(PDB code 1NB1) shows them to be very similar except for the more flexible loop 6 of cyclo-[GGG]kB1[T] 
(Fig. 5B). 
 
 
 
Figure 3. Hα secondary shift comparison of native kB1 (empty squares with dashed line) and cyclo-
[GGG]kB1[T] (filled squares with solid line). The Hα secondary shifts were calculated by subtracting 
random coil shifts from the experimental Hα shifts. The white box highlights loop 6, where the extra residues 
TGGG were introduced by the SrtA-mediated cyclization. 
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Figure 4. TOCSY spectrum (upper panel) and NOESY spectrum (lower panel, with enlarged HA region) of 
cyclo-[GGG]kB1[T] recorded at 298 K, 90% H2O/10% D2O. The upper panel shows the spin systems by 
vertical lines, except Trp19 which was not observable in the TOCSY, while the lower panel highlights the 
sequential walk, except for Pro13, Pro20 and Pro28. 
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Figure 5. (A) Superimposition of the 20 lowest energy structures of cyclo-[GGG]kB1[T] shown in blue with 
disulfide bonds shown in orange. (B) Comparison of cyclo-[GGG]kB1[T] in blue with native kB1 in red 
(PDB ID:1NB1) by superimposition of residues 1-24 of cyclo-[GGG]kB1[T] against residues 1-24 of the 
native kB1 structure. Disulfide bonds shown in orange. Highlighting the similarities between the two 
structures across loop 1-5 and the increased flexibility of loop 6 by insertion of the sSrtA sorting-motif. 
RMSD across heavy backbone atoms for residues 1-24 cyclo-[GGG]kB1[T] / 1-24 kB1 is 0.461.  
 
 
3.6.4. Hemolytic Activity and Serum Stability Assay on Cyclo- [GGG]kB1[T] 
Native kB1 possesses mild hemolytic activity (15, 51), which is undesired in a pharmaceutical context. Thus, 
to assess the effects of SrtA cyclization on the novel kB1 analog, the hemolytic activity of cyclo-
[GGG]kB1[T] and linear oxidized [GGG]kB1[TGG] was determined and compared with that of the native 
peptide. Compared with native kB1, both peptides exhibited significantly less hemolytic activity (Fig.6A). 
After 24h of incubation, 50μM native kB1 lysed 64% of human erythrocytes, whereas in the same time 
period, only 6 or2%of erythrocytes were lysed by the same concentration of cyclo-[GGG]kB1[T] or linear 
oxidized [GGG]kB1[TGG], respectively. The reduced hemolytic activity is consistent with previous 
mutagenesis studies on kB1, which showed that linearization or strategic replacement of certain residues can 
abrogate hemolytic activity (72, 73). 
 
To determine the effects of SrtA-mediated cyclization on the stability of the peptide, cyclo-[GGG]kB1[T] 
was incubated in human serum. Encouragingly, its stability was comparable with that of native kB1, with 
only a slight reduction in peptide survival observed. After a 24-h incubation, 77.4 and 95.9% of the starting 
concentration of cyclo-[GGG]kB1[T] and kB1, respectively, was still present (Fig. 6B). Interestingly, 71% of 
linear oxidized [GGG]kB1[TGG] also remained in human serum after 24 h. In contrast, a linear 12-mer 
control peptide, without any disulfide bond, was completely degraded within the first 1 h. 
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Figure 6. Hemolytic and serum-stability assay on cyclo-[GGG]kB1[T]. (A) Percentage of hemolysis by 
cyclo-[GGG]kB1[T] compared to native kB1 included as a positive control. (B) Percentage of peptide 
remaining after 0, 1, 2, 3, 5, 8, 11 and 24 h incubation in human serum. The data are presented as means ± 
standard deviation (SD). 
 
 
3.6.5. Oxidation and Cyclization of [G]Vc1.1[GLPETGGS] 
α-Conotoxin Vc1.1 was successfully synthesized with a SrtA sorting motif at the C terminus and an 
additional Gly residue at the N terminus. Acm protecting groups on Cys4 and Cys17 were used for selective 
disulfide bond formation of CysII–CysIV (Fig. 7A). As for cyclo-[GGG]kB1[T], two approaches, namely 
oxidation prior to cyclization and cyclization prior to oxidation, were attempted to obtain the cyclo-
[G]Vc1.1[GLPET]. The former approach gave rise to only a low yield (~1%) of oxidized product following 
Acm removal. In contrast, isomerization during oxidative folding was averted by cyclizing the linear 
precursor [G]Vc1.1[GLPETGGS] prior to oxidation. The cyclization performed in the presence of 10 mM 
Chapter 3. Semienzymatic cyclization of disulfide-rich peptides using sortase A 
 
57 
 
TCEP resulted in one major product with ~50% yield. The two disulfide bonds in the cyclic reduced 
[G]Vc1.1[GLPET] were then successfully formed via a two-step oxidation process with_15% yield. The 
linear precursor [G]Vc1.1[GLPETGGS], cyclic reduced [G]Vc1.1[GLPET], and cyclic oxidized 
[G]Vc1.1[GLPET] (hereafter named cyclo-[G]Vc1.1[GLPET]) showed a change in retention time after each 
reaction (Fig. 6B). The molecular mass and purity of the desired products for each step were confirmed by 
MALDI-TOF and RP-HPLC (Fig. 7B). 
 
3.6.6. NMR Analysis of Cyclo-[G]Vc1.1[GLPET] 
The structure of cyclo-[G]Vc1.1[GLPET] was deduced using secondary Hα chemical shifts determined from 
TOCSY and NOESY spectra. A comparison of the secondary shifts of cyclo-[G]Vc1.1[GLPET] with both 
native and chemically cyclized Vc1.1 (3) suggested no significant difference in the overall structure. 
Cyclization of cyclo-[G]Vc1.1[GLPET] was confirmed by observation of a sequential Hα-NHi+1 NOE 
between the C and N termini (Fig. 8). 
 
3.6.7. SrtA Reaction for SFTI-1 
For this single disulfide-bonded peptide, the SrtA reaction was performed at pH 8.5 to achieve cyclization 
and oxidation in a one-pot reaction. After 9 h, ~70% of the linear precursor had been converted to the cyclic 
oxi- dized form based on the RP-HPLC profile (peak at 20 min; Fig.7C). The mass of cyclic oxidized 
[GG]SFTI-1[LPET] was confirmed by MALDI-TOF (Fig. 7C). After a 24-h incubation, the peak at 20 min 
decreased, and a peak at 22.8 min increased in height and was found to contain both cyclic oxidized and 
hydrolyzed linear [GG]SFTI-1[LPET]. 
 
3.6.8. NMR Analysis of Cyclo-[GG]SFTI-1[LPET] 
Purified cyclized and oxidized cyclo-[GG]SFTI-1[LPET] and wild type SFTI-1 (both peptides_95% pure) 
were analyzed using TOCSY and NOESY experiments (Fig. 9). Two distinct conformations, in an 
approximate 9:1 ratio, were observed for cyclo-[GG]SFTI-1[LPET]. The secondary shifts of the major 
conformation were almost identical with those of wild type SFTI-1 (Fig. 7D). The minor conformation 
appears to be due to cis-trans isomerization of a proline residue. Pro8 in wild type STFI-1 is in the cis-
conformation, with strong NOEs observed between Ile7 Hα and Pro8 Hi+1. By contrast, in cyclo-[GG]SFTI-
1[LPET], two sets of NOEs interacting with either δ-proton or α-proton of Pro8 were observed, suggesting 
that Pro8 exists in both cis and trans conformations (49). 
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Figure 7. (A) Cyclization strategy of [G]Vc1.1[GLPETGGS] and [GG]SFTI-1[LPETGG] by SrtA. (B) 
Retention time and MALDI-TOF analysis of linear precursor [G]Vc1.1[GLPETGGS], cyclic reduced and  
cyclic oxidized [G]Vc1.1[LPET]. The peptide status is shown with schematic representations. (C) One-pot 
reaction of oxidation and cyclization of [GG]SFTI-1[LPETGG]. Time course analysis of SrtA reaction by 
RP-HPLC (left), MALDI-TOF data (right) of linear precursor [GG]SFTI-1[LPETGG] and cyclic 
oxidised(cyclo)-[GG]SFTI-1[LPET]. (D) Hα secondary shift comparison of cyclo-[GG]SFTI-1[LPET] and 
wild type SFTI-1. (E) Hα secondary shift comparison of cyclo-[G]Vc1.1[GLPET], wild type Vc1.1, and 
previously published data of orally active cVc1.1. Sorting motif is shown in a dashed box. 
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Table 1: Energies and structural statistics for the family of 20 lowest energy cyclo-[GGG]kB1[T] structuresa.  
 
Energies (kcal/mol) 
Overall -975.7 ± 38.5 
Bonds 20.5 ± 1.4 
Angles 52.5 ± 4.3 
Improper 17.4 ± 2.3 
Van der Waals -96.1 ± 4.7 
NOE 0.3 ± 0.03 
cDih 0.3 ± 0.2 
Dihedral 129.7 ± 1.6 
Electrostatic -1100.3 ± 36.4 
MolProbity Statistics  
Clashes (>0.4 Å / 1000 atoms) 12.8 ± 4.1 
Poor rotamers 0.3 ± 0.4 
Ramachandran Outliers (%) 0.0 ± 0.0 
Ramachandran Favoured (%) 87.6 ± 2.7 
MolProbity score 2.3 ± 0.2 
MolProbity score percentile 56.2 ± 13.4b 
Atomic RMSDc (Å)  
Mean global backbone (1-24) 0.53 ± 0.14 
Mean global heavy (1-24) 1.11 ± 0.25 
Mean global backbone (1-33) 1.53 ± 0.58 
Mean global heavy (1-33) 1.90 ± 0.53 
Distance Restraints  
Intraresidue (i-j = 0) 59 
Sequential (/i-j/ = 1) 169 
Medium range (/i-j/ < 5) 53 
Long range (/i-j/ > 5) 107 
Hydrogen bonds 10 
Total 398 
Dihedral angle restraints  
f 26 
Ψ 20 
c1 6 
Total 53 
Violations from experimental restraints  
Total NOE violations exceeding 0.3 Å 0  
Total Dihedral violations exceeding 3.0° 0  
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Figure 8. NMR spectra of cyclo-[G]Vc1.1[GLPET]. TOCSY spectrum (upper panel) and NOESY spectrum 
(lower panel) recorded at 298 K, 90% H2O/10% D2O. There was a subset of extra residues found to be from 
Gly1 to Ser4 and Glu14 to Gly22 with overlapping or similar chemical shifts to the major conformer. This is 
caused by cis-trans isomerization of Pro19 in the linker (GLPETG), but it did not affect the overall structure 
of cyclo-[G]Vc1.1[GLPET].   
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Figure 9. NMR spectra of cyclo-[GG]SFTI-1[LPET]. TOCSY spectrum (upper panel) and NOESY 
spectrum (lower panel) recorded at 298 K, 90% H2O/10% D2O. 
 
3.7. DISCUSSION 
Disulfide-rich cyclic peptides offer an attractive framework for the development of stable bioactive peptides 
with pharmaceutical potential. They display a remarkable degree of functional plasticity and high stability. 
Accordingly, interest has been shown both in the cyclization of linear disulfide-rich peptides (especially 
those isolated from venoms) and the development of native cyclotides as therapeutics and in their use as 
scaffolds for the grafting of pharmaceutically relevant epitopes onto the native cyclotide framework (74, 75). 
A bottleneck in the development of these peptides as potential therapeutics, however, is the production of 
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linear precursors and their subsequent cyclization and folding. NCL (using t-butoxycarbonyl chemistry) has 
been the preferred strategy for the production of disulfide-rich cyclic peptides, but this approach requires 
reaction conditions that cannot always be achieved using Fmoc chemistry or recombinantly expressed 
proteins. We therefore investigated SrtA-mediated cyclization as a mechanism for the increased efficiency of 
one of the steps in cyclic peptide production, namely head-to-tail cyclization of synthetically produced 
peptides. Specifically, we explored the possibility of using SrtA to enzymatically cyclize SFTI-1, Vc1.1 
(with a linker), and kB1 and showed that SrtA offers an efficient, safe, and cost-effective method for the 
cyclization of disulfide-rich peptides ranging in size from 14 to 29 amino acids with 1–3 disulfide bonds. 
 
The presence of a native Leu-Pro-Val in loop 6 of kB1 made this peptide an ideal model for cyclization 
using SrtA. These three residues fortuitously form a part of the penta-amino acid sorting motif, LPXTG, and 
cyclization was achieved with minimal disruption to the native sequence of kB1. In NCL-based synthesis of 
kB1, the cyclization and oxidation is carried out in a one-pot fashion. However, the reaction requires a two-
step procedure when using SrtA for cyclization, with oxidation occurring either after or before SrtA-
mediated cyclization. In our hands, the order of the reaction (i.e. oxidation/cyclization versus 
cyclization/oxidation) had a significant effect on the yield of correctly folded peptide. Despite the minimal 
changes introduced in kB1 by SrtA cyclization, no correctly folded peptide was produced when oxidation 
occurred after cyclization. Small changes in the amino acid composition of cyclotides can have profound 
effects on the refolding of synthetic forms (6,20), and it is possible that the introduction of the TGGG amino 
acid sequence in loop 6 of kB1 had a negative effect on the oxidative refolding of the cyclic form. The 
proximity of the cyclization point to CysI (Fig. 1) might also have adversely affected oxidative folding. The 
only region of significant structural perturbation in cyclo-[GGG]kB1[T] was for the Leu-Pro-Val residues 
immediately preceding CysI, and, when combined with restraints imposed by cyclization, conformational 
variations in this region of the reduced, cyclized peptide might have prevented correct disulfide formation. 
 
Production of correctly folded cyclo-[GGG]kB1[T] was achieved by oxidative refolding prior to cyclization 
with SrtA. Monitoring of the cyclization reaction showed what appeared to be intermediates at various stages 
of the reaction (Fig. 2B), but by 24 h, the reaction had efficiently converted the linear peptides to the cyclic 
form in _49% yield. Several pieces of NMR evidence suggest that cyclo- [GGG]kB1[T] adopts the fold of 
native kB1: (i) Pro20 adopts a cis-conformation as in native kB1; (ii) The HN of Trp19 is not observed in 
TOCSY spectra but is observed in NOESY spectra, as characteristically applies to kB1; (iii) The HB of 
Pro20 is shifted upfield to -0.26 ppm; (iv) the protonation/deprotonation of Glu3 significantly affects the 
chemical shifts of HN of Asn11 and Thr12; (v) the χ1 dihedral angles of all six cysteine residues agree with 
those for kB1, providing strong evidence for an identical disulfide connectivity. Consistent with this 
connectivity, NOEs between Cys1 Hβ2/Hβ3 to Cys15 Hβ3 and Cys10 Hβ2/Hβ3 to Cys22 Hβ2 were 
observed (NOEs between Cys5Hβ and Cys17Hβ could not be unambiguously identified due to extensive 
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spectral overlap). Interestingly, NOEs between Hβ protons of non-connected cysteine residues, including 
Cys10–Cys15, Cys1–Cys22, and Cys15–Cys22, were also observed, but this is in complete accordance with 
a study on native kB1 by Rosengren et al. (54), where it was suggested that for cyclic cystine knot peptides, 
H_ cross-peaks are not the preferred diagnostic tool for determining disulfide connectivity due to the close 
proximity of all disulfide bonds. From the extensive evidence noted above, especially the fact that the two 
peptides share identical χ1 dihedral angles for all of the Cys residues, we were confident that we produced 
cyclo-[GGG]kB1[T] with the native disulfide connectivity. Thus, we calculated the structure of cyclo-
[GGG]kB1[T] using the cysteine connectivities as native kB1 (PDB code 1NB1). 
 
The hemolytic activity of cyclo-[GGG]kB1[T] was significantly reduced compared with native kB1. 
Because structural perturbation of cyclo-[GGG]kB1[T] was minimal (Fig. 5), the loss of hemolytic activity is 
presumably due to the effects of the residues introduced into loop 6 upon cyclization. Previous grafting 
experiments utilizing kB1 have also shown the abrogation of hemolytic activity after relatively minor 
changes to the primary sequence; for example, the grafting of the vascular endothelial growth factor 
sequence (RRKRRR) into loop 2, 3, 5, or 6 significantly reduced the hemolytic activity of kB1 (20). 
The effects of single point mutations on the hemolytic activityof kB1 have also been extensively studied (73). 
The hemolytic activity of kB1 was dramatically reduced by Ala substitution on a specific set of residues, 
including the last three residues of loop 6 (Leu27, Pro28, and Val29). Similar results were observed during 
Lys substitution at the same positions (69). Barry et al.(72) also noted the complete loss of hemolytic activity 
of linearized kB1 with the RNGLP sequence deletion. All of the studies suggest that the hemolytic activity of 
kB1 can be diminished when a less hydrophobic residue is introduced into the last three positions of loop 6. 
In kalata B2, a close homolog of kB1, loop 6 forms part of a hydrophobic interface that mediates interactions 
between the cyclotide and the plasma membrane (76). In this context, the loss of hemolytic activity after the 
introduction of additional residues to loop 6 suggests the interruption of critical membrane/peptide 
interactions in this region of the peptide. 
 
The residues introduced into loop 6 might have also contributed to the slight reduction in stability of cyclo-
[GGG]kB1[T] relative to the native peptide. Chemical shifts for these residues differed little from random 
coil values, suggesting that structural disorder at the cyclization point made the peptide slightly more 
susceptible to plasma proteases than native kB1. This disorder was also confirmed in the NMR solution 
structure of [GGG]kB1[T], with loop 6 displaying markedly increased disorder compared with native kB1. 
The serum stability results show that the cystine knot formation is crucial for stability because linear 
oxidized [GGG]kB1[TGG] was largely (~71%) intact after 24 h. 
 
The sortase-catalyzed process requires modest modifications in order to render peptides amenable to 
cyclization. In this work, the cyclization point was chosen on the basis of a pre-existing Leu-Pro-Val motif in 
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loop 6, which overlapped with the SrtA recognition motif. This fortuitous coincidence resulted in the 
introduction of three fewer non-native amino acids than would be required using a different cyclization point. 
Analysis of chemical shifts showed that apart from differences of ~0.5 ppm in the Leu-Pro-Val residues of 
the cyclization point, the remainder of the SrtA cyclized peptide exhibited very little structural perturbation. 
Loop 6 of cyclotides exhibits the greatest diversity in structure, sequence, and length (77), and the lack of 
structural perturbation in this case reflects the ability of this loop to accommodate a range of structural 
motifs without affecting the overall fold of the peptide. Accordingly, the use of this loop for cyclization 
should provide a convenient and simple mechanism for production of synthetic cyclotides for a variety of 
applications. 
 
To test the generality of SrtA-mediated cyclization, we investigated if it could be applied to other small 
disulfide-rich peptides, such as_-conotoxin Vc1.1 and SFTI-1. MALDI-TOF and NMR analysis confirmed 
that their cyclized and oxidized structures were similar to the native structures. In contrast to kB1, 9 h of 
SrtA reaction appeared to be sufficient to obtain the maximum yield for cyclo-[GG]SFTI-1[LPET], 
presumably due to its smaller size. Beyond this incubation time, some hydrolysis of the peptide was found to 
occur, resulting in linearization because the final product still contains a LPETG motif. Interestingly, 
introduction of the sortase motif in SFTI-1 (cyclo-[GG]SFTI-1[LPET]) gave rise to cis-trans isomerization 
of Pro8, as highlighted by the observation of strong NOEs between both Ile7 Hαi to Pro8 Hαi+1 (cis) and Ile7 
Hαi to Pro8 Hδi+1 (trans). Although the LPXTG motif was introduced to the cyclization loop of SFTI-1, 
presumably placing the motif next to the Asp14 made the structure of the peptide less constrained than the 
wild type. This is consistent with a previous study showing that Ile7, Pro8, Pro9, and Asp14 are important 
for structural integrity (49). In that study, when Asp14 was replaced with Ala, the turn region was 
destabilized, resulting in cis-trans isomerization of Pro13 (49). Although the isomerization site is different, 
introduction of the SrtA sorting motif appears to have destabilized the turn region, giving rise to the minor 
conformation observed by NMR. 
 
The work described here demonstrates the applicability of the SrtA method for the cyclization of different 
classes of disulfide-rich peptides without significant structural perturbation to the overall peptide fold. We 
have shown that this method is applicable whether the peptides are cyclic in their native form, such as SFTI-
1 containing one disulfide bond or kB1 with a three-disulfide bond cyclic cystine knot motif, or whether the 
peptide is linear in its native form and the cyclization site is introduced by the addition of a linker, such as 
for cVc1.1. SrtA mediated head-to-tail cyclization works optimally with peptides larger than 12-mers, 
excluding the SrtA sorting signal (40). Cyclotides are typically 28–37 amino acids in size, making all 
characterized cyclotides suitable for SrtA cyclization. In addition, other disulfide-rich peptides (e.g. 
conotoxins (78) or defensins (79, 80)) are also within this size range, making SrtA mediated cyclization a 
possibility for a wide range of peptides of therapeutic interest. Importantly, the ability to place the SrtAtags 
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at any position within a peptide sequence makes it possible to introduce cyclization points anywhere in the 
peptide of interest and thus minimize disruption of biologically or structurally important motifs. Thus, 
peptide bond closure of linear precursors through sortase-catalyzed circularization represents a simple, safe, 
and effective method not only for the production of synthetic cyclotides but also for the introduction of 
increased stability and bioavailability to other disulfide-rich peptides with therapeutic value. 
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4.3. Abstract  
Disulfide-rich peptides isolated from cone snails are of great interest as drug leads due to their high 
specificity and potency toward therapeutically relevant ion channels and receptors. They commonly 
contain the inhibitor cystine knot (ICK) motif comprising three disulfide bonds forming a knotted 
core. Here we report the first successful enzymatic backbone cyclization of a linear ICK-containing 
peptide κ-PVIIA, a 27-amino acid conopeptide from Conus purpurascens, using a mutated version 
of the bacterial transpeptidase, sortase A. Although a slight loss of activity was observed compared 
to native κ-PVIIA, cyclic κ-PVIIA is a functional peptide that inhibits the Shaker voltage-gated 
potassium (Kv) channel. Molecular modeling suggested that the decrease in potency may be related 
to the loss of crucial, but previously unidentified electrostatic interactions between the N-terminus 
of the peptide and the Shaker channel. This hypothesis was confirmed by testing an N-terminally 
acetylated κ-PVIIA, which showed a similar decrease in activity. We also investigated the 
conformational dynamics and hydrogen bond network of cyc-PVIIA, both of which are important 
factors to be considered for successful cyclization of peptides. We found that cyc-PVIIA has the 
same conformational dynamics, but different hydrogen bond network compared to those of κ-
PVIIA. The ability to efficiently cyclize ICK peptides using sortase A will enable future protein 
engineering for this class of peptides and may help in the development of novel therapeutic 
molecules. 
 
 
Keywords: κ-PVIIA, inhibitory cystine knot, cyclization, sortase A 
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4.4. Introduction  
 Peptides are undergoing an exciting revival of interest due to recent technological advances 
in protein and peptide engineering (1). These advances have led to an increase in interest from the 
pharmaceutical industry in using peptides in a number of therapeutic applications because, unlike 
small molecules, peptides tend to be highly selective and typically very potent for a specific target. 
However, a drawback often associated with peptides is a short half-life due to a lack of proteolytic 
stability. One way to improve the stability of a peptide is through backbone or side chain 
cyclization, as this reduces susceptibility to proteases and, in some cases, improves activity (2) and 
potentiates orally delivered activity (2-4). One class of peptides that has gained particular interest is 
venom-derived disulfide-rich peptides due to their inherent stability (brought about by the high 
number of cysteine residues) and ability to selectively and potently inhibit voltage-gated potassium 
(KV), calcium (CaV) and sodium (NaV) channels. This inhibitory activity is particularly relevant 
given the involvement of these channels in numerous pathologies, including pain, stroke, epilepsy 
and multiple sclerosis (5-8). 
 κ-PVIIA is a 27-amino acid peptide isolated from the venom of the purple cone snail, Conus 
purpurascens (9). It has been reported to block the conductance of the Shaker Kv channel of 
Drosophila melanogaster with an IC50 of 60 ± 3 nM (9-11). Three-dimensional structural analysis 
and a complete alanine scan suggested that the peptide inhibits the channel by physically occluding 
the pore (11-13). NMR structural analyses showed that κ-PVIIA has an inhibitor cystine knot (ICK) 
(12,13) – a unique structural motif characterized by a triple-stranded anti-parallel β-sheet connected 
by three disulfide bonds, forming a knotted core. The ICK significantly contributes to the stability 
of peptides (14,15). The disulfide connectivity of the ICK motif is CI-CIV, CII-CV and CIII-CVI, and 
a common sequence patterns is: CX3-7CX3-6CX0-5CX1-4CX4-13C, (X being any amino acid) (16).  
 The ICK motif is found in a broad spectrum of phyla, including animals, plants, and fungi, 
with a particularly large prevalence in the venoms of cone snails, spiders and scorpions (17). 
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Interestingly, the ICK is widespread in venoms regardless of the pharmacological target, 
mechanism of action, or the species from which the peptides are extracted. κ-PVIIA is a member of 
the O1 conotoxin gene superfamily (9,18,19), and contains an ICK motif with CX6-CX6-CCX3-
CX5-C cysteine spacing. In addition to κ-PVIIA, this family comprises a diverse series of 
conotoxins with an ICK motif; for example, ω-conotoxin MVIIA (20), μ-conotoxin GS (21), δ-
conotoxin PVIA (22), and μO-conotoxin MrVIB (23), which influence CaV and NaV channels 
(Figure 1a) (24,25).  
 One class of peptides that is structurally related to the O1 conotoxin superfamily is the 
cyclotides (26). This family of plant-derived peptides comprises a cystine knot motif that is 
embedded within a cyclic backbone, a motif referred to as a cyclic cystine knot (CCK) (15). Six 
loops protrude from the core and are thought to direct the activity of cyclotides, which have been 
referred to as a natural combinatorial template (27,28). The combination of the cystine knot coupled 
with the cyclized backbone makes this family of peptides ultrastable and able to withstand harsh 
chemical, enzymatic or thermal conditions (29). In addition, their use in African folk medicinal teas 
suggests that they have a degree of oral bioavailability (30).  
Chemical cyclization has been used in a few cases to improve the pharmaceutical properties of ICK 
peptides by making them more cyclotide-like (31,32). Cyclotides are typically sequentially 
assembled using standard Boc solid-phase peptide synthesis and cyclized using native chemical 
ligation (33-35). Recent reports describe the production of cyclotides using Fmoc compatible 
methods (36,37). We also recently showed that cyclization of disulfide-rich peptides, including 
cyclotide kalata B1, sunflower trypsin inhibitor-I (SFTI-I) and cyclic Vc1.1, could be achieved 
using the bacterial transpeptidase, sortase A (SrtA), as an alternative to chemical ligation methods 
(38). In addition, another recent study demonstrated successful backbone cyclization of a 
recombinant cyclotide precursor of MCoTI-II using a mutant SrtA (P94S/D160N/D165A/K196T) 
(39). 
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SrtA, originally isolated from Staphylococcus aureus, recognizes the penta-amino acid LPXTG 
motif (X = any amino acid) and cleaves the peptide bond between Thr and Gly, forming a thioacyl 
enzyme intermediate. The intermediate then undergoes nucleophilic attack by Glyn, which results in 
the formation of a new peptide bond between Thr and Glyn (40). SrtA has been widely used in 
protein engineering (41,42), and efforts to improve its catalytic activity were recently successful; 
specifically, through the use of a directed evolution strategy leading to the modified SrtA 
(P94R/D160N/D165A/K190E/K196T), hereafter referred to as SrtA5º, with significantly enhanced 
ligation activity (43). 
Little is known about the subtype selectivity of κ-PVIIA across KV channels and with the increasing 
interest in the potential treatment of multiple sclerosis by KV1.3 channel inhibition (44), we chose 
κ-PVIIA as a model system not only to enzymatically cyclize an ICK peptide, but also to search for 
potential targets in addition to Shaker. Following the successful cyclization of kalata B1, SFTI-I 
and cyclic Vc1.1 using SrtA, we investigated whether cyclization of κ-PVIIA could be achieved by 
a semi-enzymatic approach using SrtA5º and determined how it would affect the activity and the 
stability of the peptide. This study describes the synthesis, oxidation and cyclization using SrtA5º of 
linear κ-PVIIA (Figure 1b) and reports its serum stability. Structural analysis using nuclear 
magnetic resonance (NMR) allowed us to compare the structures of cyclic κ-PVIIA (cyc-PVIIA) 
with κ-PVIIA; electrophysiological studies and molecular dynamics simulations provided insights 
into differences in interaction between cyc-PVIIA, κ-PVIIA and Shaker, and allowed us to define 
the κ-PVIIA KV channel selectivity profile. 
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Figure 1. (a) Sequence alignment of O1 gene superfamily conotoxins displaying an ICK motif. (b) 
Schematic representation of the experimental procedures used to cyclize κ-PVIIA. 
 
4.5. Materials and Methods 
4.5.1. Peptide synthesis 
Linear peptides were synthesized by solid-phase peptide synthesis using an automatic peptide 
synthesizer (Symphony®, Protein Technologies, Inc. USA) following standard Fmoc chemistry 
protocols. 2-Chlorotrityl chloride resin was used for [GGG]PVIIA[LPETGG], whereas rink amide 
resin was used for linear κ-PVIIA to achieve C-terminal amidation. κ-PVIIA with N-terminal 
acetylation was produced by treating the resin with 6% acetic anhydride/0.2 M DIPEA in DMF 
following completion of elongation of the peptide. Peptides were released from the resins using 
trifluoroacetic acid (TFA)/triisopropylsilane/water (95:2.5:2.5) at room temperature for 2 h. TFA 
was removed using a rotary evaporator, and peptides were precipitated with ice-cold diethyl ether, 
dissolved in 50% v/v acetonitrile (ACN) containing 0.05% v/v TFA and lyophilized. Peptides were 
purified using reversed-phase high performance liquid chromatography (RP-HPLC) and the mass 
was confirmed using mass spectrometry.  
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4.5.2. Oxidative folding of peptides 
κ-PVIIA and GGG-PVIIA-LPETGG were oxidized in 50 mM Tris pH 7.5, 1 mM GSH, 0.5 mM 
GSSG at 4 °C for 4–5 days. The progress of oxidation was monitored by analytical RP-HPLC with 
a gradient from 0–50% v/v ACN (0.05% v/v TFA) over 50 min with a flow rate of 0.3 mL/min 
using an analytical C18 column (Agilent ZORBAX 300SB-C18, 5 μm, 2.1 x 150 mm). The 
oxidation yield was calculated based on HPLC profile. The mixture was purified by RP-HPLC 
using a 0.5%/min gradient, and the molecular weight was confirmed using mass spectrometry. 
 
4.5.3. SrtA5º expression 
SrtA5º (43) was expressed as previously described (45). Briefly, an overnight culture of E.coli 
BL21 (DE3) transformed with SrtA5º plasmid was cultured in the presence of 50 μg/mL kanamycin 
until OD600=0.7. Protein expression was induced by addition of isopropyl-β-D-1-
thiogalactopyranoside (IPTG) to a concentration of 1 mM for 3 h at 37 °C. Cells were harvested by 
centrifugation and resuspended in lysis buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 10 mM 
imidazole, 10% v/v glycerol, 20 μg/mL DNase I). Cells were sonicated, the supernatant was 
collected and the protein was purified using Ni-Sepharose (HisTrap FF, GE Healthcare). Fractions 
containing SrtA5º were combined and the buffer was exchanged using a PD-10 desalting column 
(GE Healthcare). 
 
4.5.4. Cyclization of peptides using SrtA5°  
For cyclization, 50 μM of the peptide was incubated with 50 μM of SrtA5º in reaction buffer (50 
mM Tris, pH 7.5, 150 mM NaCl, 10 mM CaCl2) at 37 °C. Cyclization progress was monitored 
using RP-HPLC with a gradient of 0–50% v/v ACN (0.05% v/v TFA) over 50 min with a flow rate 
of 1 mL/min using an analytical C18 column (GraceSmartTM RP18, 5 μm, 4.6 x 150 mm). When the 
majority of linear peptide was deemed to be cyclic, the peptide was separated from SrtA5º using a 
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centrifugal concentrator (10 kDa), the solution containing the cyclic peptide was loaded onto a 
semipreparative C18 column (Phenomenex, Jupiter 5UC18, 300 Å, 250 x 10.0 mm, 5 μm) and 
eluted with a gradient of 36–45% ACN (0.05% TFA) over 30 min with a flow rate of 3 mL/min. 
The molecular mass of purified cyclic-[GGG]PVIIA[LPET] was confirmed by matrix-assisted laser 
desorption/ionization time of flight (MALDI-TOF) mass spectrometry. Fractions showing the 
correct mass were lyophilized for further assays. 
 
4.5.5. NMR spectroscopy and structure calculations 
Cyc-PVIIA was dissolved in 90% H2O, 10% D2O (v/v) or 99.96% D2O at a concentration of 1 mM 
and ~pH 3.5. Two-dimensional NMR spectra were acquired at 298K on a Bruker Avance 600 MHz 
NMR spectrometer equipped with a cryogenically cooled probe (Bruker, Karlsruhe, Germany). 
Spectra were recorded with 4096 data points in the F2 and 512 increments in the F1 dimension for 
TOCSY, NOESY, E.COSY, DQF-COSY, 2048 data points and 256 increments for 1H-13C HSQC, 
and 2048 data points and 128 increments for 1H-15N HSQC. Sequential assignment and structure 
calculations were performed as previously described (46). Briefly, The peaks in the NOESY spectra 
with 100 ms mixing time were picked manually, intraresidual and sequential NOEs were assigned, 
and a list of interproton distances was generated using the AUTO and CALC function in CYANA 
(47). Following structural refinement within CNS (48), a set of 20 structures with the lowest 
energies, no NOE violations greater than 0.2 Å and no dihedral violations greater than 2.0º, was 
chosen for MolProbity analysis (49). PyMOL and MOLMOL (50) were used for generating figures 
and final superimposition. 
 
4.5.6. Two-electrode voltage-clamp recording from Xenopus oocytes 
Shaker-IR (IR for inactivation removed) (51,52), rKV2.1Δ7 (53,54), hKV1.3 (55), rKV1.6 (56,57), 
rNaV1.4 (58), and hNaV1.6 (59,60) were used in this study. The rKV2.1Δ7 construct contains seven 
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point mutations in the outer vestibule, rendering the channel sensitive to agitoxin-2 (61). cRNA of 
all constructs and mutants was synthesized using T7/SP6 polymerase (Message Machine kit, Life 
Technologies, USA) after linearizing the sequenced DNA with appropriate restriction enzymes. 
Channel constructs were expressed in Xenopus laevis oocytes and studied following 1–2 days 
incubation after manual cRNA injection as described before (62). Leak and background 
conductances, identified by blocking the channel with agitoxin-2, were subtracted for all KV 
channel currents shown. Voltage-activation relationships were obtained by measuring tail currents 
for KV channels and a single Boltzmann function was fitted to the data. Voltage-activation 
relationships were recorded in the absence and presence of different toxin concentrations. The ratio 
of currents (I/I0) recorded in the presence (I) and absence (I0) of toxin was calculated for various 
strength depolarizations. The value of I/I0 measured in the linear phase at 0 mV was taken as 
Fraction unblocked. The IC50 of the toxin for KV channels was calculated using the Hill equation. 
Off-line data analysis was performed using Clampfit 10 (Molecular Devices, USA) and Origin 7.5 
(Originlab, USA). 
 
4.5.7. Molecular modeling  
The molecular model used for the studies of interaction between the Shaker K+ channel and linear 
κ-PVIIA was kindly provided by Mhadavi and Kuyucak (63). A model of the interaction between 
cyc-PVIIA and the Shaker K+ channel was built by homology with Modeller 9v13 (64) using the 
model of Mhadavi and Kuyucak and the solution structure of cyc-PVIIA as templates. The 
homology model was then embedded in a pre-equilibrated 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) bilayer: the shaker channel was placed in the bilayer and POPC residues 
that overlap with the channel were removed. SPC water molecules were added to the system and 
sodium and chloride ions were added to simulate a physiological concentration of 150 mM sodium 
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chloride. The simulated system contained 100 POPC molecules, ~9,000 water molecules, 23 
sodium ions and 26 chloride ions. After 10,000 steps of steepest descent minimization, the system 
was equilibrated for 10 ns while progressively releasing position restraints on the chanel and toxin. 
The system was then simulated for 100 ns without restraint. All simulations used the Gromos 54a7 
force field (65), the v-rescale thermostat (66), the Parrinello-Rahman barostat (67), and the reaction 
field method (68) to simulate the effect of long range dipole-dipole interactions. The electrostatic 
potential generated by the Shaker K+ channel was computed using APBS software (69). Molecular 
dynamics simulations of cyc-PVIIA and κ-PVIIA individually in solution were carried out using the 
Amber 99SB-ILDN force field (70). Each peptide was embedded in a water box of ~2,600 SPC 
water molecules, containing sodium and chloride ions at 150 mM concentrations. All molecular 
dynamics simulations were carried out using the Gromacs 5.1 molecular dynamics engine (71). 
 
4.5.8. Serum stability assay 
The stability of native and cyc-PVIIA in human serum was tested at a peptide concentration of 20 
μM using a method previously described (72).  
 
4.6. Results and Discussion 
4.6.1. κ-PVIIA precursor synthesis, oxidation and cyclization 
κ-PVIIA and the linear precursor [GGG]PVIIA[LPETGG] were synthesized by Fmoc chemistry. 
Oxidative folding was monitored by analytical HPLC over time, and both peptides showed a similar 
profile, with one prominent peak after 4 days (Figure 2a). For cyclization, we used a mutated S. 
aureus SrtA which has improved catalytic activity compared to wild-type SrtA (43). Among the 
mutant SrtAs described by Chen et al., we tested the two most active (i) 
P94S/D160N/D165A/K196T and (ii) P94R/D160N/D165A/K190E/K196T (SrtA5º) using GFP-
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LPETGG as the substrate. In our hands, SrtA5º showed slightly better catalytic activity compared to 
the tetramutant, and consequently was used in subsequent experiments (data not shown). The linear 
oxidized [GGG]PVIIA[LPETGG] was incubated with SrtA5º for cyclization, and progress was 
monitored by RP-HPLC. Based on calculations of peak area derived from HPLC, 46% and 57% of 
conversion from linear [GGG]PVIIA[LPETGG] to cyclic-[GGG]PVIIA[LPET] was observed after 
3.5 h and 8 h, respectively (Figure 2b, c). The peak eluting before cyc-PVIIA contained a peptide 
with the same mass of cyclic peptide and was assumed to be an isomer, but did not yield sufficient 
material for further analysis. An attempt to synthesize κ-PVIIA by Boc-chemistry using an 
automatic synthesizer was unsuccessful; therefore, cyclization by native chemical ligation was not 
achieved.  
 
Figure 2. Oxidation and cyclization of [GGG]PVIIA[LPETGG]. (a) RP-HPLC profile of 
[GGG]PVIIA[LPETGG] oxidation. The asterisk represents the major peak of linear oxidized 
product. (b) Cyclization progress of [GGG]PVIIA[LPETGG] over time using SrtA5º and (c) 
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MALDI-TOF analysis of linear oxidized (calculated monoisotopic mass: 3992.7 Da) and cyclic 
oxidized PVIIA (calculated monoisotopic mass: 3860.6 Da).  
 
4.6.2. NMR solution structure of cyc-PVIIA  
Linear oxidized [GGG]PVIIA[LPETGG] and cyc-PVIIA were analysed by two-dimensional 1H 
NMR. The peaks for both peptides in the amide proton region of the NMR spectra were well 
dispersed and all protons could be assigned by the sequential assignment procedure using TOCSY 
and NOESY spectra (73). Secondary Hα chemical shift comparison confirmed them to be similar to 
native κ-PVIIA (PDB identifier 1AV3) (12) and the positive secondary shifts for residues Q6-C8, 
K19-C20 and K25-V27 indicated the presence of the characteristic β-sheet secondary structure 
(Figure 3a). Backbone cyclization was confirmed by the presence of a αHi-NHi+1 NOE observed 
between Thr31 and Gly32, indicating peptide bond formation of the C-terminal LPET and N-
terminal GGG motif of cyc-PVIIA.  
 
The three-dimensional structure of cyc-PVIIA was calculated using 384 distance restraints, as well 
as 17 φ, 17 ψ, four χ1 dihedral angle restraints and four hydrogen bonds derived from a D2O 
exchange experiment. The structure of cyc-PVIIA calculated using CYANA (47) was refined 
further in a water shell using CNS (48). The 20 conformers with the lowest energy were chosen for 
structural statistical analysis and showed a root mean square deviation of 0.91 ± 0.25 Å across the 
backbone, excluding the flexible loop 2 (residues F9-D14) and the disordered linker (residues L28-
G34) (Table I). Cyc-PVIIA showed high similarity to κ-PVIIA (PDB identifier 1AV3) (12) across 
the overall structure, except in the linker region (Figure 3b). As seen in other members of the O1 
conotoxin superfamily, including MVIIA (20) and MrVIB (74), loop 2 of PVIIA is the most 
flexible region (not including the linker) based on RMSD comparison of each loop of NMR 
structures. To determine if cyclization introduced any changes in backbone flexibility of the 
structure, the Cα root-mean-square fluctuation (RMSF) of κ-PVIIA and cyc-PVIIA were measured 
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from molecular dynamics simulations. Overall, both peptides showed similar RMSF profiles 
(Figure 3c). Loop 2 of cyc-PVIIA had slightly less flexibility than that of native PVIIA, which is 
consistent with cyclization being suggested to introduce structural rigidity and prevent disulfide 
bond shuffling (2). 
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Figure 3. (a) Secondary Hα chemical shift comparison of κ-PVIIA and cyc-PVIIA. Residues 
forming β-sheets are indicated with arrows. (b) The 20 lowest-energy structres of κ-PVIIA (PDB 
identifier 1AV3, left) (12) and cyc-PVIIA (PDB identifier 2N8E, right) superimposed over the 
backbone residues 2–7 and 15–26. Disulfide bonds are shown in grey with Roman numerals. (c) 
Root-mean-square fluctuation (RMSF) highlighting the flexibility of each loop of native and cyc-
PVIIA.  
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Table I. Energies and structural statistics for the family of 20 lowest energy cyc-PVIIA 
structures.  
Energies (kcal/mol) 
Overall –1119.8 ± 73.9 
Bonds       14.1 ± 1.5 
Angles       44.5 ± 5.2 
Improper       18.3 ± 4.9 
Dihedral     158.5 ± 3.3 
van der Waals   –125.0 ± 3.3 
Electrostatic –1230.3 ± 77.7 
NOE         0.1 ± 0.0 
cDih         0.1 ± 0.1 
MolProbity statistics 
Clashes (> 0.4Å/1000 atoms)         7.5 ± 2.5 
Poor rotamers         1.0 ± 1.0 
Ramachandran outliers (%)         0.0 ± 0.0 
Ramachandran favored (%)a       93.3 ± 4.1 
RMSDb from mean structure (Å) 
Mean global backbone (residues 3–8, 15–27)       0.91 ± 0.25 
Mean global heavy (residues 3–8, 15–27)       1.78 ± 0.26 
Mean global backbone (residues 1–34)       1.65 ± 0.31 
Mean global heavy (residues 1–34)       2.42 ± 0.30 
Number of distance restraints 
Intraresidue (i-j = 0)                  139 
Sequential (|i-j| = 1)                  149 
Medium range (|i-j| < 5)                    46 
Long range (|i-j| ≥ 5)                    43 
Hydrogen bonds                     4 
Disulfide bonds                     3 
Total                 384 
Number of dihedral angle restraints 
φ                  17 
ψ                  17 
χ1                    4 
Total                  38 
Violations from experimental restraints 
Total NOE violations exceeding 0.2 Å                    0 
Total dihedral violations exceeding 2.0°                    0 
Note: Data are presented as mean ± S.D. a The remaining (6.7%) were found in the 
allowed regions of the Ramachandran plot. b Mean RMSD was calculated using 
MOLMOL (50).  
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4.6.3. Native and cyclic κ-PVIIA inhibit Shaker 
To evaluate the effect of cyclization on toxin activity, κ-PVIIA and cyc-PVIIA were tested on the 
Shaker KV channel expressed in Xenopus oocytes. κ-PVIIA completely blocked Shaker currents at 
1 μM over a wide range of voltages, whereas the same concentration of the cyclic peptide only 
partially blocked the channel (Figure 4a). Fitting the concentration-dependence of Shaker block 
with the Hill equation revealed an IC50 value for native κ-PVIIA of 80 ± 5 nM, which is comparable 
to that previously published, 60 ± 3 nM (9,11). In contrast, an IC50 value ~10-fold higher was 
observed for cyc-PVIIA (824 ± 60 nM). Both κ-PVIIA and cyc-PVIIA displayed a slope of 1.1 ± 
0.1, suggesting a toxin:channel ratio of 1:1, which is commonly observed for pore-blocking toxins 
(Figure 4b). As the ion-conducting pore of KV channels is known to be conserved (75), both native 
and cyc-PVIIA were tested on other KV channels, including rKV2.1Δ7, hKV1.3, rKV1.6. Of the 
tested channels, 1 μM κ-PVIIA only slightly blocked rKV1.6, whereas cyc-PVIIA had no effect 
(Figure 4c). Although Shaker has been used as a model for studying other Kv channels due to the 
high degree of homology, our results suggest that a ligand of Shaker does not necessarily bind to 
other Kv channels. Similar experimental or modeling results were also obtained previously using 
Kv1.1 and Kv1.2, (10,63,76). Finally, neither peptide is active on rNaV1.4 and hNaV1.6.  
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Figure 4. Inhibitory toxin activity on Drosophila 
Shaker and rKV1.6 (a) 1 μM of κ-PVIIA 
completely blocks Shaker-IR (inactivation 
removed) currents over a wide voltage range 
whereas the same concentration of the cyc-PVIIA 
and N-terminally acetylated κ-PVIIA only 
partially block the channel. Representative 
example traces shown (left) were selected from n 
= 5 recordings under each condition at a voltage 
of 20 mV (100 ms) followed by a voltage-step to 
–70 mV (100 ms) to evoke tail currents (holding 
potential was –90 mV). Voltage-activation 
relationships (right) were obtained by plotting tail 
currents vs applied voltage step. Black lines and 
markers represent control currents and grey lines 
and markers show the response on currents 
following application of toxin. (b) Fitting the 
concentration-dependence for toxin, block of 
Shaker-IR with the Hill equation reveals an IC50 
value for the κ-PVIIA of 80 ± 5 nM (black 
squares), cyc-PVIIA is 824 ± 60 nM (grey filled 
circles) and that of N-terminally acetylated κ-
PVIIA is 1616 ± 98 nM (grey empty circles). κ-
PVIIA, cyc-PVIIA, and acetylated κ-PVIIA fits 
display a slope of ~1.1 ± 0.1, suggesting a 
toxin:channel ratio of 1:1. The data is presented 
as mean ± s.e.m. (c) 1 μM κ-PVIIA weakly 
blocks rKV1.6 whereas cyc-PVIIA has no effect 
(n = 5). Example traces shown on the left were 
evoked by depolarizing the channel to 0 mV 
followed by –50 mV (tail) from a holding 
potential of –90mV. Black lines and markers 
represent control currents and grey lines and 
markers show the response on currents following 
application of toxin. 
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4.6.4. The N-terminus of κ-PVIIA is required for electrostatic interaction with Shaker. 
Previous molecular modeling studies have predicted how κ-PVIIA binds to Shaker based on 
structural analyses and mutagenesis studies (11,13,63,77). Initially, recognition of κ-PVIIA by 
Shaker takes place via electrostatic interactions between positively charged residues on the surface 
of the peptide and negatively charged residues on the extracellular side of the channel (77). The 
charged residues play an important role in adjusting the conformation of the peptide in the binding 
process until Lys7 of κ-PVIIA inserts into the pore of the channel and blocks the flow of potassium 
ions. In addition to Lys7, several residues were found to have a critical role in binding; for example, 
Arg2 of κ-PVIIA interacts strongly with Asp447 of the channel and Phe9 of κ-PVIIA and Phe425 
make hydrophobic interactions (63,77).  
We developed a model of cyc-PVIIA bound to the Shaker channel using the model of Mahdavi and 
Kuyucak (63). In our model, the binding mode of cyc-PVIIA was predicted to be generally 
unchanged compared with that of κ-PVIIA (Figure 5a-c). The stability of the cyc-PVIIA and Shaker 
channel interaction was substantiated by a 100 ns molecular dynamics simulation. This simulation 
was analyzed using the backbone RMSD of Shaker, cyc-PVIIA and the position of cyc-PVIIA on 
the Shaker (Figure 5d-g). The transmembrane helices of the Shaker channel were very rigid and did 
not deviate significantly from the starting conformation with a backbone RMSD of ~1 Å during the 
entire simulation. The backbone RMSD of the entire channel including transmembrane helices and 
loops was on average 2.2 Å, indicating the loops were more flexible during the simulation. The 
conformation of the cyc-PVIIA was also very stable as its backbone RMSD was ~1 Å (excluding 
cyclization linker) (Figure 5g). The change of position of cyc-PVIIA on the Shaker was evaluated 
by computing the backbone RMSD of the peptide (excluding the linker) after fitting on the Shaker 
transmembrane helices. The average RMSD of the cyc-PVIIA position (~2.5 Å) is comparable to 
the backbone RMSD of the Shaker, which is mostly accounted by the flexibility of the loops, thus 
suggesting that the binding mode of cyc-PVIIA to the channel is preserved. This is further 
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supported by an overlay of the starting and final binding modes of the simulation (Figure 5d-f), 
which shows excellent conservation of the relative position of Lys7 and of the interface. 
Despite the unchanged binding mode after cyclization, cyc-PVIIA showed decreased activity 
(Figure 4a), and this was assumed to be due to loss of electrostatic interaction between the 
electronegative potential generated by Glu418 and Glu422 on the turret of Shaker and the N-
terminus of κ-PVIIA (Figure 5a-c). To test this hypothesis,  N-terminally acetylated PVIIA was 
synthesized and indeed found to have ~20-fold lower activity (IC50, 1616 ± 98 nM) than κ-PVIIA 
when tested on Shaker (Figure 4a,b) confirming that the N-terminus of κ-PVIIA is required for full 
inhibition of the conductivity of Shaker. However, we expect that the loss of electrostatic 
interaction could possibly be compensated by incorporation of a positively charged residue in the 
linker.  
 
4.6.5. The conformations of κ-PVIIA and cyc-PVIIA are similar upon binding to Shaker, but 
the hydrogen bond networks differ. 
Although the overall backbone conformations of cyc-PVIIA and native κ-PVIIA in the NMR 
solution structures are very similar, Cys1 and Arg2, which are adjacent to the cyclization linker, 
resided in different spatial locations in the cyclized and native peptides (Figure 6b,c). By contrast, 
molecular models suggest that these two residues have similar conformations and the interactions at 
the interface with Shaker. We investigate here if the difference of affinity between the cyclized and 
linear form could be partially explained by difference in the unbound state. An overlay of the 
unbound and bound peptide conformations suggests that Cys1 is displaced by 3.0 Å for κ-PVIIA 
and 2.5 Å for cyc-PVIIA. In contrast, the hydrogen bond networks of Arg2 for the native and cyclic 
peptides are quite different when they are bound and unbound to Shaker (Figure 6). The change of 
the hydrogen bond networks established by Arg2 side chain was studied using 100 ns molecular 
dynamics simulations. Arg2 of κ-PVIIA forms stable hydrogen bonds with Lys7 and Cys16 and 
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transiently hydrogen bonds with Asp14. On the other hand, Arg2 of cyc-PVIIA lacks hydrogen 
bonds with Lys7 or Cys16 but also forms a transient hydrogen bond with Asp14. The models 
suggest that hydrogen bond network of unbound κ-PVIIA is more similar to the bound state than 
that of cyc-PVIIA. Although it is not certain whether this difference contributes to decreased 
activity of cyc-PVIIA, it appears likely that the two hydrogen bonds between Arg2 and Lys7, and 
Arg2 and Cys16 stabilize the conformation of κ-PVIIA upon binding to Shaker. 
 
 
Figure 5. Model of interactions of κ-PVIIA and cyc-PVIIA with the Shaker channel, (a) View of 
the extracellular entrance of the channel in the molecular model of κ-PVIIA in complex with 
Shaker (63). The solvent-accessible surface of the channel is colored according to the Poisson-
Boltzmann electrostatic potential it generates, as computed by the APBS software (69), with a scale 
ranging from -4 kT/e (red) to +4 kT/e (blue). The extracellular loop of each of the four subunits of 
the channel creates an electronegative potential with which the positively charged residues R22 and 
K25 and N-terminus of κ-PVIIA interact on three different sides of the peptide. (b) Side view of the 
κ-PVIIA/Shaker complex highlighting two glutamic acids located on the Shaker turret, E418 and 
E422 that contribute to generate the electronegative potential surrounding the N-terminus of κ-
PVIIA. The side chain of K7 of κ-PVIIA is also shown deeply buried in the ion channel selectivity 
filter located. (c) Molecular model of the complex between cyc-PVIIA and Shaker, which suggests 
that the binding mode is globally similar to that of the linear peptide apart from the absence of 
electrostatic interactions between the N-terminus and the Shaker channel. (d) Complex between 
cyc-PVIIA and Shaker at the start of the molecular dynamics simulation carried out in a POPC lipid 
membrane environment and explicit solvent. Cyc-PVIIA is in orange and Shaker is in purple; K7 is 
shown using stick representation. (e) Complex between cyc-PVIIA and Shaker at the end of the 
molecular dynamics simulation. Cyc-PVIIA is in dark green and Shaker is in light green; K7 is 
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shown using stick representation; POPC lipids are shown as grey balls. (f) superimposition of first 
and final frame of the simulation as represented in (d) and (e). (g) Evolution of backbone RMSD 
from the initial conformation during the 100 ns molecular dynamics simulation of cyc-
PVIIA/Shaker embedded in a POPC lipid membrane. The backbone RMSD values were computed 
using the transmembrane helices of the Shaker only (red), all the Shaker channel residues (green), 
cyc-PVIIA residues (light blue) and the position of cyc-PVIIA (blue), which is the backbone 
RMSD of cyc-PVIIA computed after fitting on the structure of the transmembrane helices. 
 
 
 
Figure 6. Hydrogen bond network established by Arg2 of κ-PVIIA and cyc-PVIIA. Hydrogen bond 
network of (a) Arg2 of κ-PVIIA when bound to Shaker in the model (63), (b) Arg2 of κ-PVIIA 
Arg2 in the NMR solution structure (PDB identifier 1AV3) (12), and (c) Arg2 in the molecular 
model of unbound cyc-PVIIA. The evolution of the Arg2 hydrogen bond network of κ-PVIIA (d) 
and cyc-PVIIA (e) was studied using 100 ns molecular dynamics simulations. In these simulations, 
Arg2 of κ-PVIIA formed stable hydrogen bonds with Lys7 and Cys16 and transiently established a 
hydrogen bond with Asp14. In contrast to the linear peptide, Arg2 of cyc-PVIIA did not form 
hydrogen bonds with Lys7 and Cys16 but it established a hydrogen bond more frequently with 
Asp14 than Arg2 of the linear peptide.   
 
 
4.6.6. κ-PVIIA and cyc-PVIIA serum stability 
To determine the effect of cyclization on stability, native and cyc-PVIIA were incubated in human 
serum. The majority of native κ-PVIIA was still detectable after 12 h; this was expected given that 
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the ICK motif is known to contribute to peptide stability. Indeed, a high percentage of acyclic kalata 
B1, which is topologically similar to κ-PVIIA because of its knotted conformation, remains in 
serum even after 24 h (38). Surprisingly, only ~50% of cyc-PVIIA was detectable in serum after 12 
h (Figure 7). One interpretation of this finding is that the additional constraint introduced by 
cyclization has made it more susceptible to proteolysis, thus highlighting the importance of 
optimizing the length and sequence of a linker in cyclisation studies.  
 
Figure 7. Serum stability assay on native and cyc-PVIIA. Percentage of remaining peptide 
following 0, 3, 6, 9 and 12 h incubation in human serum is presented as mean ± s.e.m of triplicates. 
 
4.7. Conclusion 
The ICK motif is found in many venom peptides that have therapeutic potential, but chemical and 
protein engineering is typically required to achieve suitable pharmaceutical properties for this motif. 
This study demonstrates that cyclization of an ICK motif-containing conotoxin is achievable via 
transpeptidation using SrtA. The linear oxidized peptide precursor of κ-PVIIA was efficiently 
cyclized, producing cyc-PVIIA with a head-to-tail cyclic backbone. The overall backbone structure 
and conformational dynamics of cyc-PVIIA is similar to native κ-PVIIA; however, following 
cyclization the peptide has partially reduced activity on the Shaker KV channel. The decrease in 
activity appears to be due to the removal of previously unrecognized electrostatic interactions 
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between the N-terminus of the peptide and negatively charged residues within the channel. Overall, 
the results of this study suggests that criteria which need to be considered in the head-to-tail 
backbone cyclization of ICK peptides include the effect of terminal mutations on activity, as well as 
the intramolecular hydrogen bond network and the conformational dynamics of the peptides. The 
study reveals that SrtA is an efficient tool for cyclizing disulfide-rich peptides that are inaccessible 
to cyclization using traditional synthetic methods. 
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5.1.   Overview 
Chemical synthesis of cyclotides is advantageous in terms of being able to make chemical 
modifications or substitution of a specific amino acid, or to incorporate unnatural amino acids or 
fluorescent labels in a peptide. However, producing large amounts of cyclotides would be 
expensive and for cyclotides to be attractive as future therapeutics, alternative routes of production 
are necessary. Recombinant expression of cyclotides on the other hand is desirable because it could, 
in principle, be more cost-effective than solid phase peptide synthesis. In addition to economic 
benefits, recombinant expression might simplify the process of purification significantly, especially 
for disulfide-rich peptides if the peptides can be correctly folded in a host cell. Chemical synthesis 
of disulfide-rich peptides, including cyclotides, typically requires multiple purification steps to 
ensure removal of scavengers, side chain protecting groups, and impurities including side products 
and disulfide bond isomers. Therefore, alternative methods to achieve correct folding, such as 
recombinant expression, have been sought to boost the production of proteins/peptides containing 
disulfide bonds.  
 
There are three methods most commonly used. Firstly, expression carried out in the bacterial 
periplasm where disulfide oxidoreductases and isomerases catalyze the formation of disulfide bonds 
(1). This approach requires the use of a signal peptide to directly export protein from the cytoplasm 
to the periplasm. Although yield of final product from periplasmic expression may not be as high 
compared to cytoplasmic expression, the environment in the cytoplasm is not ideal for disulfide 
bond formation due to the presence of numerous reductases and reducing agents such as glutathione. 
While translocation of a protein to the periplasm takes place by a signal peptide, which needs to be 
encoded by DNA in an expression vector, disulfide bond formation is catalyzed by DsbA. For 
example, MalE which is located at the N-terminus of the gene encoding MBP directs secretion of 
MBP into the periplasmic space. (In other words, the MalE sequence needs be deleted from the 
gene when MBP is used as a fusion protein for cytoplasmic expression.)  
 
The second approach to fold proteins in host cells is using fusion protein partners such as bacteria- 
derived DsbA (2,3), DsbC (4) and protein disulfide bond isomerase (PDI) (5-7) from eukaryotes 
that can help fusion protein substrates fold even in the cytoplasm. Thirdly, engineered E. coli strains 
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such as OrigamiTM(DE3)(Novagen), Rosetta-gamiTM(Novagen), and SHuffle®(NEB) have all been 
shown to overcome reductive properties of cytoplasm. 
 
Recently, a protocol describing the recombinant expression of a range of disulfide-rich peptides in 
E. coli was published (8). The authors systematically described parameters to consider including 
bacterial culture media, induction conditions, lysis methods, and fusion proteins. It is worth noting 
that in ~30 disulfide-rich peptides they tried to express, access to the desired product was achieved 
in 75% of the cases described (8). In this chapter, the possibility of inexpensive production of kalata 
B1 by expressing a linear kalata B1 precursor in bacterial periplasm was investigated based on the 
successful semi-enzymatic cyclization of synthetic kalata B1 shown in Chapter 3. In Chapter 3, the 
introduction of tri-Gly into kalata B1 made loop 6 more flexible than in the native protein. In 
addition, the SrtA-cyclized kalata B1 was slightly less stable than the native kalata B1 (9). To 
reduce this flexibility, a di-Gly was installed at the N-terminus of kalata B1. Whereas Klint et al. (8) 
used TEV protease to cleave a linear disulfide-rich peptide from the fusion protein, linear kalata B1 
precursor was designed to be cleaved using SrtA and simultaneously cyclized in vitro. A schematic 
representation of the map of gene encoding MBP-kalata B1 fusion protein for bacterial periplasmic 
expression and the cyclization strategy are shown in Figure 1. 
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Figure 1. Strategy for cyclization of MBP-LPETGG-kalata B1-TGG expressed in E. coli 
periplasm. (A) Schematic representation of the pLic-MBP expression vector for bacterial 
periplasmic expression of disulfide-rich peptides. The figure was adapted from Klint et al (8). (B) 
The linear oxidized [GG]kalata B1[TGG] containing the SrtA recognition motif at both the N- and 
C-termini undergoes an intramolecular transpeptidation reaction catalyzed by SrtA to form cyclic 
[GG]kalata B1[T]. 
 
 
5.2.   Experimental procedures 
5.2.1.   Design of expression vector 
A synthetic gene encoding the kalata B1 precursor, [GG]kalata B1[TGG], was codon optimized for 
expression in E. coli and cloned into a modified pLic-MBP expression vector which encodes N-
terminal His6 tag (10) by Geneart AG (Regenburg, Germany).  
 
5.2.2.   Bacterial culture 
Escherichia coli BL21 (DE3) transformed with the expression plasmid, pLic-MBP-
[LPETGG]kalataB1[TGG] was cultured in the presence of ampicillin (100 μg/mL) until the OD600 
reached ~0.7. Protein expression was induced by adding isopropyl β-D-thiogalactopyranoside 
(IPTG) to a final concentration of 1 mM, and incubating for 3 h at 30°C or overnight at 18°C. Also, 
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another E. Coli strain, SHuffle® T7 Express lysY (NEB, C3030H), was transformed with the same 
expression plasmid and cultured at room temperature until the OD600 reached ~0.7. Subsequently, 
protein expression was induced by adding IPTG to a final concentration of 1 mM, and incubating 
overnight at 18°C. 
 
5.2.3. Bacterial cell lysis 
The cells were harvested by centrifugation at 6000 x g for 20 min at 4°C and cell pellets were 
resuspended in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 25 mM imidazole, 10% 
glycerol). Small scale trial lysis was carried out using (i) repeat of freezing and thawing of cells, (ii) 
sonication, (iii) FastBreakTM, (iv) osmotic shock using sucrose buffer (50 mM Tris pH 7.5, 20% 
sucrose w/v) with or without proteinase inhibitor to delineate optimal lysis condictions. Cell debris 
was removed by centrifugation at 12,000 x g for 30 min at 4°C.  
 
5.2.4.   Purification of fusion protein 
The lysate was subjected to metal ion affinity chromatography using a 5 mL Ni2+ sepharose FF 
column (HisTrap FF, GE Healthcare). The column was washed extensively with lysis buffer (see 
above) following sample loading. MBP-kalata B1 was eluted with a linear gradient over 10 column 
volumes using elution buffer (50mM Tris-HCl, pH 7.5, 150 mM NaCl, and 500 mM immidazole). 
Fractions containing the fusion protein were buffer-exchanged (50 mM Tris-HCl, 150 mM NaCl, 
10 mM CaCl2 and 10% glycerol). 
 
5.2.5.   SrtA cleavage and peptide purification 
Two SrtA: substrate ratios were attempted. First, 50 μM purified His6-MBP-LPETGG-kalata B1-
TGG was incubated with the same concentration of wild-type ∆59 SrtA or SrtA5° at pH 7.5 and at 
room temperature. Second, 150 μM purified His6-MBP-LPETGG-kalata B1-TGG was incubated 
with 30 μM SrtA5° at pH 6 for 4 h. Both reactions were subjected again to the Ni2+ affinity column 
to remove SrtA as well as MBP, and the flow-through was collected to purify the cleaved the 
peptide using RP-HPLC.  
 
5.2.6. Refolding of cyclic-[GG]kalata B1[T]  
Cyclic-[GG]kalata B1[T] was dissolved in 0.1 M NH4HCO3 (pH 8) with 3 M urea and 5 mM DTT 
to a final concentration of 0.5 mg/mL and incubated at 37°C for 30 min to reduce its cystines. After 
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purification using RP-HPLC with a gradient from 20 to 50% ACN (0.05% TFA) over 30 min, the 
cyclic reduced [GG]kalata B1[T] was re-oxidized in 50% isopropyl alcohol (v/v), 0.1 M NH4HCO3 
with 1 mM reduced glutathione at pH 8 for ~24 h at room temperature (11). The oxidized product 
was purified by RP-HPLC using a gradient from 30 to 50% ACN (0.05% TFA) over 20 min.  
 
5.2.7. NMR analysis 
Purified cyclic-[GG]kalata B1[T] was dissolved in 10% D2O/H2O (v/v), pH 3.5 and subjected to 
one-dimensional and two-dimensional TOCSY experiments to be compared to the structure of cyc-
[GGG]kalata B1[LPET] as described in Jia et al. (9) (Also in Chapter 3). 
 
 
5.3.   Results  
5.3.1. Expression of MBP-[LPETGG]-kalata B1[TGG] 
In the first round of kalata B1 protein expression, E. coli cells transformed with kalata B1 precursor 
construct, linear kalata B1 fused at the C-terminus of MBP including MalE signal sequence (Figure 
1), were lysed by sonication in the buffer excluding proteinase inhibitor. However, upon cleavage 
of MBP-kalata B1 using wild-type SrtA, no cleaved peptide was detected. In order to determine if it 
was because kalata B1, which is located at the C-terminus of MBP, was degraded by proteinases 
released during cell lysis, cell lysis was carried out again in the presence or absence of proteinase 
inhibitors. Simultaneously, several additional lysis methods were investigated in order to identify 
the ultimate method to extract MBP-[LPETGG]kalata B1[TGG] (~46 kD). Lysis methods included 
a gentle method using FastBreakTM, osmotic shock (which extracts out only periplasmic expression), 
mechanical lysis using sonication and freeze-thaw method.  
The SDS-PAGE analysis showed a protein band size for MBP-[LPETGG]kalataB1[TGG] 
consistent throughout the process from cell lysis to purification regardless of lysis methods or the 
presence of the proteinase inhibitor in the lysis buffer. In terms of yield, while the osmotic shock 
method resulted in the lowest amount of the fusion protein, the lysate resulting from this extraction 
method was found to contain the least impurities of any of the methods. The other three lysis 
methods showed similar intensity of the protein band from the lysate or lysate supernatant sample 
except when FastBreakTM was used without the proteinase inhibitor (Figure 2A). The lysate 
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supernatant from each method was purified using affinity chromatography showing one major 
product (Figure 2B). 
 
 
Figure 2. Expression of kalata B1 precursor and SrtA-based cyclization (A) SDS-PAGE 
analysis of four different bacterial cell lysis methods, (B) Fast protein liquid chromatography 
(FPLC) profile of MBP-kalata B1, (C) SDS-PAGE showing progress of cyclization sampled at 
different times. 
 
5.3.2. Kalata B1 precursor cleavage by SrtA5º 
The purified MBP-kalata B1 from each lysis method was subjected to cleavage and cyclization 
using SrtA5° which has better catalytic activity than the wild-type SrtA. Surprisingly SrtA5° 
cleaved the linker (LPETGG) between MBP and kB1 of every sample from the various lysis 
methods and cyclized the precursor of kB1 very efficiently. Figure 2(C) shows the time course of 
the SrtA reaction on MBP-[LPETGG]kalata B1[TGG]. The cyclization was complete within 1 h 
and the final product showed cyclized and oxidized mass of cyc-[GG]kB1[T] after purification 
(Figure 3). The total yield of peptide showing the correct mass was about 1 mg as a result of 2 L 
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bacterial culture. Other peaks showing the same mass did not yield enough sample for NMR 
analysis. 
 
Figure 3. Purification of cyclised [GG]kalata B1[T] (A) HPLC profile of cyclic [GG]kalata B1[T] 
purification after SrtA5°+MBP-kalata B1 reaction. Fraction marked with▼ was subjected to NMR 
analysis, (B) MALDI-TOF analysis of cyclized oxidized [GG]kB1[T]. 
 
5.3.3. Periplasmic expression of [GG]kalata B1[TGG] did not achieve correct folding. 
The structure of recombinant cyclic [GG]kalata B1[T] was compared to the synthetically produced 
but enzymatically cyclized cyclo-[GGG]kalata B1[T] studied in Chapter 3. Although the 
recombinant cyclic [GG]kalata B1[T] appeared to be folded from the one-dimensional spectrum 
displaying widely spread peaks in the amide proton region, the chemical shift of each peak was 
different when superimposed with cyclo-[GGG]kalata B1[T] described in Chapter 3 (Figure 4). 
Further comparison with TOCSY spectra confirmed that their folding states were indeed different 
to each other (Figure 4). As it was reported that expressed disulfide-rich venom peptides are 
generally more soluble when the temperature is lowered to 16°C before induction (8), induction of 
expression at 18°C (which was the lowest temperature possible with the incubator available) for the 
same BL21 strain was attempted. However, overexpression of the MBP-kalata B1 fusion protein 
was not successful (Figure 5A). When the same expression strategy was applied to the SHuffle® 
strain, overexpression of MBP-kalata B1 was observed (Figure 5A), and the SrtA-mediated 
cleavage and cyclization of [GG]kalata B1[T] was successful (Figure 5B). However, two major 
isomers of [GG]kalata B1[T] were found from purification using RP-HPLC (Figure 5C). 
Unfortunately, both isomers appeared to have different structures to that of synthetically made and 
correctly folded [GGG]kalata B1[T] (Figure 6).  
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Figure 4. Comparison between recombinant cyclic [GG]kalata B1[T] and cyclo-[GGG]kalata 
B1[T] (Chapter 3) at pH 3.5 (A) 1D 1H spectra shows difference in the amide region between the 
two peptides, (B) 2D TOCSY spectrum of recombinant [GG]kalata B1[T] shows that its amide 
region is not as widely spread as that of cyclo-[GGG]kalata B1[T], which is shown in (C). 
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Figure 5. Expression of MBP-kalata B1 precursor and cleavage by SrtA. (A) SDS-PAGE 
analysis of MBP-kalata B1 precursor expression in BL21 and SHuffle® T7 express lysY 
strains,which was induced overnight at 18°C. (B) SrtA5° reaction on MBP-kalata B1 expressed in 
the SHuffle® strain. (C) HPLC profile of SrtA-cleaved and cyclized kalata B1. 
 
 
Figure 6. One-dimensional NMR spectra of synthetic [GGG]kalata B1[T] made by native 
chemical ligation, and the two isomers of [GG]kalataB1[T] derived from bacterial expression. 
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5.3.4. Refolding of cyclic-[GG]kalata B1[T] results in correct disulfide bond connectivities. 
 
Cyclic-[GG]kalata B1[T] with incorrect folding that resulted from expression using SHuffle® was 
completely reduced and subjected to oxidative folding. The peaks collected from 35% to 40% on 
the ACN gradient showed masses corresponding to the cyclic oxidized [GG]kalata B1[T] (Figure 7). 
The peak at ~40% on the ACN gradient (Figure 7; red arrow) was chosen for NMR characterization, 
as the native kalata B1 is hydrophobic and elutes later than its isomers from in vitro oxidation. The 
one-dimensional NMR spectrum was highly similar to that of synthetically made [GGG]kalata 
B1[T] (Figure 8). 
 
 
Figure 7. RP-HPLC profile of oxidation of cyclic-[GG]kalata B1[T]. The peak indicated with 
an arrow was lyophilized and analyzed to NMR experiment. 
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Figure 8. Comparison of one-dimensional NMR spectra between the synthetic [GGG]kalata 
B1[T] and refolded [GGG]kalata B1[T] after expression.   
 
 
5.4. Discussion  
In this chapter, bacterial periplasmic expression of the kalata B1 precursor, MBP-
[LPETGG]kalataB1[TGG], was attempted to enable cost-effective and efficient mass production of 
a cyclotide. The purpose of expression with the fusion protein, MBP, was for enhanced solubility 
and the His6 tag was for easy purification by affinity chromatography. Among the methods 
investigated to extract the MBP-[LPETGG]kalataB1[TGG], sonication, using FastBreakTM, and 
freez-thaw methods showed similarly good yield, but sonication would be more suitable to carry 
out large volume of bacterial culture than other methods. Although lysis by osmotic shock resulted 
in the sample with the least impurities as it allows extraction of proteins in the periplasmic space, 
the yield of the fusion protein was much lower than those from the other methods. This observation 
suggests two possibilities; (i) the yield of the fusion protein appears to be low from the cell lysate 
obtained by osmotic shock because the lysis condition was not optimal for complete bacterial cell 
breakage, or (ii) export from the cytoplasm to periplasm was not effective and thus the majority of 
the MBP-kalata B1 fusion protein remained in the cytoplasm in a reduced state. There are three 
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major pathways (12) involved in the translocation of polypeptides from the cytoplasmic membrane 
into the periplasm of Gram-negative bacteria: the Sec pathway (12), the signal recognition particle 
(SRP) pathway (13,14) and the Tat pathway (15,16). The Sec pathway transports polypeptides post-
translationally, whereas the SRP pathway does it cotranslationally. While these two pathways 
translocate unfolded polypeptides from the cytoplasm to the periplasm via Sec translocon, Tat 
pathway transports only folded polypeptides via Tat translocon. MalE favors the Sec pathway along 
with other signal peptides such as OmpA, PelB, Lamb, PhoA and MglB (17). If the translocation of 
MBP-[LPETGG]kalataB1[TGG] was indeed an issue, it is probably worth trying signal peptides 
that favor SRP pathway such as DsbA, SfmC, TolB, and TorT(17). 
 
The expressed and purified MBP-[LPETGG]kalataB1[TGG] was cleaved by SrtA5° and cyclization 
of [GG]kalataB1[TGG] was immediately achieved. Unfortunately, cyclic [GG]kalataB1[T] 
appeared to have a different structure compared to the cyclo-[GGG]kalataB1[T], which was 
successfully cyclized by SrtA (9), when analyzed by NMR. This is most likely due to misfolding 
because of non-native disulfide-connectivity. The proton signals in the TOCSY spectrum of 
recombinant [GG]kalataB1[T] were not as dispersed as those for cyclo-[GGG]kalataB1[T], and it 
was not possible to find characteristic spectral ‘markers’ of native kalata B1 such as NOEs 
reflecting Pro20 in a cis-conformation and the characteristic chemical shifts for HN of ASN11, HB 
of Pro20.   
 
Assuming the translocation of the fusion protein across the cytoplasmic membrane was not 
effective, it is possible that the kalata B1 precursor was expressed with reduced cysteines and 
subsequently formed wrong disulfide bonds in the step of lysis or cyclization in which pH 7~8 of 
buffer was used. On the other hand, if the fusion protein was misfolded in periplasm, one way to 
troubleshoot the problem is reducing the temperature of bacterial culture after addition of IPTG 
because induction temperature is an important factor to limit aggregation of recombinant protein 
expression (18,19). To test the latter hypothesis, induction at lower temperature was tried using two 
bacterial strains. While BL21 did not express the desired protein after overnight IPTG induction at 
18°C, SHuffle® over-expressed MBP-kalata B1 at the same condition. SHuffle® is an engineered 
E.coli strain to produce protein with disulfide bond formation within its cytoplasm. This strain 
expresses a choromosomal copy of the disulfide bond isomerase DsbC, which aids the correction of 
misfolded proteins into their correct form (20). Given that the SHuffle® strain performs the best at 
low temperature such as 16°C and at 1 mM IPTG (20), a similar strategy was attempted in this 
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study. Although no correctly folded [GG]kalata B1[T] was found after SrtA cleavage and 
cyclization, substantial amount of isomers were produced for refolding. Refolded [GG]kalata B1[T] 
appeared to have a highly similar structure to that of synthetically made [GG]kalata B1[T] when 
examined using NMR. This result implies that [GG]kalta B1[T] can be more efficiently produced 
via expression in the cytoplasm in the reduced state followed by SrtA cyclization and in vitro 
folding.   
 
While this project was being pursued, a study demonstrated the backbone cyclization of a 
recombinant cystine-knot peptide, MCoTI-II, by SrtA (21). The authors of that study expressed 
MCoTI-II with GST fusion protein with a His6 tag and placed the sorting motif, LPETGG, only at 
the C-terminus of MCoTI-II. At the N-terminus a TEV sequence followed by tri-Gly was used 
instead of the sorting motif for cleavage of the peptide from the fusion protein. Folding of MCoTI-
II was achieved while MCoTI-II was being cleaved by TEV protease because of the oxidative 
condition of the buffer. The authors also used mutant SrtA (22) with better catalytic activity than 
the wild-type SrtA to cyclize McoTI-II.  
 
The ultimate goal of recombinant expression of a cyclotide would be to achieving both oxidation 
and cyclization in cellular environment. Cyclization and secretion of the eGFP, in the cytosol and 
endoplasmic reticulum (ER) lumen of S. cerevisiae and mammalian HEK293T cells was achieved 
utilizing SrtA (23). A linear substrate protein was equipped with an N-terminal signal peptide that 
displays a glycine residue after cleavage and a C-terminal sortase recognition motif followed by a 
Myc epitope tag and an ER retention signal (Myc-HDEL) which allows observation of substrate 
recognition by SrtA followed by entering the secretory pathway. S. cerevisiae was transformed with 
the substrate protein expression plasmid and the pGAL-ER-SrtA plasmid. Sortase (of S.pyogenes) 
was active in the ER lumen and subsequently cyclic protein was secreted which could be regulated 
by galactose-inducible ER-SrtA expression (23).  
 
Although the strategy used in this chapter did not achieve a correctly folded kalata B1, there are 
many factors that can be optimized such as changing the induction temperature, signal peptide 
sequence, fusion protein partners or E. coli host strains to name a few. Nevertheless, this study 
highlights the potential to produce cyclic peptides with disulfide bonds formed via recombinant 
expression. Recently, an enzyme involved in the biosynthesis of cyclotides, asparaginyl 
endopeptidase (AEP), was successfully isolated from Clitoria ternatea, and a related enzyme was 
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recombinantly expressed (24-26). Hopefully, with tools including SrtA and AEP at hand, 
recombinant expression of cyclotides (with or without a linker region) will be possible in the near 
future. 
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6.1. Overview 
As described in previous chapters, cyclotides have been used extensively as drug scaffolds to 
accommodate therapeutically useful linear peptide sequences to confer stability. For example, linear 
peptides with proangiogenesis (1), regulation of p53 tumor suppressor pathway (2) or 
immunoregulatory (3) activity have been successfully grafted into cyclotides. As cyclotides are 
being developed for clinical applications, a more detailed understanding of their immunological 
properties is desirable. For example, the immunogenicity of cyclotide scaffolds, the immunological 
effect caused by conformational constraints introduced to the epitope, and how the compact 
structure of cyclotides affect the process required to generate MHC-restricted epitopes essential for 
T-cell help in the production of antibodies are all unknown factors because cyclotides have not been 
systematically explored as immunogens. 
 
In the context of studying the biosynthesis of cyclotides, generating antibodies against cyclotides 
can be useful e.g. to localize the peptides in plant tissues. Cyclotides originate from their precursor 
proteins in plants, and the backbone is cyclized by asparaginyl endopeptidase (AEP) during post-
translational processing (4,5). However, more information on the mechanism and distribution of 
cyclotides and their linear precursor needs to be elucidated. Therefore, antibodies that specifically 
bind to and distinguish cyclotides from their linear precursors would help characterize the location 
and timing of the conversion of linear precursors into the corresponding cyclotides. To date, such 
studies have been achieved using MALDI imaging (6), MALDI-TOF mass spectrometry and an 
antibody elicited against the precursor protein of kalata B1, Oak 1 (~14 kDa), as an immunogen (7). 
The Oak 1 antibody was able to detect kalata B1 in an immunoblot analysis, but showed limited 
sensitivity (7).  
 
In general, peptide-based immunization suffers limitations because of the inefficient delivery of 
peptides to professional antigen presenting cells (APCs) (8). This is because peptides are often 
intrinsically weak due to poor chemical and physical stability. This drawback for peptides as 
immunogens can be overcome by delivering peptides using carriers like nanoparticles or 
microspheres (8,9). Another strategy improving peptides as immunogens is conjugation to an 
antibody. For example, the use of an antibody targeting MHC class II can efficiently deliver 
antigens to dendritic cells (10-12). Hopefully bringing the antibody-antigen complex to the 
dendritic cells can process the antigen in the context of MHC class II products and subsequently 
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lead to the generation of T-helper cells, which is crucial for an effective secondary antibody 
response (13).  
 
Recently, a camelid (alpaca)-derived single-domain antibody fragment, VHH, was reported to 
target mouse a MHC class II molecule, namely VHH7 (14). Camelids, whose members include 
camels, llama, and vicugna, produce not only conventional antibodies, but also heavy-chain-only 
antibodies in which VHH exists as an antigen-binding domain (i.e., variable domain). VHH can be 
easily identified from heavy-chain antibodies after immunizing a camelid, via cloning the VHH 
repertoire of B cells and panning by phage display (15). They bind an antigen with nanomolar 
affinity (16), highly soluble, and are much smaller than conventional antibodies (~15 kDa vs. ~150 
kDa). These characteristics have led to the bacterial recombinant expression of VHHs (14,17) 
which is more straightforward and cost-effective than general antibody recombinant expression in 
mammalian cells. 
 
In this thesis, click chemistry was employed to conjugate a cyclotide to an anti-class II MHC VHH 
(14) to improve its immunogenicity. The purpose of using anti Class II VHHs derives from their 
ability to deliver attached payloads to the very same cells responsible for antigen presentation in 
vivo, including dendritic cells.A non-natural amino acid was incorporated during cyclotide 
synthesis to enable a subsequent click reaction with a DBCO-modified anti MHC Class II VHH (18) 
(Figure 1). This strategy overcomes the fact that cyclotides lack a free N- and C-terminus, contain 
only fully oxidized cysteines and in their natural form have no amino acid residue enabling 
conjugation to a carrier protein. The comparatively small size of cyclotides also makes the presence 
of an adequate set of T helper epitopes unlikely, a complication confounded by the compact fold 
and the presence of three disulfide bonds, each of which is presumably required to be reduced for 
antigen presentation to occur. Whereas the range of chemical modifications available for site-
specific attachment of the antigenic cargo was limited in previous conjugation studies (19), here a 
sortase-catalyzed reaction that affords both excellent yields (20,21) and absolute site specificity (22) 
was used. There are other enzymes used for antibody conjugation, such as transglutaminase (TGase) 
(23) (Figure 2A) or formylglycine-generating enzyme (FGE) (24) (Figure 2B). However, TGases 
tend to have low substrate specificity (25), and reconstituted FGE has poor activity in vitro (26) and 
requires the addition of a CuI cofactor to improve its activity (27).  
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Two cyclotides were examined for immunogenicity: MCoTI-I in its native form with the exception 
of the single azido-lysine substitution, and MCoTI-I with a HA epitope grafted into loop 6, here 
after referred to as MCoTI-HA (Figure 1A). It was found that conjugating cyclotides to an alpaca-
derived single domain antibody VHH targeting MHC class II product, VHH7 (14) dramatically 
improves the induction of antibodies reacting with cyclotides. Surprisingly, MCoTI-HA does not 
induce HA-specific antibodies and show less reactivity with a commercially available anti HA 
antibodies. Our results suggest that constraining the conformation of a particular sequence will 
hamper its reactivity against antibodies raised against the sequence. The data is also relevant for the 
design of peptide derivatives with enhanced or reduced immunogenicity.   
  
 
 
Figure 1. (A) Sequence of MCoTI-I and MCoTI-HA (HA-tag shown in light blue). The site of 
azidolysine is shown in bold. (B) Schematic representation of Cu-free click reaction between 
cyclooctyne and azide, (C) Schematic illustration of conjugation strategy. VHH7 targeting antigen 
presenting cells (APCs) expressed with sorting motif, LPETGG, gets equipped with 
dibenzylcyclooctyne (DBCO) by SrtA reaction and subsequently conjugated with MCoTI-I (shown 
in cartoon representation) possessing azidolysine. 
 
 
6.2. Experimental procedures 
6.2.1. Peptides synthesized 
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All the peptides were synthesized following the Fmoc-chemistry protocol outlined in Chapter 2. 2-
Chlorotritylchloride resin and an unnatural amino acid, Fmoc-Lys(N3)-OH (Chem-Impex 
International) were used for the synthesis of MCoTI-I and MCoTI-HA, for conjugation to VHH7. 
Cyclization was achieved following the strategy described by Cheneval et al. (28). The cyclic 
reduced peptides were oxidized in 0.1 M NH4HCO3 at pH 8. The probe peptides used in SrtA 
reaction, Gly-Gly-Gly-Cys-NH2 and Gly-Gly-Gly-HA-tag (YPYDVPDYA)-NH2 and linear HA-tag 
peptides were assembled on rink amide resin.  
 
 
Figure 2. Schematic representation of other enzymatic modification strategies (A) 
Transglutaminase catalyzes transamination of Gln in the LLQGA recognition sequence installing 
diverse amines. (B) Formylglycine generating enzyme (FGE) converts thiol of the cysteine to an 
aldehyde group, which subsequently goes through reactions with aminooxy or hydrazide probes. 
 
 
 6.2.2. Nuclear magnetic resonance (NMR) analysis 
MCoTI-I and MCoTI-HA were subjected to structure calculation as described in Chapter 4. Briefly, 
peptides were dissolved in 90% H2O/10% D2O (v/v) or 100% D2O to a final concentration of 0.5 
mM at pH 3. All two-dimensional NMR spectra were acquired at 298 K, except for temperature 
coefficient experiments (283-308 K), on a Bruker Avance 600-MHz NMR spectrometer equipped 
with a cryogenically cooled probe (Bruker, Karlsruhe, Germany).  
 
 6.2.3. Expression of recombinant VHH7 and Enhancer protein (VHH raised against green 
fluorescent protein) 
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E. coli glycerol stocks for expression of recombinant VHH7 and Enhancer VHH were obtained 
from Prof. Hidde Ploegh’s laboratory at the Whitehead Institute for Biomedical Research, 
Cambridge, MA, USA, and expressed as described previously (29). Briefly, the gene encoding a 
His6 tagged VHH and LPXTG motif near the C-terminus was cloned in pHEN6 expression vector 
for periplasmic expression. Protein expression was induced by addition of 1 mM IPTG at 
OD600=0.7 and cells were grown overnight at 30ºC. The periplasmic expression was harvested by 
osmotic shock and VHHs purified by Ni-NTA affinity and PD-10 desalting columns (GE 
Healthcare Life Sciences). 
 
6.2.4. Maleimide-thiol reaction on Gly-Gly-Gly-Cys-NH2 
Purified GGGC peptide (~80 μmol) was dissolved in PBS and dibenzylcyclooctyne-maleimide 
(DBCO-maleimide) (40 μmol, Click Chemistry Tools) dissolved in DMF was added. The reaction 
was incubated at room temperature overnight and subjected to purification using RP-HPLC with a 
gradient of 0‒40% ACN (0.05% TFA) over 40 min to remove unreacted GGGC peptide. Fractions 
showing correct mass were lyophilized (18).  
  
6.2.5. Modification of VHH7 using SrtA  
SrtA heptamutant (30) of S. aureus (20 μM final concentration) and GGGC(DBCO)-NH2 (1 mM 
final concentration) were added to the VHH (200 μM final concentration) in sortase buffer (50 mM 
Tris, pH 7.5, 150 mM NaCl). The reaction was incubated at room temperature for ~4 h. His6-tagged 
SrtA and unreacted VHH were removed by Ni-NTA agarose and VHH-GGGC(DBCO) was 
purified using Superdex 75 size exclusion column and purity was analysed by SDS-PAGE. 
 
6.2.6. Conjugation of a cyclotide to VHH7 
80 μM of VHH equipped with DBCO and 160 μM MCoTI-I or MCoTI-HA containing azidolysine 
were conjugated in PBS at 4 ºC overnight. Conjugation progress was monitored by SDS-PAGE and 
LC-MS. Additionally, GGG-HA-tag was ligated to the C-terminus of VHH by SrtA reaction. 
 
6.2.7. Immunization and serum collection 
BALB/C mice (6 weeks old) were immunized with 2.8 nmol of peptides (MCoTI-I, MCoTI-HA, 
HA) or VHH-peptide conjugates together with 50 μg of polyinosinic:polycytidylic acid (poly I:C) 
and 25 μg αCD40. Mouse blood was collected by cheek bleeding and serum was separated using 
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BD Microtainer™ tube. All described procedures were approved by the Massachusetts Institute of 
Technology Committee on Animal Care.  
 
6.2.8. SDS-PAGE and Western blot 
Enhancer-peptide conjugates were subjected to SDS-PAGE at 80 V for 100 min and transferred to 
nitrocellulose membrane at 60 V for 120 min. The presence of protein samples on the nitrocellulose 
membrane was determined by Ponceau staining. Anti-sera collected from mice was used as primary 
antibody after 1:1000 dilution and anti-mouse IgG, horseradish peroxidase conjugated antibody was 
used for detection. For commercially available antibodies, monoclonal anti-HA antibody produced 
in mouse (Sigma-Aldrich, MO, #H3663 and Cell Signaling Technology, MA, #2367), anti-HA 
rabbit polyclonal antibody (Y-11, Santa Cruz Biotechnology, TX, #sc-805) were used.  
   
6.3. Results  
6.3.1. Click handle installation on MCoTI-I and a probe for VHH7 
To conjugate MCoTI peptides to VHH7 using a strain-promoted click reaction, click handles such 
as azide or cyclooctyne needed to be attached to MCoTIs and two strategies were tried: (i) an NHS 
(N-hydroxysuccinimide) ester reaction for chemical conjugation to the primary amine of lysine 
(Figure 3A), (ii) incorporation of azidolysine during the synthesis of MCoTIs. Given that MCoTI-I 
has only one lysine, modification using NHS ester activated DBCO was attempted first, but yielded 
less than 50% modification of the peptide in the reaction and required additional purification 
(Figure 4). Therefore, a second strategy was chosen to produce MCoTIs with a click handle. GGGC 
was used as a probe in the SrtA reaction to modify VHH7 and was equipped with DBCO via a 
maleimide-thiol reaction (Figure 3B).  
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Figure 3. Schematic representation of peptide modification strategies (A) NHS (N-
hydroxysuccinimide) ester reaction for chemical conjugation to a primary amine of lysine, (B) 
Maleimide-thiol reaction for chemical conjugation to a sulfhydryl. R represents a labeling reagent 
(DBCO). 
 
 
 
 
 
Figure 4. DBCO NHSester modification on MCoTI-HA. (A) LC profile of the reaction. The 
peak rising at 0.7 min contained unmodified MCoTI-HA and the peak rising at 0.9 min contained 
DBCO-modified MCoTI-HA. (B) Mass data corresponding to 0.7 min (upper) and 0.9 min (lower).  
 
 
 
6.3.2. Bacterial expression, SrtA-mediated modification of VHH7, and conjugation to MCoTI-
I / MCoTI-HA 
VHH7 with the SrtA motif near the C-terminus was expressed in the bacterial periplasm in order to 
have a disulfide bond formed. After purification by affinity and size exclusion chromatography, 
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purity and yield was analysed by SDS-PAGE (Figure 5A) and GGGC(DBCO) was coupled at the 
C-terminus via SrtA reaction. Subsequently, the click reaction between the azido-lysine of the 
MCoTIs and cyclo-octyne (DBCO) was performed in aqueous buffer at neutral pH, thus avoiding 
any unwanted side reactions, and yielded VHH7 modified at its C-terminus with either McoTI-I or 
McoTI-HA. Identity of the VHH7-McoTI-I and VHH7-McoTI-HA adducts after 21 h was 
confirmed by SDS-PAGE (Figure 5B), which yielded polypeptides of the expected sizes, and 
further verified by LC-MS (Figure 5C).  
 
 
 
Figure 5. VHH7 and its conjugation to cyclotides (A) Commassie stained gel showing expression 
of VHH7 lane1: E.coli culture media collected after IPTG induction, 2: E.coli lysate, 3: flow-
through sample collected after loading the lysate to Ni-NTA agarose column, 4-12: fractions 
collected after size-exclusion chromatography, (B) Instant blue stained gel showing the progress of 
click reaction between VHH7-GGGC(DBCO) and MCoTI-I / MCoTI-HA, (C) Mass of modified 
VHH7 after SrtA reaction and conjugates after click reaction. 
 
 
6.3.3. NMR analysis of MCoTI-I and MCoTI-HA 
The amide region of both peptides was well dispersed in the TOCSY and NOESY spectra and the 
sequential connectivity could be readily confirmed. Comparison of the secondary Hα chemical 
shifts between MCoTI-I and MCoTI-HA showed that grafting of the HA-tag did not affect the 
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overall structure integrity of MCoTI-I (Figure 6A). Additional two-dimensional experiments were 
subsequently performed to determine three-dimensional structures of both peptides. Chemical shifts 
obtained for 1H, 13C, 15N are shown in Tables 1 and 2. Potential residues involved in hydrogen bond 
network were also found from temperature coefficient (Table 3, 4) and D2O exchange experiments. 
Dihedral angle restraints for the backbone ϕ, ψ angles were predicted by TALOS using the Hα, Cα, 
Cβ, HN, and N chemical shifts in addition to 3JHN-Hα coupling constants measured from antiphase 
cross-peak splitting in the DQF-COSY spectrum (Table 5).  
 
For each of MCoTI-I and MCoTI-HA, an ensemble of 20 minimum-energy structures was selected 
from the structures calculated and refined in a water shell using CNS. Structural statistics are 
summarized in Table 6. Initially, grafting of the HA-tag was anticipated to make the structure of 
MCoTI-I more rigid because the HA-tag sequence includes two prolines. Proline is 
conformationally rigid because of its fixed ϕ torsion angle of -60°. Therefore, flexibility of each 
loop was compared between MCoTI-I and MCoTI-HA based on Hβ chemical shifts of Cys as well 
as RMSD values. In general, a large βH chemical shift separation for an individual methylene pair 
of protons indicates that the pair is located in a highly structured environment (31). A similar 
degree of Hβ chemical shift separation was observed for the cysteines of both peptides, suggesting 
that the Pro-rich HA-tag did not dramatically affect the flexibility of MCoTI-I, although slightly 
larger Hβ separation of CysIV was found for MCoTI-HA (0.15 ppm versus 0.08 ppm). RMSD 
values for each loop measured using MolMol (32) agreed with this result (Table 7). 
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Figure 6. Structural comparison of MCoTI-I and MCoTI-HA. (A) Hα secondary-shift 
comparison of MCoTI-I and MCoTI-HA. (B) Superimposition of the 20 lowest energy structures of 
MCoTI-I (left) and MCoTI-HA (right). Disulfide bonds are shown in grey in both structures. 
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Table 1. Chemical shifts (ppm) of MCoTI-I 
 
 
 
  
H N NE HA HB HG HD HE CA CB CG CD Others
1 Gly 8.21 108.4 - 4.13,3.85 - - - - 47.87 - - -
2 Gly 8.11 108.1 - 3.96,3.95 - - - - 47.05 - - -
3 Val 8.47 121.1 - 4.06 1.99 0.95,0.85 - - 65.05 35.37 23.34,23.60 -
4 Cys 8.69 126.6 - 5.14 2.91,2.90 - - - 54.88 43.71 - -
5 Pro - - - 4.45 2.32,2.33 1.94,2.04 3.89,3.83 - 65.85 35.19 29.85 54.11
6 Lys - - - 4.42 1.88,1.65 1.36,1.48 1.70,1.70 3.01,            3.02 61.61 33.99 27.47 31.49
7.55:HZ, 
126.79:NZ, 
44.61:CE
7 Ile 7.65 120.3 - 4.42 1.89 1.35,0.88, 1.13 0.86 - 62.9 42.99
20.42,       
29.33 16.45
8 Leu 8.67 126.2 - 4.49 1.56,1.72 1.49 0.76,0.77 - 57.06 44.17 29.82
26.41,         
27.36
9 Gln 8.7 - 112.57 4.57 2.00,1.74 2.37,2.47 - 6.99,7.51 57.95 34.39 36.38 -
10 Arg 8.74 127.6 119.69 4.48 1.69,1.61 1.21,1.21 2.88,2.97 6.96 58.4 33.49 30.49 45.42
11 Cys 8.4 115.8 - 4.87 3.03,3.21 - - - 56.75 50.66 - -
12 Arg 9.45 117.9 116.64 4.47 1.75,1.90 1.65,1.65 3.21,3.20 7.31 58.85 34.92 29.76 45.62
13 Arg 8.09 117 119.47 4.75 2.03,1.81 1.58,1.47 3.15 7.16 56.43 35.54 28.35 46.04
14 Asp 9.31 123.5 - 4.13 2.85,3.01 - - - 60.97 40.83 - -
15 Ser 8.19 111.1 - 4.3 4.12,3.84 - - - 62.69 64.86 - -
16 Asp 7.72 120.4 - 4.64 3.04,3.06 - - - 58.29 44.94 - -
17 Cys 8.07 117.5 - 4.99 2.74,2.85 - - - 54.81 43.26 - -
18 Pro - - - 4.64 1.95,2.32 2.03,2.11 3.42,3.87 - 64.87 35.13 30.11 52.61
19 Gly 8.48 106.5 - 3.79,3.84 - - - - 49.93 - - -
20 Ala 8.41 125.1 - 4.5 1.41 - - - 54.36 21.03 - -
21 Cys 8.23 117.3 - 4.7 3.23,3.31 - - - 58.74 48.24 - -
22 Ile 9.04 113.2 - 4.43 1.93 1.09,0.98, 0.87 0.83 - 58.32 43.97
22.09,     
28.66 17.01
23 Cys 8.94 120.4 - 4.98 2.51,2.81 - - - 57.63 40.79 - -
24 Arg 8.14 128.6 118.19 4.35 2.07,2.53 1.76,1.63 3.26,3.27 6.91 59.07 33.8 30.51 45.94
25 Gly 8.9 108.2 - 3.94,3.95 - - - - 49.47 - - -
26 Asn 7.81 115.7 - 4.72 3.34,2.88 - 7.56,6.60 - 54.84 39.63 - - 108.55: ND
27 Gly 8.41 107.3 - 3.72,4.01 - - - - 48.99 - - -
28 Tyr 7.31 119.8 - 5.28 3.06,2.66 - 6.86 6.71 59.77 44.32 - -
29 Cys 8.81 120.7 - 5.39 3.17,2.83 - - - 58.26 43.57 - -
30 Gly 9.79 109.6 - 3.94,4.54 - - - - 48.32 - - -
31 Ser 8.84 116 - 4.54 3.91,3.98 - - - 62.3 66.66 - -
32 Gly 9.1 111.4 - 4.42,3.90 - - - - 47.29 - - -
33 Ser 8.67 115.9 - 4.46 3.91,3.91 - - - 61.76 66.2 - -
34 Asp 8.6 119.6 - 4.82 2.90,2.95 - - - 55.7 41.19 - -
Chapter 6. Conjugation of a cyclotide to a single domain antibody to elicit an immune response 
 
131 
 
 Table 2. Chemical shifts (ppm) of MCoTI-HA 
 
 
 
  
H N NE HA HB HG HD HE CA CB CG CD Others
1 Gly 7.62 106.91 - 3.89,3.89 - - - - 48.01 - - - -
2 Gly 8.05 108.13 - 3.99,3.99 - - - - 47.59 - - - -
3 Val 8.2 118.19 - 4.22 2.04 0.94,0.89 - - 65.06 35.95 23.77,24.02 - -
4 Cys 8 122.58 - 5.04 2.23,2.28 - - - 55.29 42.17 - - -
5 Pro - - - 4.4 1.93,2.30 2.01,1.96 3.71,3.76 - 65.84 35.04 30.19 53.64 -
6 Lys 8.06 121.23 - 4.32 1.72,1.87 1.46,1.40 1.62 3.33 58.98 34.38 27.76 32.86 56.32:CE
7 Ile 7.56 120.36 - 4.26 1.85 0.86,1.13,  1.37 0.85 - 62.94 42.48 29.58,20.21 16.14 -
8 Leu 8.47 125.76 - 4.35 1.58 1.51 0.73,0.71 - 57.6 44.05 29.72 26.20,27.40 -
9 Gln 8.69 124.93 112.15 4.57 1.98,1.78 2.42,2.35 - 6.92,7.48 57.68 34.02 36.36 - -
10 Arg 8.71 127 119.68 4.45 1.68,1.63 1.26 2.99,2.91 6.97 58.8 33.48 30.49 45.48 -
11 Cys 8.39 115.99 - 4.87 3.18,3.00 - - - 56.55 50.49 - - -
12 Arg 9.37 117.89 119.74 4.45 1.74,1.89 1.63 3.18 7.3 58.54 34.79 29.73 45.65 -
13 Arg 8.06 116.75 119.45 4.72 1.81,2.04 1.45,1.56 3.14,3.15 7.14 56.45 35.47 28.36 45.96 -
14 Asp 9.41 122.97 - 4.13 2.92,3.10 - - - 60.57 40.06 - - -
15 Ser 8.21 111.46 - 4.3 4.12,3.83 - - - 62.71 64.81 - - -
16 Asp 7.68 120.31 - 4.63 3.02,3.05 - - - 58.13 44.76 - - -
17 Cys 8.03 117.58 - 5.01 2.77,2.64 - - - 54.57 42.8 - - -
18 Pro - - - 4.59 2.10,2.31 1.93,2.02 3.86,3.35 - 64.96 34.6 29.97 52.82 -
19 Gly 8.44 106.35 - 3.84,3.84 - - - - 49.95 - - - -
20 Ala 8.24 125.25 - 4.46 1.32 - - - 54.21 21.45 - - -
21 Cys 8.13 115.45 - 4.55 3.16,3.01 - - - 57.51 45.15 - - -
22 Ile 8.83 112.12 - 4.42 1.84 0.84,0.99,      0.80 0.7 - 61.58 44.1 28.88,22.13 17.22 -
23 Cys 8.6 119.86 - 4.94 2.50,2.77 - - - 57.59 40.66 - - -
24 Arg 8.17 128.68 117.96 4.31 2.48,2.05 1.66,1.47 3.20,3.19 6.76 59.35 34.04 31.07 45.65 -
25 Gly 8.79 108.06 - 3.95,3.95 - - - - 49.49 - - - -
26 Asn 7.82 115.79 - 4.7 3.32,2.88 - 7.58,6.65 - 54.91 39.66 - - 108.67:ND
27 Gly 8.38 107.22 - 3.98,3.69 - - - - 48.91 - - - -
28 Tyr 7.27 116.5 - 5.28 2.62,3.01 - 6.83 6.7 59.57 44.37 - - -
29 Cys 8.82 120.58 - 5.38 3.10,2.77 - - - 58.04 43.2 - - -
30 Gly 9.66 109.07 - 4.36,3.85 - - - - 48.35 - - - -
31 Tyr 8.59 119.63 - 4.63 2.76,3.02 - 7.16 6.91 60.5 40.7 - - -
32 Pro - - - 4.28 1.81,2.22 1.89,1.94 3.44,3.82 - 65.64 34.39 30.32 53.33 -
33 Tyr 7.88 118.77 - 4.45 3.12,2.83 - 7.15 6.84 61.21 41.25 - - -
34 Asp 8.42 116.8 - 4.61 2.94,2.84 - - - 55.73 40.19 - - -
35 Val 7.65 118.86 - 4.48 2.07 0.88,0.93 - - 62.23 35.7 23.20,22.86 - -
36 Pro - - - 4.28 1.67,2.15 1.94 3.76,3.66 - 66.01 34.6 30 53.53 -
37 Asp 8.26 117.26 - 4.48 2.75,2.83 - - - 55.51 40.23 - - -
38 Tyr 7.77 119.57 - 4.44 2.99,3.00 - 7.06 6.79 60.58 41.01 - - -
39 Ala 8.16 126.04 - 4.29 1.31 - - - 55.17 21.13 - - -
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Table 3. Temperature coefficients of MCoTI-I. Amino acid residues involved in hydrogen bonds 
are highlighted in yellow (i.e. temperature coefficients less negative than -4.7 ppb/K) 
No. a.a. Temperature (K)   283 288 293 298 303 308 ppb/K 
1 G 8.281 8.255 8.235 8.213 8.183 8.161 -4.8 
2 G 8.216 8.174 8.145 8.113 8.08 8.049 -6.6 
3 V 8.592 8.549 8.512 8.469 8.415 8.376 -8.7 
4 C 8.816 8.772 8.728 8.687 8.638 8.594 -8.9 
5 P               
6 K               
7 I 7.708 7.687 7.669 7.653 7.624 7.608 -4 
8 L 8.785 8.746 8.709 8.67 8.625 8.59 -7.9 
9 Q           
10 R 8.841 8.804 8.769 8.739 8.694 8.663 -7.1 
11 C 8.422 8.412 8.406 8.4 8.384 8.376 -1.8 
12 R 9.486 9.472 9.462 9.444 9.433 9.421 -2.6 
13 R 8.118 8.108 8.102 8.084 8.075 8.069 -2.1 
14 D 9.416 9.38 9.342 9.309 9.277 9.241 -7 
15 S 8.318 8.272 8.232 8.194 8.147 8.108 -8.4 
16 D 7.755 7.746 7.735 7.723 7.706 7.697 -2.4 
17 C 8.127 8.108 8.091 8.072 8.052 8.033 -3.8 
18 P               
19 G 8.586 8.552 8.512 8.484 8.439 8.411 -7.1 
20 A 8.504 8.47 8.44 8.413 8.377 8.347 -6.2 
21 C 8.271 8.258 8.244 8.231 8.205 8.19 -3.3 
22 I 9.069 9.074 9.058 9.042 9.014 8.988 -3.4 
23 C 8.989 8.974 8.964 8.942 8.928 8.909 -3.2 
24 R 8.188 8.173 8.16 8.143 8.129 8.119 -2.8 
25 G 9.007 8.964 8.932 8.898 8.858 8.821 -7.3 
26 N 7.837 7.828 7.821 7.811 7.8 7.792 -1.8 
27 G 8.436 8.429 8.417 8.411 8.398 8.387 -2 
28 Y 7.328 7.319 7.312 7.306 7.292 7.288 -1.6 
29 C 8.856 8.834 8.825 8.81 8.79 8.778 -3.1 
30 G 9.827 9.815 9.803 9.79 9.77 9.756 -2.9 
31 S 8.96 8.915 8.873 8.835 8.787 8.751 -8.4 
32 G 9.215 9.17 9.139 9.102 9.057 9.022 -7.7 
33 S 8.784 8.75 8.706 8.669 8.625 8.586 -8 
34 D 8.692 8.658 8.628 8.597 8.56 8.528 -6.5 
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Table 4. Temperature coefficients of MCoTI-HA. Amino acid residues involved in hydrogen 
bonds are highlighted in yellow (i.e. temperature coefficients less negative than -4.7 ppb/K) 
No. a.a. Temperature (K)   283 288 293 298 303 308 ppb/K 
1 G 7.641 7.628 7.632 7.625 7.616 7.605 -1.3 
2 G 8.141 8.108 8.085 8.052 8.029 8.002 -5.5 
3 V 8.34 8.292 8.254 8.2 8.163 8.116 -8.9 
4 C 8.025 8.018 8.017 8 7.992 7.971 -2.1 
5 P               
6 K               
7 I 7.638 7.606 7.593 7.567 7.549 7.528 -4.3 
8 L 8.545 8.517 8.501 8.469 8.444 8.411 -5.3 
9 Q 8.797 8.762 8.733 8.691 8.656 8.614 -7.3 
10 R 8.833 8.791 8.759 8.714 8.68 8.635 -7.8 
11 C 8.423 8.411 8.409 8.398 8.387 8.377 -1.8 
12 R 9.422 9.408 9.399 9.374 9.365 9.343 -3.1 
13 R 8.094 8.081 8.077 8.06 8.06 8.045 -1.9 
14 D 9.516 9.477 9.45 9.415 9.382 9.346 -6.7 
15 S 8.342 8.298 8.262 8.214 8.176 8.131 -8.4 
16 D 7.725 7.71 7.707 7.688 7.678 7.662 -2.5 
17 C 8.091 8.07 8.06 8.036 8.02 7.998 -3.7 
18 P               
19 G 8.55 8.512 8.484 8.445 8.416 8.377 -6.8 
20 A 8.306 8.282 8.269 8.238 8.222 8.197 -4.3 
21 C 8.182 8.166 8.151 8.13 8.118 8.095 -3.4 
22 I 8.886 8.865 8.852 8.827 8.812 8.79 -3.8 
23 C 8.657 8.637 8.625 8.603 8.59 8.565 -3.6 
24 R 8.213 8.202 8.194 8.179 8.172 8.156 -2.2 
25 G 8.89 8.855 8.828 8.792 8.763 8.726 -6.5 
26 N 7.854 7.842 7.838 7.826 7.819 7.81 -1.7 
27 G 8.412 8.401 8.396 8.38 8.374 8.358 -2.1 
28 Y 7.304 7.295 7.287 7.274 7.267 7.256 -1.9 
29 C 8.862 8.844 8.839 8.823 8.813 8.795 -2.5 
30 G 9.699 9.685 9.677 9.661 9.647 9.629 -2.7 
31 Y 8.692 8.656 8.63 8.593 8.561 8.524 -6.6 
32 P               
33 Y 8.044 7.991 7.942 7.884 7.837 7.779 -10.5 
34 D 8.506 8.474 8.457 8.424 8.404 8.376 -5.1 
35 V 7.744 7.71 7.688 7.656 7.631 7.602 -5.6 
36 P               
37 D 8.388 8.341 8.305 8.258 8.224 8.18 -8.2 
38 Y 7.833 7.815 7.8 7.779 7.761 7.735 -3.8 
39 A 8.267 8.248 8.212 8.161 8.122 8.078 -7.9 
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Table  5. Dihedral angle restraints for MCoTI-I and MCoTI-HA 
MCoTI-I 
  
MCoTI-HA 
No. amino acid 
dihedral 
angles 
min. 
value 
max. 
value 
3J 
HN-Hα No. 
amino 
acid 
dihedral 
angles 
min. 
value 
max. 
value 
3J 
HN-Hα 
4 CYS PSI 111.5 158.7   2 GLY PHI -84.3 -44.3   
5 PRO PSI -54 -14   3 VAL PHI -150 -90 ~8Hz 
6 LYS PHI -88.1 -48.1   4 CYS PSI 113.7 157.1   
9 GLN PHI -190.6 -50.6   5 PRO PSI -51.5 -11.5   
9 GLN PSI 116.5 171.8   6 LYS PHI -90.3 -50.3   
10 ARG PHI -222.2 -16.2   7 ILE PHI -150 -90 ~9Hz 
10 ARG PSI 86.2 184.3   9 GLN PHI -166.8 -71.5   
11 CYS PHI -169.3 -126   9 GLN PSI 111.7 172.7   
11 CYS PSI 136.1 188.8   10 ARG PHI -157.1 -16.1   
11 CYS CHI1 30 90   10 ARG PSI 87.6 186.8   
12 ARG PHI -131.5 -45.1   11 CYS PHI -166.2 -122.2   
12 ARG PSI -62.9 15.4   11 CYS PSI 131.7 178.5   
13 ARG PHI -182.3 -82.7   11 CYS CHI1 30 90   
13 ARG PSI 113.2 185.2   12 ARG PHI -134 -47.2   
13 ARG CHI1 30 90   12 ARG PSI -62.1 17.4   
14 ASP PHI -81 -41   13 ARG PHI -180.3 -88.4   
14 ASP PSI -57.6 -17.6   13 ARG PSI 115.9 184.2   
15 SER PHI -84.8 -44.8   13 ARG CHI1 30 90   
15 SER PSI -53.9 -13.9   14 ASP PHI -80.7 -40.7   
15 SER CHI1 30 90   14 ASP PSI -57.5 -17.5   
16 ASP PHI -95.5 -53   15 SER PHI -84.6 -44.6   
16 ASP PSI -53.3 -13.3   15 SER PSI -53.1 -13.1   
17 CYS PHI -138 -31.5   16 ASP PHI -95.7 -53.5   
17 CYS PSI 65.2 168.7   16 ASP PSI -53.7 -13.7   
20 ALA PHI -90 -30 ≤ 5Hz 17 CYS PHI -147.8 -29.2   
21 CYS PHI -90 -30 ≤ 5Hz 17 CYS PSI 54.1 171.2   
21 CYS CHI1 -90 -30   20 ALA PHI -90 -30 ≤ 5Hz 
22 ILE PHI -152.5 -112.5   21 CYS PHI -90 -30 ≤ 5Hz 
22 ILE PSI 135.2 175.2   22 ILE PHI -153.8 -113.8   
23 CYS PHI -88.6 -48.6   23 CYS PHI -88.9 -48.9   
23 CYS PSI 118.7 169.8   23 CYS CHI1 150 210   
23 CYS CHI1 150 210   25 GLY PHI -82.9 -42.9   
25 GLY PHI -82.2 -42.2   25 GLY PSI -61.5 -21.5   
25 GLY PSI -60.5 -20.5   26 ASN PHI -86.8 -46.8   
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26 ASN PHI -87.3 -47.3   26 ASN PSI -55.4 -15.4   
26 ASN PSI -51.8 -11.8   26 ASN CHI1 30 90   
26 ASN CHI1 30 90   28 TYR CHI1 -90 -30   
28 TYR CHI1 -90 -30   29 CYSS PHI -100.1 -34.7   
29 CYSS CHI1 -90 -30   29 CYSS CHI1 -90 -30   
30 GLY PHI -80.9 -40.9   30 GLY PHI -84.4 -44.4   
30 GLY PSI -62.2 -22.2   31 TYR PHI -82.1 -42.1   
31 SER PHI -86.4 -46.4   31 TYR CHI1 -90 -30   
31 SER PSI -62 -22   33 TYR PHI -88.6 -48.6   
32 GLY PHI -83.5 -43.5   33 TYR PSI -55 -15   
32 GLY PSI -60.5 -20.5   34 ASP PHI -94 -54   
 
34 ASP PSI -47.6 2.3   
34 ASP CHI1 30 90   
35 VAL PHI -115.6 -39.8   
36 PRO PSI -51.9 -11.9   
37 ASP PHI -91.2 -51.2   
37 ASP PSI -39.1 1.6   
37 ASP CHI1 30 90   
38 TYR PHI -150 -90 13.8Hz 
 
*Note: Backbone dihedral restraints for residues written in red were inferred from 3JHN-Hα coupling 
constants, with ϕ restraind to 120 ± 30° for a 3JHN-Hα greater than 8 Hz, and -60 ± 30° for a 3JHN-Hα 
less than 5 Hz. 
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Table  6. Energies and structural statistics for MCoTI-I and MCoTI-HA 
Energies (kcal/mol) MCoTI-I  MCoTI-HA  
Overall -1015.10 ± 28.33 -1195.31 ± 27.15 
Bonds 13.69 ± 1.60 13.88 ± 1.37 
Angles 41.28 ± 2.98 41.94 ± 4.64 
Improper 16.94 ± 2.76 19.31 ± 2.41 
Dihedral 140.60 ± 1.51 160.63 ± 2.00 
van der Waals -118.47 ± 4.79 -150.84 ± 7.56 
Electrostatic -1110.04 ± 32.34 -1281.23 ± 33.17 
NOE 0.04 ± 0.02 0.01 ± 0.01 
cDih 0.85 ± 0.46 0.99 ± 0.34 
   
MolProbity statistics     
Clashes (>0.4Å/1000 atoms) 14.67 ± 4.55 10.73 ± 5.14 
Poor rotamers 0.33 ± 0.62 0.06 ± 0.26 
Ramachandran outliers (%) 0.00 ± 0.00 0.00 ± 0.00 
Ramachandran favored (%)a 88.96 ± 3.89 88.71 ± 3.88 
   
RMSDb from mean structure (Å)     
Mean global backbone (residues 8-30) 0.91 ± 0.27 0.74 ± 0.21 
Mean global heavy (residues 8-30) 1.98 ± 0.30 1.68 ± 0.30 
   
Distance restraints     
Intraresidue ( i-j=0 ) 67 42 
Sequential ( |i-j|=1 ) 81 109 
Medium range ( |i-j|<5 ) 35 55 
Long range ( |i-j|≥5 ) 58 76 
Hydrogen bonds 5 5 
Disulfide bonds 3 3 
Total 249 290 
   
Dihedral angle restraints     
φ 23 28 
ψ 16 20 
χ1 7 11 
Total 46 59 
   
Violations from experimental restraints  
Total NOE violations exceeding 0.2 Å 0 0 
Total dihedral violations exceeding 2.0° 0 0 
a The rest (11.04%, 11.29%) were found in the allowed regions of the Ramachandran plot. 
b Mean RMSD was calculated using MOLMOL. 
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Table  7. RMSD values of each loop of MCoTI-I and MCoTI-HA  
  Residue RMSD*  MCoTI-I (Å) MCoTI-HA (Å) 
Loop 1 4–11 bb 1.10 ± 0.39 1.05 ± 0.51 
heavy 2.11 ± 0.65 2.24  ± 0.72 
Loop 2 11–17 bb 0.42 ± 0.13 0.44 ± 0.17 
heavy 1.97 ± 0.47 1.64 ± 0.35 
Loop 3 17–21 bb 0.44 ± 0.22 0.58 ± 0.47 
heavy 0.71 ± 0.26 0.93 ± 0.77 
Loop 4 21–23 bb 0.16 ± 0.06 0.14 ± 0.05 
heavy 0.33 ± 0.12 0.26 ± 0.09 
Loop 5 23–29 bb 0.20 ± 0.07 0.22 ± 0.09 
heavy 1.27 ± 0.49 0.90 ± 0.34 
Loop 6 1–4,  29–34/39# 
bb 2.67 ± 0.80 2.51 ± 0.82 
heavy 3.25 ± 0.88 3.39 ± 1.01 
 
*Measured using MolMol. 
#34/39 refers to MCoTI-I and MCoTI-HA numbering, respectively.  
 
 
6.3.4. Mouse immunization and western blot analysis 
BALB/C mouse received five injections 2.8 nmol (~50 μg) of the VHH7_MCoTI-I, 
VHH7_MCoTI-HA or VHH7-HA adducts at 14-day intervals. Equimolar amount of peptide 
samples, MCoTI-I and MCoTI-HA were also used for immunization. Following primary injection, 
mouse anti-sera were collected after the second boost injection for assessment of antigen-specific 
immunoglobulins by immunoblots. To distinguish between antibodies specific for HA, cyclotide or 
a combination of the two target molecules based on an unrelated VHH was produced, the llama 
anti-GFP referred to as enhancer (33). We also assessed reactivity on unmodified VHH7, on 
enhancer modified with the HA epitope and on unmodified enhancer. Because the enhancer is also 
equipped with an LPETG sortase recognition motif near its C-terminus, the identical click 
conjugation strategy employed for the production of VHH7-MCoTI-I and VHH7-MCoTI-HA was 
used. The HA epitope was attached to the enhancer in a conventional sortase-catalyzed reaction, 
using GGG-HA as the incoming nucleophile.  
 
First, reactivity of the antiserum of MCoTI-I and VHH7_MCoTI-I was compared with MCoTI-I. 
Whereas anti-MCoTI-I did not show any reactivity to the samples on the immunoblot (Figure 7A), 
anti-VHH7_MCoTI-I showed strong reactivity to 50 pmol of cyclic MCoTI-I (Figure 7B). 
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Interestingly, the anti-VHH_MCoTI-I showed much higher reactivity towards the cyclic MCoTI-I 
over the linear counterpart (Figure 7B). From the comparison between anti-VHH_MCoTI-I and 
anti-VHH_MCoTI-HA, similar reactivity on adducts formed between enhancer and MCoTI-I or 
MCoTI-HA was observed. Ten picomole of enhancer_McoTI-HA was readily detectable using anti-
sera of either VHH7_MCoTI-I or VHH7_MCoTI-HA. The serum produced after the forth 
immunization failed to react with unmodified VHH7, or with HA-modified enhancer. Interestingly, 
both anti VHH7_MCoTI-I and VHH7_MCoTI-HA reacted with a partial linear peptide (16-mer) 
derived from MCoTI-I. Of 16 the amino acid residues, 12 amino acids are in common between 
MCoTI-I and MCoTI-HA (Figure 8C,D). Using the same set of samples, the reactivity of anti-sera 
of VHH7-HA was also tested, but did not show any band implying the HA-tag alone was not 
antigenic enough under this experimental condition. Mice immunized with equimolar amounts of 
peptides also did not produce anti-sera to react with MCoTI-I or HA-tag. Anti-sera of 
VHH7_MCoTI-I and VHH7_MCoTI-HA showed reactivity after the second boost injection (data 
not shown), although the result shown below (Figure 8) was obtained using serum samples 
collected after the fourth boost injection.  
 
6.3.5. Reactivity between MCoTI-HA and monoclonal anti HA antibody 
The next question asked was whether an epitope inserted into a constrained cyclotide scaffold can 
react with commercially available HA-tag antibody given that anti VHH7-MCoTI-HA did not react 
with linear HA. Interestingly, monoclonal HA-tag antibody showed no or less activity to HA-tag in 
the MCoTI-I scaffold compared to the reactivity to the linear HA-tag (Figure 9). Similarly, 
polyclonal HA-tag antibody also showed slightly less reactivity to MCoTI-HA than the linear HA. 
 
 
Figure 7. Conjugation with VHH7 increases 
the immunogenicity of MCoTI-I. (A) Antiserum 
of MCoTI-I showed no reactivity with any 
samples on the immunoblot. (B) antiserum of 
MCoTI-I conjugated with VHH7 showed 
different reactivity to linear and cyclic MCoTI-I. 
Both antisera collected from mice were used as 
the primary antibody after 1:2000 dilution; anti-
mouse IgG horseradish peroxidase-conjugated 
antibody was used for detection.   
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Figure 8. Antisera reactivity against MCoTI-I and linear HA-tag (A) Mouse immunization and 
serum collection schedule. The antisera used for western blot in this figure was collected at the 
point shown in red, (B) Sequence of 16-mer highlighted in pink within MCoTI-I. Sequence of 
MCoTI-HA is also shown for comparison, (C) Western blot was performed using antisera of 
VHH7_MCoTI-HA and (D) VHH7-MCoTI-I. Both sera showed reactivity against cyclic and linear 
MCoTIs. Whereas no reactivity against linear HA-tag was found, anti VHH7_MCoTI-HA reacted 
with 16mer derived from MCoTI-I indicating HA-tag was not recognized because of its small size 
(9 amino acid residues). Enhancer protein used for conjugation of peptides for comparative transfer 
from SDS gel to nitrocellulose membrane was also used as a negative control.      
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Figure 9. Reactivity between MCoTI-HA and commercially available anti HA antibody (A) 
HA-tag constrained in the MCoTI-I scaffold was either not detected by monoclonal HA antibody, 
or (B) showed less reactivity than linear HA-tag by another monoclonal HA antibody and (C) 
polyclonal HA antibody. 
 
 
6.4. Discussion 
Plant-derived cyclotides are remarkably stable due to their unique structure comprising a head-to-
tail cyclic backbone and three disulfide bonds in their knotted core. They have been intensively 
studied for therapeutic application as well as elucidation of their biosynthesis. However, the 
immunogenicity of cyclotides has not been systematically studied for either purpose, even though 
such knowledge would be highly desirable: (i) to have better a better understanding of cyclotides in 
a clinical setting or (ii) to generate cyclotide specific antibodies to detect them in plant tissues, 
which might provide information on the location and timing of events in the biosynthesis of 
cyclotides.    
 
Peptide-based immunization is usually inefficient because the delivery of peptides to professional 
APCs is often hampered by their weak chemical and physical stability. To overcome such 
drawbacks, peptide antigens are delivered using nanoparticles (8), or using antibodies targeting 
receptors on APCs such as DNGR-1 (34), DEC205 (35,36), Dectin-1 (37), DCIR2 (36), CD11c 
(38), Langerin (39) FcγR (40) and MHC class II products (10-12). Targeting APCs enables efficient 
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cross-presentation of an antigen and thus has been drawing attention for immunotherapy (11). In 
particular, targeting MHC class II products, which are expressed on the number of myeloid cells 
including dendritic cells, neutrophils, and activated macrophages, can potentially be applied to 
imaging immune response taking place during anticancer therapy as myeloid cells surround the 
tumor (14). 
 
In this study, a cyclotide MCoTI-I was conjugated to the VHH7, an alpaca-derived single domain 
antibody fragment specific for MHC Class II, to attempt generation of a MCoTI-I specific antibody.  
Given that antigen delivery in a stable manner is an issue in peptide-based vaccine, the possibility 
for MCoTI-I to elicit epitope-specific antibodies was also tested using HA-tag peptide as a proof-
of-concept. MCoTI-I and MCoTI-HA were synthesized, cyclized and oxidized as described, with 
one modification, namely the inclusion of an azido-lysine residue (Figure 1). The cyclic nature of 
both peptides obviously precludes their expression as genetic fusions with antibodies or antibody 
fragments, and the absence of readily modifiable functional groups hampers covalent attachment to 
carrier proteins more generally. We thus resorted to a click reaction to enable the conjugation of 
MCoTI-I and MCoTI-HA bearing the single azido-modifications to a suitably modified protein 
carrier. While click reaction has been typically achieved by involving copper as a catalyst, copper-
free and strain-promoted click reaction used in this study has comparable kinetics to the traditional 
method but with non-cytotoxic effect (41), and has been used in other conjugation studies 
(18,30,42).  
 
VHH7, isolated by phage display from a library constructed using peripheral blood lymphocytes 
from an alpaca immunized with total mouse splenocytes, was conveniently expressed in bacterial 
cells unlike full-length antibodies that require more cumbersome production in mammalian cells. 
VHH7 reacts with murine class II MHC products, as inferred from a lack of reactivity on cells from 
MHC Class II -/- mice (14,42) and capturing MHC Class II positive cells from mouse peripheral 
blood using immobilized VHH7 (43). VHH7 has been previously used to generate bispecific 
constructs by fusion with an anti-GFP VHH, using a strategy extended here to the production of 
VHH7-McoTI-I and VHH7-McoTI-HA adducts (42). 
 
An immunization strategy that avoids the use of noxious complete Freund’s adjuvant and instead 
used a combination of anti-CD40 and the TLR3 agonist poly I:C was employed (44). The former 
activates antigen presenting cells such as dendritic cells (45), whereas the latter up regulates co-
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stimulatory molecules essential for an optimal adaptive immune response (46). Although the serum 
produced after the forth immunization failed to react with unmodified VHH7, which is consistent 
with the poor immunogenicity of soluble monomeric VHHs, strong reactivity was observed with 
MCoTI-I or MCoTI-HA. Of particular interest is the complete absence of immunoreactivity with 
HA-modified enhancer. The HA epitope tag is frequently used in all manner of genetically 
modified proteins to track their presence and distribution. The HA epitope contained in MCoTI-HA 
is identical in sequence to that recognized by the commonly used anti-HA monoclonal antibodies. 
The failure of MCoTI-HA to elicit antibodies that recognize enhancer-HA can be attributed to 
conformational constraints imposed by grafting the HA epitope into loop 6 of MCoTI-HA (Figure 
1). The HA epitope, when placed at the C-terminus of enhancer or VHH7 is unlikely to assume the 
constrained conformation present in MCoTI-HA. In the course of immunization, antigen processing 
may or may not have occurred, as the experiments did not directly address this issue. Should 
opening of the cyclotide have occurred in concert with reduction of the three disulfides, a linear HA 
epitope could have been produced, the presence of which would have been expected to elicit 
antibodies reactive with enhancer-HA. Given that antiserum raised against MCoTI-HA showed 
reactivity with the linear 16-mer peptide derived from loop 1 and 6 of MCoTI-I (Figure 6), it can be 
assumed that certain loops of a cyclotide have a better chance for antigen processing because of 
rigidity. In fact, the structure determination showed that loop 6 of MCoTI-I is the most flexible loop 
because of high contents of Gly, and replacing the amino acid composition with HA-tag did not 
change the flexibility (Table 7). This issue could be elucidated by additional immunoblot 
experiments to check reactivity between each loop and the antiserum, and further investigation on 
how MCoTI-I is processed by antigen presenting cells. However, commercially available 
polyclonal sera or a certain monoclonal antibody raised against the HA epitope do show some 
measure of reactivity with MCoTI-HA, demonstrating that the production of antibodies that 
recognize constrained epitopes is possible, as corroborated by the existence of many antibodies that 
show a conformation-sensitive pattern of recognition.  
 
In conclusion, antibody generation against MCoTI-I was examined in this study. The conjugation of 
MCoTI-I to a VHH targeting MHC class II product significantly improved immunogenicity of the 
cyclotide, but antisera raised against the cyclotide reacted with both linear and cyclic version of 
MCoTI-I, thus feasibility of cyclotide conformation-specific antibody generation still remains to be 
investigated. In addition, no reactivity between the antiserum raised against MCoTI-HA and linear 
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HA-tag epitope implies that most of antibodies present in the serum are capable of recognizing the 
highly constrained peptide.    
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In this thesis, disulfide-rich peptides were engineered using sortase A (SrtA) with the main focus on 
two peptide families, namely cyclotides and neurotoxins. A summary of the cyclized peptides 
examined in this thesis is shown in Table 1. The major goal to achieve using SrtA was to efficiently 
cyclize linear peptides, thus providing an alternative option to native chemical ligation (NCL). 
Although NCL has been the most commonly used method for cyclization to date, it favours Boc-
chemistry thus needing the use of dangerous reagents such as hydrogen fluoride. Methods have 
been developed for NCL to be Fmoc-chemistry compatible or enable ligation based on the use of 
coupling reagents (1-3), demonstrating the importance and active interest in this field. As another 
alternative option, enzyme-based ligations have also been drawing attention, with SrtA from 
Staphylococcus aureus becoming a leading enzyme in the field due to its efficient catalytic activity 
and site-specificity.  
 
Table 1. Disulfide-rich peptides cyclized by sortase A in this thesis 
Peptide No. of 
disulfide 
bonds 
No. of 
amino 
acids 
Structural 
description 
SrtA 
used 
Order of 
cyclization and 
oxidation 
[GG]SFTI-
1[LPETGG] 
1 (I-II) 22 cyclic backbone wild-
type 
one-pot reaction 
[G]α-Vc1.1 
[GLPETGG] 
2 (I-III,II-
IV) 
22 globular 
conformation 
wild-
type 
cycliation 
→ oxidation  
[GGG]kalata B1 
[TGG] 
3 (I-IV, II-
V, III-VI) 
35 cyclic cystine 
knot 
wild-
type 
 oxidation 
→ cyclization 
[GG]kalata B1 
[TGG] 
3 (I-IV, II-
V, III-VI) 
34 cyclic cystine 
knot 
mutant oxidation in 
vivo(misfolding) 
[GGG]κ-PVIIA 
[LPETGG] 
3 (I-IV, II-
V, III-VI) 
36 inhibitor cystine 
knot 
mutant oxidation 
→ cyclization 
 
 
This thesis has provided a strategy for the SrtA-catalyzed cyclization of disulfide-rich peptides. Its 
general applicability was proven by cyclizing three different peptides, kalata B1, α-conotoxin Vc1.1, 
and SFTI-1 in Chapter 3. All three peptides, which have a different number of disulfide bonds and 
different structures, were efficiently cyclized via site-specific transpeptidation by SrtA. This proof-
of-concept study became a basis for SrtA-catalyzed cyclization to convert an ICK peptide to CCK 
(as shown in Chapter 4) and for the recombinant expression of kalata B1 (Chapter 5). While using a 
one-pot reaction to achieve both oxidation and cyclization was possible for SFTI-1, which has one 
disulfide bond, separate steps for cyclization and folding were required for kalata B1 and α-Vc1.1. 
Optimization was also required to decide the order of cyclization and oxidation due to the 
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complexity introduced by the presence of multiple disulfide bonds. While hydrolysis of cyclic 
peptides was prevented by monitoring the SrtA reaction in this thesis, methods to overcome the 
reversibility of the SrtA-catalyzed reaction (2,4-6) should be applied in future studies. Reducing the 
number of isomers caused by disulfide bond shuffling should also be considered to improve the 
yield of cyclic disulfide-rich peptides during the SrtA reaction. Disulfide bond shuffling observed 
during the cyclization is presumably caused by the cysteine protease nature of SrtA. Stepwise 
formation of disulfide bonds using different thiol protecting groups or selenocysteines can 
potentially improve the yield and should be considered in future study.  
 
In an important result, the standard SrtA reaction was successfully applied to κ-conotoxin PVIIA 
and demonstrated the possibility of cyclization of conopeptides from the O1 gene superfamily, none 
of which had ever previously been cyclized. However, decreased activity was observed after 
cyclization due to the loss of electrostatic interaction between the N-terminus of native κ-PVIIA 
and the shaker channel. The result shows the importance of identifying active sites of a peptide so 
that peptide modification can be made without losing activity. A molecular modeling study would 
help to understand the interaction between the peptide and its target. In Chapter 4, the native and 
cyclic PVIIA were compared using molecular modeling, and a difference in the electrostatic 
interaction with the shaker channel was identified between the two peptides. They also had different 
hydrogen bonding networks, which are presumably caused by the linker used for cyclization. 
Therefore, optimization of the linker residues should be included in future research to achieve 
identical or improved molecular dynamics after cyclization. Unfortunately, limited therapeutic 
potential was found for cyclic-PVIIA based on activity screening on multiple ion channels. 
However, the success in cyclization is encouraging, as the strategy can be readily extended to other 
topologically similar peptides in the O1 superfamily, including the currently marketed drug ω-
MVIIA (ziconotide, Prialt®).  
 
In conjunction with the cyclization of synthetic peptides, the simplicity of the SrtA reaction 
mechanism can mediate the recombinant expression of cyclic disulfide-rich peptides. In this thesis, 
bacterial expression of the kalata B1 precursor was attempted and was coupled with backbone 
cyclization using SrtA. Periplasmic expression facilitated disulfide bond formation within bacterial 
cells, and maltose binding protein (MBP) used as a fusion protein aided solubility of expressed 
kalata B1. The SrtA recognition motif was introduced at both the N- and C-termini of the kalata B1 
sequence (LPXTGG-kalata B1-LPVTGG) so that SrtA can not only cleave kalata B1 from MBP but 
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also cyclize it. Although the mutant SrtA, Srt5°, efficiently cleaved and cyclized expressed kalata 
B1, the resultant cyclic peptide was misfolded. However, refolding of cyclic-[GG]kalata B1[T] 
resulted in correct disulfide bond formation. Therefore, a new expression strategy for kalata B1 may 
be to exclude the signal peptide from the DNA sequence to have kalata B1 in a reduced state in the 
cytoplasm of E. coli and then to fold it in vitro. Based on the results obtained by using different 
bacterial strains, as well as changing the induction temperature, the lysis method, and parameters of 
the SrtA reaction, it can be concluded that MBP-kalata B1 can be expressed in the cytoplasm of 
BL21 cell at 30°C and subjected to the sortase A (Srt5°) reaction for less than 2 h to prevent 
hydrolysis. Furthermore, co-expression of SrtA and peptide precursors in the cytoplasm should be 
considered in future to achieve cyclic kalata B1 within the bacterial cells, thereby minimizing the 
expression costs. 
 
The site-specific ligation activity of SrtA not only enabled efficient cyclization of disulfide-rich 
peptides, but was also used for conjugation of a cyclotide to another protein. Specifically, the 
cyclotide MCoTI-I was conjugated to a single-domain antibody (sdAb, VHH), which targets MHC 
Class II products expressed on antigen presenting cells. The immunogenicity of MCoTI-I was 
significantly improved and mouse serum sampled after immunization showed high reactivity with 
MCoTI-I. Cyclotide specific antibodies can be useful as an immunohistochemistry tool, for 
example, to visualize their locations in plant tissues, thus providing more information on the 
biogenesis of cyclotides. Similarly, cyclotide antibodies could be potentially be applied to animal 
tissue sections to track how cyclotides are processed in vivo after administration for therapeutic 
purposes.  
 
Although advanced techniques such as MALDI imaging are currently available, it is desirable to 
perform histological staining using antibodies after mass measurements to allow a histology-
directed analysis of the mass spectra. Such immunohistochemistry requires antibodies with high 
selectivity and sensitivity. Conformation specific antibodies for cyclotides, which were not isolated 
in this thesis, would help to detect cyclotides in vivo. By doing so, we can find out under what 
circumstances cyclotide scaffolds lose their rigidity given that various gastrointestinal systems have 
varying pH and proteases. In a similar context, cyclotide antibodies would also allow us to study 
cyclotides via biological approaches at the cellular level, thus revealing intracellular trafficking or 
antigen processing upon endocytosis of cyclotides into antigen presenting cells. However, the most 
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obvious potential of the conjugation strategy, as shown in Chapter 6, is targeted delivery of 
cyclotides. This means an epitope grafted onto a cyclotide scaffold can be delivered to the target in 
a stable and efficient manner.  
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As noted throughout this thesis, peptides are great drug candidates because they have high 
specificity and potency towards their targets. Therefore, peptide drugs potentially require lower 
dose administration than conventional drugs, with therefore a lower chance of side effects. However, 
peptides tend to have short plasma half-lives and poor oral bioavailability, and thus require 
structure-based design or engineering approaches to improve their stability and bioavailability. 
Among a number of technologies developed to address these issues, cyclization of linear peptides 
and grafting a bioactive peptide onto a cyclotide framework have been shown to make 
therapeutically relevant peptides orally active (1,2). 
 
Overall, this thesis has shown how sortase A (SrtA) can be used to engineer naturally occurring 
disulfide-rich peptides. A cyclotide kalata B1, α-conotoxin Vc1.1, and sunflower trypsin inhibitor-1 
(SFTI-1) were successfully synthesized with the C-terminal SrtA recognition motif (LPXTG) and 
the N-terminal oligoglycine nucleophile, and subsequently cyclized by SrtA. The strategy to 
produce kalata B1, which has a unique topology called a cyclic cystine knot (CCK), using SrtA was 
extended to two additional studies. First, κ-conotoxin PVIIA, which has a linear cystine knot 
conformation, was efficiently converted to a cyclic cystine knot by SrtA. Second, SrtA was applied 
to kalata B1 precursor (maltose binding protein-LPETGG-kalata B1-LPVTGG) expressed in the 
periplasm of E. coli. Although periplasmic expression followed by SrtA-mediated cyclization 
resulted in misfolded kalata B1, subsequent refolding in vitro was successful. Therefore, cyclization 
prior to oxidation of expressed kalata B1 precursor can potentially reduce the cost of production 
significantly compared to that of chemical synthesis.  
 
In addition to head-to-tail cyclization, SrtA-catalyzed reaction coupled with strain-promoted click 
chemistry was attempted to conjugate a cyclotide to a nanobody, VHH7. A non-natural amino acid 
was incorporated during cyclotide synthesis to enable a subsequent click reaction with a DBCO-
modified VHH7. This strategy has overcome the fact that cyclotides lack a free N- and C-terminus, 
contain only fully oxidized cysteines, and in their natural form have no amino acid residue enabling 
conjugation to a carrier protein. The conjugation facilitated targeted delivery of cyclotides to 
antigen presenting cells in an attempt to examine cyclotides as immunogens. Mouse immunization 
and immunoblot analysis revealed that the VHH7-MCoTI-I conjugate elicits antibodies against 
cyclic or linear MCoTI-I, whereas MCoTI-I alone did not show any obvious antibody response. 
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The SrtA-catalyzed reaction used in this thesis achieved both absolute site specificity and excellent 
yields of engineered peptides. However, the necessity of a LPXTG motif hinders the production of 
cyclotides with native amino acid sequences. Recently, asparaginyl endopeptidase (AEP), a 
transpeptidase involved in the biosynthesis of cyclotides with site-specific activity (3), was 
successfully expressed in bacterial cells (4). Therefore, it is now possible to semi-enzymatically 
produce cyclotides without a linker sequence. As SrtA and AEP share a similar mechanism of 
transpeptidation, strategies and results shown in this thesis can be used as a basis for AEP-mediated 
peptide engineering. By utilizing these novel engineering strategies, we can enrich the current pool 
of peptide-based drug leads available for therapeutic development.  
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 DNA sequence of [LPETGG]kalataB1[TGG] and restriction enzyme sites available in pLIC 
expression plasmid. The amino acid translation of [LPETGG]kalataB1[TGG] corresponding 
to the DNS sequence is shown in bold. 
 
 
